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ABSTRACT 
 
Introduction:  A study in 2005 found that Epidermal Growth Factor Kinase Inhibitors 
(EGFRki) could promote Retinal Ganglion Cell (RGC) axonal regeneration in vivo when 
delivered to the crushed Optic Nerve (ON).  The axon regenerative effects of these EGFRki 
were attributed to their blockade of the Epidermal Growth Factor Receptor (EGFR), and 
EGFR activation was hence suggested to lead to growth cone collapse and failed RGC axon 
regeneration. 
 
Aims:  To investigate the role of EGFR in RGC axonal regenerative failure, and to elucidate 
the mechanisms of action by which EGFRki promote RGC axonal regeneration. 
 
Methods:  Immunohistochemistry and immunocytochemistry to visualize activated EGFR 
(pEGFR)  Primary retinal cultures to examine the actions of EGFRki such as AG1478 on 
RGC in vitro.  ELISA to examine the conditioned media from these cultures for 
NeuroTrophic Factors (NTF).  Intravitreal (ivit) injections of EGFRki (PD168393) into Optic 
Nerve Crush (ONC) recipient rats to attempt to elicit in vivo regeneration.  The 
implantation of PD168393-impregnated collagen matrices into ONC recipient rats to 
attempt to elicit in vivo regeneration.  PCR on retinal lysates to detect NTF mRNA. 
 
Results:  No pEGFR was detected on RGC axons, either in the retina or in the ON of any 
treatment or control group.  pEGFR was detected on almost all ON and retinal glial types 
prior to injury and almost all glial types exhibited increased pEGFR levels post-ONC.  A sub 
population (~30%) of RGC cell bodies were pEGFR+ but this proportion did not change 
between control and treatment groups.  AG1478 was shown to disinhibit RGC in Nogo-P4 
inhibited primary retinal cultures but ELISA on conditioned media for various NTF 
detected none, however PCR detected mRNA for several of these NTF in retinal lysates.  
Ivit PD168393 failed to elicit RGC survival or axonal regeneration in vivo.  Intra ON 
implantation of PD168393-impregnated collagen matrices appeared to promote 
significant RGC axonal regeneration post-ONC, but did not affect RGC survival.   
 
Discussion:  Several models explaining the in vitro regenerative and in vivo neuritogenic 
actions of EGFRki were developed.  These included the abrogation of various harmful 
glially mediated processes, the stimulation of NTF release by local glia and the stimulation 
or blockade of several other non-EGFR dependent signalling cascades by EGFRki. 
 
Conclusions:  The axogenic and neuritogenic actions of EGFRki in vitro and in vivo were 
confirmed.  The identification of numerous other means by which EGFRki could indirectly 
promote RGC axonal regeneration, including by acting on targets other than EGFR 
allowed the construction of a combinatorial model of how EGFRki effect axonal 
regeneration, and the original hypothesis positing EGFR as an intra-axonal component of 
a growth cone collapsing signalling cascade was disgarded. 
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Chapter 1 
General Introduction 
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1.1 The Central Nervous System 
The vertebrate Central Nervous System (CNS) consists of the brain and the spinal cord.  
The brain, comprising tens of billions of neurons and glial cells, and many times that 
number of axons and dendrites, is responsible for decoding, analysing and sorting sensory 
information, as well as generating appropriate motor, endocrine and physiological 
responses.  The brain also forms, stores and recalls associations between events - 
memories - and, in higher organisms, performs complex cognition and generates emotion 
and consciousness.  The spinal cord contains the axons and some of the cell bodies of the 
neurons responsible for relaying sensory information to, and motor and endocrine 
responses from, the brain.  The CNS also includes, as part of the brain, the retinae and the 
optic nerves (ON).  The retina is the neural tissue of the eye responsible for the initial 
detection of light, its subsequent conversion into electrical action potentials (APs), and 
finally the conduction of these APs along axons projected by retinal neurons to the 
relevant areas of the brain.  Collectively, these retinofugal (‘retina-fleeing’) axons form 
the ON.  The CNS is enveloped by the cranial meninges, surrounded by cerebro-spinal 
fluid (CSF) and isolated from the rest of the body by the blood brain barrier (BBB).  The 
BBB is a system of endothelial cell tight-junctions in the capillaries supplying the brain, 
abutted on the CNS side by the end feet of astrocytes.  These astrocytes form the glia 
limitans, a network of astrocytic processes which separate CNS tissue from the overlying 
layer of the meninges.           
 Unlike our peripheral nervous system (PNS), or even the CNS of fish or reptiles, 
the mammalian CNS does not regenerate after injury, with the result that severed CNS 
tracts do not reinnervate their targets and any neurons lost are not replaced. 
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1.2 Why does the CNS fail to regenerate? 
The catastrophic and permanent functional consequences of human CNS injury, including 
paralysis, loss of sensation, and loss of bowel and bladder continence, have been 
recognised and described since at least 3500 B.C (Edwin Smith papyrus, 1930).  In the 
5,510 years since then it is only in the last century or so that the CNS has been studied at 
the cellular level, with the pioneering work of Cajal at the beginning of 20th century.  Cajal 
showed that some axons did in fact regenerate from the severed end of an ON into a 
sutured-on segment of peripheral nerve, critical evidence that the CNS was not utterly 
incapable of regeneration.  It was not until the late 1970s that further steps were taken 
towards successful CNS regeneration with the work of Aguayo and David ( 1981, 1985) 
and Richardson et al. (1980) confirming that the severed axons of the damaged adult CNS 
are not intrinsically incapable of regrowth, as had previously been thought.  By impanting 
living peripheral nerve grafts or ‘bridges’ into the brain (Richardson et al. 1980) or 
between the undamaged spinal cord and brain stem of adult rats and mice, so as to 
connect the brain stem and upper thoracic spinal cord, it was shown that, axons from CNS 
neurons would grow several cm into and across these grafts and that these axons were at 
least partially myelinated by Schwann cells (Aguayo et al 1981, David and Agauyo 1981).  
This robust CNS axon growth in a PNS environment suggested that the environment of 
the CNS itself played a large part in the CNS regenerative failure.   Further evidence for 
the difference in regenerative permissiveness when a subsequent study showed that 
these invading CNS axons will readily regenerate significant distances after being crushed 
(David and Aguayo 1985), and that ON fibres regenerated up to 2cm into grafted 
peripheral nerve sections (So and Aguayo, 1985).  The extremely important discovery that 
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proteins within CNS myelin are strongly inhibitory to axon growth led to the production of 
an antibody which significantly dinsihibted CNS neurite outgrowth in vitro (Caroni and 
Schwab 1988a, b) and promoted modest regeneration in the spinal cord in vivo (Schnell 
and Schwab 1990).  However, the discovery that embryonic CNS neurons exhibited 
substantial growth when implanted into the adult CNS (Wictorin and Bjorklund, 1992) 
strongly suggested that there was also an intrinsic reduction in inherent regenerative 
capacity in adult CNS neurons.  By the year 2000 3 separate myelin derived proteins had 
been identified: myelin associated glycoprotein (MAG) (McKerracher et al. 1994), 
oligodendrocyte-myelin glycoprotein (OMgp) (Wang et al. 2002) and Nogo-A and –C 
(Caroni and Schwab 1988a, Chen et al. 2000, GrandPre et al. 2000, Prinjha et al. 2000).  It 
was subsequently discovered that each of these proteins bind to and signal through the 
the Nogo receptor (NgR) (Fournier et al. 2001) and that this receptor signalled through its 
coreceptors Lingo (Mi et al. 2004) and either p75NTR (Wang et al. 2002) or TROY (Park et 
al. 2005). Surprisingly, it became apparent that inactivating either the individual proteins, 
or the NGR receptor itself yielded modest in vivo regeneration at best, and that even 
inactivating the downstream signalling molecules RhoA or ROCK, did not promote 
extensive in vivo axogenesis (Fischer et al. 2004a,b, Benowitz and Yin, 2007).  Other 
studies showed that certain growth antagonistic molecules such as Netrin-1 and MAG 
were actually growth promoting in utero/immediately post natal, demonstrating that 
adult CNS neurons respond to the environment differently to PNS and even embryonic 
CNS neurons (Cai et al 2001, Shewan et al 2002).  The discovery that such switches from 
growth promotion to growh retardation are in fact triggered by changes in levels of 
intraneuronal cAMP (Cai et al. 2001) showed that the internal growth state of the CNS 
neuron was potentially at least as important as the surrounding environment, confirming 
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the early findings of Wictorin and Bjorklund (1992).     
 In less than a third of a century, the previously non-existent field of CNS repair has 
expanded to become a major branch of neuroscience and medicine, with millions of 
pounds being spent yearly on researching potential therapies.  Alongside the landmark 
studies mentioned above, thousands of others have investigated and uncovered the 
events, tissues, cells, proteins, genes, factors and signalling pathways which underlie the 
failure of CNS axons to regenerate, resulting in the identification of several major barriers 
to CNS regeneration.  These include the death of damaged neurons, the growth-hostile 
nature of the injured CNS and the tendency for many injured CNS neurons to rapidly 
abort any attempts at regeneration. 
 
1.2.1   Many neurons die in response to CNS injury and are not replaced 
Between 2 and 3 days after CNS injury, many mammalian CNS neurons begin to die.  
Contributing factors include mechanical cellular damage caused by the initial injury, 
infection, secondary cellular damage by invading macrophages (Danton and Dietrich 
2003), myelin stripping by lymphocytes (Crocker et al. 2006), glutamate excitotoxicity as a 
hypoxic response (Sasaki et al. 2005) and damage from Reactive Oxygen Species (ROS) 
released by activated microglia/macrophages during phagocytosis (Smith et al. 1998).  
Cell death has traditionally been described as either of two processes: a passive, cell 
damage-mediated process termed necrosis and an active program of cell-suicide known 
as apoptosis.  Necrosis is characterised by cell swelling, organelle destruction and, 
eventually, cell lysis and fragmentation, provoking an inflammatory response (Yakovlev 
and Faden 2004).  Conversely, cells undergoing apoptosis disassemble their cytoskeleton 
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and organelles whilst maintaining membrane integrity, and disintegrate into apoptotic 
bodies which are phagocytosed by neighbouring cells and thus do not instigate an 
inflammatory response (Yakovlev and Faden 2004).  The extent to which each of these 
two processes mediate neuronal death is dependent on the nature and location of the 
CNS insult.  Damage to primarily neuronal areas, as seen in penetrating brain injuries, 
tend to cause local neuronal death through necrosis brought about by ischaemia, 
oxidative stress and glutamate excitotoxicity (Faden, 1996), whereas when the damage is 
primarily limited to axotomy (amputation of axon from neuron), and occurs remote to the 
neuron itself, as in the case of ON transection, subsequent neuronal death primarily 
results from apoptosis.  Until relatively recently it was assumed that necrosis was an 
uncontrolled process, purely resulting from disrupted cell function, but a Ca2+ mediated 
cysteine protease-dependent pathway has been identified which appears to account for 
much of the intracellular disintegration which characterises neuronal necrosis (Syntichaki 
et al., 2002, Yamashima, 2000).  Apoptosis has been extensively studied and there are 
now several known apoptotic signalling pathways, each of which ultimately culminates in 
the activation of one or more families of proteases which efficiently disassemble the cell 
from within (Yakovlev and Faden 2004, Leist and Jaattela, 2001).  First identified and best 
understood of these protease families are the caspases.  For brevity, and due to the 
extensive nature of associated literature, only caspase-dependent neuronal apoptosis will 
be described here, but for a broader picture of apoptosis see Yakovlev and Faden (2004) 
and Leist and Jaattela (2001).  The caspases (Cysteine-dependent Aspartate-directed 
proteases) mediate apoptosis through two separate but interconnected pathways.  The 
first pathway is initiated by the binding of extracellular ligands to membrane bound 
receptors, whereas the second is mediated by mitochondrial protein release.  These are 
 7 
 
respectively termed the ‘extrinsic’ and ‘intrinsic’ signalling cascades/pathways (figure 1).  
The extrinsic signalling pathway begins with ligand activation of death receptors such as 
TNF-αR and p75NTR/Sortilin receptor complex, whereas the intrinsic cascade is initiated in 
response to mitochondrial damage.  Both pathways culminate in the conversion of an 
inactive pro-caspase to an active caspase (caspases 8 and 9 respectively) which then goes 
on to activate the executioner caspases, 3, 6 and 7 (Yakovlev and Faden 2004).  These 
executioner caspases then go on to initiate cell-wide mass proteolysis, resulting in the 
disassembly of the cytoskeleton and intracellular organelles and the cessation of cellular 
metabolism (Raff, 1998).  Caspase 3 appears to be the primary executioner caspase in 
neuronal apoptosis (Yakovlev and Faden 2004, Leist and Jaattela 2001) and as such is the 
only executioner caspase shown in Figure 1.1.   
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Figure 1.1.  Caspase mediated apoptosis.  The extrinsic pathway begins with ligand binding to a death 
receptor which cleaves pro-caspase 8 to form active caspase 8.  Caspase 8 activates the executor 
caspase 3, leading to intracellular organelle and cytoskeletal proteolysis and cell death.  The intrinsic 
pathway begins with mitochondrial damage, which leads to the release of cytochrome c.  Cytochrome C 
in turn leads to the formation of the apoptosome, a structure which allosterically cleaves procaspase 9 
to form active caspase 9.  Caspase  9 then activates caspase 3, leading to cell death. Inhibitos of 
apoptotic proteins including XIAP block the activation of caspase 3, preventing apoptosis.  Mitochondrial 
damage also leads to the release of Smac/DIABLO, which inhibits XIAP, indirectly causing caspase 3 
activation and subsequent cell death.  Pro-apoptotic Bcl-2 family members form channels in the 
mitochondrial membrane, allowing the exit of Cytochrome C.  Anti-apoptotic Bcl-2 proteins prevent the 
formation of these channels. 
 
The pro-survival inhibitors of apoptosis proteins (IAP), such as XIAP, blockade executioner 
caspase activation, preventing cell death, but the IAP are themselves inactivated by 
factors such as Smac/DIABLO which are released from mitochondria in response to 
mitochondrial damage.  Anti apoptotic members of the Bcl-2 family such as Bcl-2, Bcl-x 
and Mcl-1 are located on the surface of mitochondria and prevent the release of 
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cytochrome C (Raff, 1998), blocking the intrinsic pathway and allowing IAP such as XIAP to 
prevent executioner caspase activation.     
 Although the various secondary insults to the injured CNS mentioned above 
undoubtedly cause neuronal loss through both necrotic and apoptotic processes, perhaps 
the most likely reason for neuronal apoptosis after axotomy is the resultant loss of target-
derived survival signals  (Majdan and Miller, 1999, Chao et al. 2006).  During the 
formation of the embryonic nervous system many more axons are produced than are 
needed to innervate distant targets.  Only the neurons whose axons successfully contact 
and connect with their targets survive, the others undergo apoptosis – a process referred 
to as ‘pruning’.  The neurons whose axons have successfully connected to their targets 
survive because the target cell (often another neuron) supplies the newly connected 
neuron with survival factors, which prevent the onset of apoptosis by activating the anti-
apoptotic members of the Bcl-2 family described above, and by preventing the release of 
cytochrome C which would otherwise initiate the intrinsic apoptotic pathway (Chao et al. 
2006, Yakovlev and Faden 2004).         
 These neuronal survival factors are known as neurotrophic factors (NTF) and 
include the four classical neurotrophins (NT) NGF, BDNF NT-3 and NT-4, as well as basic 
fibroblast growth factor (FGF2) and ciliary neurotrophic factor (CNTF) (figure 2).    
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  Figure 1.2.  Neuronal neurotrophic factor (NTF) signalling.  The neurotrophins (NT) NGF, BDNF, NT-3 and 
NT-4 can individually bind to and activate both their cognate Trk receptors Trk A, Trk B and Trk C, as well 
as p75NTR, a member of the TNF receptor superfamily, but signal for survival most effectively through 
complexes of Trk+p75NTR.  Basic fibroblast growth factor (FGF2) binds to FGFR1 and ciliary neurotrophic 
factor (CNTF) binds to a heterotrimeric receptor complex composed of CNTFα, GP130 and LIFRβ sub-units.  
All receptors signal for survival through the activation of ERK/MAPK and AKT which ultimately maintain 
the presence of anti-apoptotic Bcl-2 family members on mitochondrial membranes while blocking the 
activity of pro-apopototic Bcl-2 family members such as Bax (see figure 1.1).  Simultaneously, activation of 
ERK/MAPK and PKC pathways promote axonal outgrowth by modulating the activity of the Rho family of 
small GTPases; inhibiting the growth cone collapse-inducing RhoA and activating the filopodial and 
lamellipodial outgrowth inducing cdc42 and Rac (see figure 1.4 for details).  Figure taken with permission 
from Berry et al. 2008. 
 
The NTs are first synthesised and released as pro-neurotrohphins, and the attached pro- 
domain must be cleaved for NTs to function as survival factors.  The individual NTs and 
pro-NTs each preferentially bind to and activate one or more of the tropomyosin 
receptor kinase (Trk) receptors Trk A, Trk B and Trk C.  While each NT has a weak affinity 
for at least one other Trk, it is broadly the case that NGF interacts chiefly with Trk A, 
BDNF and NT-4 with Trk B and NT-3 with Trk C (Chao 2003, 2006, Berry et al. 2008).  All 
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NTs and pro-NTs also bind to p75NTR, a member of the tumour necrosis factor (TNF) 
receptor superfamily, with proNTs exhibiting a greater affinity for p75NTR than Trks and 
mature NTs preferentially binding to Trks over p75NTR.  The p75NTR is unusual in that it 
plays multiple roles simultaneously.  As a standalone receptor p75NTR can signal for both 
survival and apoptosis, depending on the nature of the ligands, coreceptors and 
intracellular signalling proteins involved (Chao 2003, Schecterson and Bothwell 2010), 
although sortilin is required as a coreceptor for the binding of pro-NTs which leads to 
apoptotic signalling (Chao 2006, Schechterson and Bothwell 2010).  The p75NTR also forms 
part of a complex with individual Trk receptors, resulting in significant increases in both 
the affinity and the specificity of the Trk-NT interaction, (Chao 2003, Schechterson and 
Bothwell 2010), e.g. both NGF and NT-3 will bind to TrkA receptors but the TrkA-p75NTR 
complex binds only NGF (Chao, 2003, 2006).  The net effect of this is that proNTs tend to 
activate p75NTR over Trk, leading to apoptotic signalling, whereas mature NTs tend to 
signal through Trk and the Trk-p75NTR complex leading to survival and axonal growth (see 
figure 1.2).  The p75NTR also acts as a coreceptor for various other ligands, including 
myelin derived growth antagonistic proteins (see figure 1.3 and accompanying text).   
 Basic fibroblast growth factor (FGF2) binds to FGFR1 and ciliary neurotrophic 
factor (CNTF) binds to a heterotrimeric receptor complex composed of the CNTFα, GP130 
and LIFRβ sub-units.  Each of these receptors signal for survival through the activation of 
ERK/MAPK and AKT which ultimately maintain the presence of anti-apoptotic Bcl-2 family 
members on mitochondrial membranes while blocking the activity of pro-apopototic Bcl-
2 family members (see figure 1.1).  Interestingly, CNTF has been identified as the most 
potent promoter of long tract regeneration in the ON, whilst having little or no 
discernable effect on RGC survival (Cui et al. (1999) and Cho et al. (1999)), whereas Li et 
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al. (2009) showed certain synthetic FGF analogues differentially promote either in vitro 
neurite outgrowth or neuronal survival but not both.  BDNF has also been reported to 
have the opposite effect; increasing RGC survival without affecting regeneration (Pernet 
and Dipollo, 2003).           
 The death of CNS neurons after injury is therefore attributable to both apoptosis 
and necrosis; the former due to the loss of target-derived NTF survival signals, and the 
latter both as a result of the initial physical injury and in response to the secondary 
insults caused by infection and the actions of inflammatory and immune cells.  
 
1.2.2  The adult CNS contains many  axon growth antagonistic factors and a 
 dearth of growth permissive molecules 
 
During in utero development and regeneration, axons grow and navigate through the 
actions of a specialised structure at their tip – the growth cone.  Axon growth inhibitory 
molecules (AGIM) are molecules which, when encountered by growth cones, cause them 
to stop, retract and even collapse completely.   These AGIM include 3 proteins derived 
from CNS myelin: myelin associated glycoprotein (MAG) (McKerracher et al. 1994 (but see 
Cai et al. 2001)), oligodendrocyte-myelin glycoprotein (OMgp) (Wang et al. 2002) and 
Nogo-A and –C (Caroni and Schwab 1988a, Chen et al. 2000, GrandPre et al. 2000, Prinjha  
et al. 2000) as well as sempaphorins, netrins, ephrins and chondroitin sulphate 
proteoglycans (CSPG) such as versican, brevican, neurocan, aggrecan, phosphacan and 
NG2 (Berry et al. 2008).  Secreted by fibroblasts, the semaphorins (especially sema-3a) 
along with the ephrins are important chemorepulsive axonal guidance cues during 
development but also contribute to abortive axonal regeneration (Kaneko et al. 2006 and 
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Goldshmit et al. 2006 respectively).  CSPGs are produced and secreted by reactive 
astrocytes post injury (Sandvig et al. 2004).        
 The reason for much of this CNS inhospitability, especially the prevalence of 
myelin derived AGIM in the CNS, is the incomplete Wallerian degeneration that follows 
CNS axotomy.  Wallerian degeneration is the active processes whereby the distal sections 
of severed axons (ie those sections no longer connected to the neuronal cell body), 
including their myelin sheathes, are actively degraded, and removed from the injury site 
(Vargas and Baress, 2007).  In the PNS, which readily regenerates after injury, distal 
sections of axons degenerate within hours-days and both Schwann cells and invading 
haematogenous macrophages phagocytose and destroy all PNS myelin – a process which 
is largely complete in mammals within 7-14 days post injury (Vargas and Baress, 2007).  In 
stark contrast to this CNS axonal debris, including myelin, is cleared over the space of 
months or years, if at all and the injury site remains full of axona debris, (see figure 1.7, 
lower panel) growth inhibitory CNS myelin and its derivative AGIM proteins (Vargas and 
Baress, 2007, Berry et al. 2008).    Schwann cells which are not in contact with intact 
axons also proliferate in response to PNS injury and release NTFs which strongly enhance 
neuronal survival and regeneration (Fawcett &Keynes, 1990).  CNS oligodendrocytes do 
not take part in myelin clearance, do not secrete significant levels of NTFs and not only do 
not proliferate in response to injury, they often die in large numbers – a process linked to 
oligodendrocytes dual need for multiple neurotrophic support and the electrical activity 
of adjacent axons (Barres et al. 1993, Vargas and Baress, 2007).  Along with the 
phagocytic role played by Schwann cells, the other primary reason for the difference in 
debris clearance rates is the difference in immune response to PNS and CNS insult.  Unlike 
the CNS which is mostly isolated from the immune system by the BBB and is thus 
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accessible only at and around the injury site, the injured blood nerve barrier (BNB) of the 
PNS is open to the immune system along the entire length of degenerating axons, 
allowing rapid influx of huge numbers of phagocytic macrophages to clear debris which 
has been marked for destruction with opsins or with the complement system (Vargas and 
Baress , 2007).  One final consequence of successfully Wallerian degeneration is the 
sparing of the basal lamina tubes of Schwann cells.   Unlike the CNS, where a single 
oligodendrocyte will myelinate multiple axons, each segement of PNS axons are 
myelinated by a single Schwann cell which wraps around the axon in its entirety, like a 
bandage around a limb, and once consolidated, constructs a basal laminal tube around 
itself.  These tubes surround the Schwann cells and the axons around which they are 
wrapped and, following Wallerian degeneration, serve as a highly permissive axon growth 
substrate, through which regenerating axons readily advance (Vargas and Baress, 2007).  
Additionally, these structures allow regenerating axons to navigate back to their targets 
unerringly as the tubes continue uninterrupted to the axons’ original target (Nguyen et al. 
2002).  Taken together, astrocytic secretion of growth inhibitory factors such as CSPG, the 
failure to clear CNS myelin and axonal debris and the lack of any equivalent to the ready-
made Schwann cell derived growth substrate and NTF supply found in the PNS equates to 
an enormous difference in the respective environments surrounding axotomised PNS and 
CNS axons.          
 To understand the mechanisms by which AGIM prevent growth cone 
advancement, and so prevent axonal regeneration in the CNS, the structure and function 
of the growth cone itself must first be described.  The neuronal growth cone consists of 
rod like structures (filopodia) interspersed with ‘veils’ (lamellipodia) projecting out from a 
central area, which abuts the end of the axon-shaft.  Once memorably referred to as ‘a 
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leukocyte on a leash’, the classical model of the growth cone, illustrated in figure 1.3, 
somewhat resembles a human hand, with the fingers as filopodia, the skin between the 
fingers as lamellipodia, the palm as the main body of the growth cone and the wrist as 
consolidated axon shaft.  The microtubules, which strengthen and stabilise the axon-
shaft, the growth cone proper and individual filopodia, can similarly be thought of as the 
‘bones’ of the wrist, hand and fingers.  Both filopodia and lamellipodia are primarily 
constructed from the small protein actin, which is polymerised in huge numbers into 
filaments termed F-actin, but whereas filopodia are organised into long slender columns, 
lamellipodia are a sheet of interconnected, meshwork-like actin filaments of varying 
length (see Figure 1.3) (Lowery and Van Vactor 2009).  Both filopodia and lamellipodia are 
situated at the outermost part of the growth cone, and extend and push outwards by 
being continually elongated at their juxtamembranous ends through the ongoing addition 
of actin monomers.  Simultaneously, polymerised sections of F-actin are removed at the 
proximal end of filopodia/lamellipodia and recycled as monomers back to the growing, 
juxtamembraneous end of the structure (Lowery and Van Vactor 2009).   
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Figure 1.3.  The growth cone.  Filopodia consisting of F-actin bundles project outwards, 
extending due to ongoing F-actin polymerisation at their tips, and the mesh-like network of F-
actin which make up lamellipodia, follow.  Microtubules extend from the soma through the 
consolidated axon shaft, and stabilise the entire structure of the growth cone, as well as 
extending into and reinforcing filopodia.  The Central (C) and Peripheral (P) domains and the 
Transition (T) zone are respectively characterised by a stabilised, relatively fixed cytoskeleton 
and an accumulation of vesicles, proteins and mRNAs required by the growth cone (C), the 
anchor-points and beginnings of the lamellipodia and filopodia (p) and a ring of contractile 
actomyosin rings which are involved in growth cone retraction and collapse.  Proteins governing 
the rates of actin polymerisation and depolymerisation are closely associated with actin 
throughout the growth cone and almost all factors affecting the course of growth cones 
ultimately impinge on these proteins.  Taken from Lowery and Van Vactor, 2009. 
 
The relative rates of these two opposing processes determine the length/size of the 
respective structure.  If the rate of actin polymerisation outstrips that of 
depolymerisation, the individual filopodium or lamellipodium will lengthen, resulting in 
local membrane expansion.   Conversely, if the rate of actin depolymerisation outpaces 
that of actin polymerisation, filopodial and lamellipodial retraction occurs, leading to local 
membrane retraction.  When polymerisation and depolymerisation rates are identical the 
growth cone can be said to be “arrested”.  When filopodial and lamellipodial retraction is 
global the result is growth cone shrinkage.  When growth cone expansion takes place 
 17 
 
primarily along the forward edge of the growth cone (i.e. to the right in figure 1.3), it will 
advance forwards in a straight line.  When filopodially and lamellipodially mediated 
expansion or contraction dominates one side of the growth cone the result is extension in 
one specific direction – the growth cone turns.      
 A further process exists, known as growth cone collapse.  Growth cone collapse 
and contraction are separate processes, the latter occurring, as described above, largely 
as a result of filopodial and lamellipodial shortening, whereas the former is characterised 
by filopodial and lamellipodial disassembly as well as the activation of contractile 
actomyosin fibres which actively pull the outermost parts of the growth cone towards its 
centre (Gallo and Letourneau 2004).      
 Crucially, the rates of actin polymerisation and depolymerisation are controlled by 
a vast array of actin-associated proteins which act as final convergence points for 
multiple, interconnected signalling networks.  Many of these networks are connected to 
membrane-bound receptors and ion channels, meaning that local actin polymerisation 
and depolymerisation, and thus the extent to which the growth cone grows, shrinks, turns 
or collapses, is strongly influenced by factors in the extra-neuronal environment.   But 
how do these cytoskeletal changes relate to AGIM and the antagonism of CNS axonal 
regeneration?          
 While all known CNS myelin-derived AGIM bind to and signal through the Nogo 
receptor (NgR) (Fournier et al. 2001) and its coreceptors Lingo (Mi et al. 2004) and either 
p75NTR (Wang et al. 2002) or TROY (Park et al. 2005), and while CSPGs, semaphorins and 
ephrins all signal through separate, specific receptors, each of these AGIM can only 
instigate growth cone collapse by first interacting with downstream intracellular proteins 
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such as RhoA (Sandvig et al. 2004, Berry et al. 2008) which in turn activate specific actin-
associated proteins including Myosin II and ADF/Cofilin (see Figure 1.4).   
   
 
Figure 1.4.  The Rho family of small GTPases mediate growth cone extension, retraction, arrest, 
collapse and turning.  Rho proteins are activated by guanidine exchange factos (GEFs) which 
convert Rho+GDP to Rho+GTP, and inactivated by the confusingly named GTPase activating 
proteins (GAPs).  RhoA, signalling, through Rho Kinase (ROCK) leads to F-actin disassembly 
(retraction) and the formation of contractile actomyosin fibres (collapse). Rac and CDC42 signalling 
lead to lamellipodial and filopodial extension respectively (extension).  Activation of RhoA plus 
Rac/CDC42 causes growth cone arrest if co-activated globally, whereas asymmetrical, focal 
activation of either/both will result in RhoA localised retraction and Rac/CDC42 localised extension, 
resulting in growth cone turning.  Modified from Lowery and Van Vactor, 2009. 
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RhoA is a member of the Rho family of small GTPases, which play key roles in growth 
cone extension, retraction, arrest, turning and collapse (see figure 1.4).  The Rho family 
members RhoA, Rac and CDC42 are profoundly important regulators of the cytoskeletal 
events underlying growth cone behaviour, their activation variously leading to localised 
growth cone collapse (RhoA), and the formation and extension of lamellipodia (Rac) and 
filopodia (CDC42) (see (Fischer et al. 2004), (Jain et al. 2004), and (Scott et al. 2003) 
respectively for examples and (Koh, 2006) or (Gallo and Retourneau 2004) for review).   
Of these three Rho family members, RhoA has been the most intensively studied, its role 
in growth cone retraction and collapse making it an obvious target for therapies aimed at 
enhancing axonal regeneration, and the knockout/inhibition/silencing of both RhoA, or its 
downstream effector kinase ROCK, has formed the basis of numerous studies seeking to 
enhance CNS regeneration (examples include Fournier et al. 2003, Kreibich et al. 2004, 
Bertrand et al. 2005, 2007 and McKerracher et al. 2006). The results of such studies have 
themselves been the subject of multiple reviews (e.g. Kubo et al. 2007, Gross et al. 2007).  
The advantage of inactivating Rho family members such as RhoA, or their respective 
downstream signalling effector proteins such as ROCK, is that all signalling pathways 
converging on that protein are blocked simultaneously.  In the case of RhoA, this renders 
multiple AGIM largely impotent.         
 As the growth cone extends its filopodia and lamellipodia within the CNS, they 
encounter factors present on, and bound to, the substrate over which the axon is 
attempting to grow.   These factors can be either conducive or antagonistic to growth 
cone adhesion.  Substrate bound anti-adhesion factors such as slits, ephrins, CSPG and 
semaphorins, signalling through RhoA/ROCK, elicit localised growth cone shrinkage or 
collapse.  In this way they prevent the growth of axons towards inappropriate targets in 
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utero by forcing the growth cone to turn away – a process known as chemorepulsion.  If 
the growth cone is surrounded on all sides by such growth antagonistic factors, as occurs 
within the injured adult CNS, the growth cone collapses as described above.  Growth cone 
adhesion-permissive factors, more commonly known as cell adhesion molecules (CAMs) 
consist primarily of constituents of the extracellular matrix (ECM) such as laminin, 
fibronectin and collagen, members of the Ig (immunoglobulin) superfamily (IgSF) of 
CAMs), and the Cadherins.          
 ECM constituents include laminins, collagens and fibronectins, each of which 
activates specific members of the Integrin receptor family present on the surface of 
lamellipodia and filopodia.  Integrin receptors are heterodimers formed of one α and one 
β subunit.  There are numerous subtypes of both, and ligand selectivity is determined by 
the extracellular binding site formed by the specific combination of particular α and β 
subunits (Lemons and Condic 2007, Hynes 2002).  RGC are known to express α1β1 and 
α1β2 integrins which function as receptors for laminin-1 and laminin-2 (merosin) (Cohen 
and Johnson, 1991).  Increased expression of integrins containing the β-1 subunit is 
associated with increased RGC neurite outgrowth (Lilienabum et al 1995, Clegg et al 2000) 
and survival (Leu et al. 2004).  Increased integrin expression has also been linked to both 
in vitro and in vivo regeneration of many neuronal phenotypes, from sensory neurons to 
Dorsal Root Ganglion Neurons (DRGN) (Lemons and Condic, 2007), whereas decreased 
integrin activation correlates with reduced regenerative potential in CNS neurons (Ivins et 
al 2000).            
 The IgSF of CAMS includes Neural Cell Adhesion Molecule (NCAM)/CD56, L1 and 
TAG-1.  Many of these proteins bind homophilically, forming attachments primarily with 
copies of themselves, whereas others bind to members of the aforementioned integrin 
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receptor family or to other IgSF CAMs (Maness and Scachner, 2007, Sakisaka and Takai, 
2005).  RGC are known to express L1 and TAG-1 (Jung et al 1997, Klöcker et al 2001), and 
NCAM (Murphy et al 2007a, b, 2009)  RGC axonal regeneration after ON transection has 
been reported to be drastically reduced in NCAM deficient mice, and NCAM expression 
has been strongly linked to RGC survival following axotomy (Murphy et al 2007b, 2009). 
Both L1 and NCAM can promote adhesion and neurite outgrowth through interactions 
with integrin receptors, but can also signal through through the semaphorin receptor 
neuropilin-1 for growth cone collapse (Maness and Schachner, 2007).  TAG-1 is reportedly 
downregulated post axotomy by CNS but not PNS axons and is upregulated in RGC axons 
following the addition of extraneous BDNF (Klöcker et al 2001), and studies in goldfish 
(Lang et al. 2001) and zebrafish (Wolman et al. 2008) have provided evidence that TAG-1 
plays an important role in growth cone guidance, growth and even correct retinotopic 
reconnection in the tectum (the structure analgous to the superior and inferior colliculi in 
lower vertebrates).          
 Cadherins are calcium dependent CAMs which primarily function to bind cells 
together.  The predominant neuronal cadherin is N-cadherin, which is which is known to 
be upregulated in regenerating zebrafish RGC (Liu et al. 2002), to increase in vitro survival 
of cultured RGC by signalling through the FGF receptor (Skaper et al. 2004), and to 
promote axonal regeneration in the embryonic spinal cord (Blackmore and Letourneau, 
2006, Skaper, 2005).  Cadherins, like many of the other CAMs described above, interact 
homophilically, meaning that filopodial and lamellipodial CAMs form homodimers with 
other CAMs present on adjacent cells, allowing axons to ‘piggyback’ across other  
cells/processes (Sakisaka and Takai, 2005).        
 Each of these CAMs then forms complexes with intra-filopodial and intra-
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lamellipodial actin bundles, anchoring the growth cone to the external surface (Lowery 
and Van Vactor, 2009).  The initial effect of this is an immediate attenuation of local actin 
depolymerisation, enhancing the rate at which the filopodium or lamellipodium is 
elongated.  With the growth cone now firmly attached to the underlying substrate, 
filopidal and lamellipodial extension continues distal to the attachment site, and the 
entire growth cone is gradually pulled forward by contractile actomyosin bundles, which 
connect the fixed substrate-receptor-F-actin complexes to F-actin arcs and microtubules 
(Lowery and Van Vactor 2009).  This growth is consolidated by subsequent microtubule 
stabilisation, and the rearmost portion of the growth cone narrows, and the microtubules 
within are compressed by F-actin arcs, forming another segment of axon shaft.  Once this 
is complete, the entire process can begin again, allowing the growth cone to crawl 
forwards incrementally, leaving consolidated axon-shaft behind and gradually elongating 
the axon.  In the absence of such adhesion molecules growth cone advance is impossible.  
It is worth noting that in addition to their other growth inhibitory effects, CSPG also bind 
laminin and neuronal cell adhesion molecule (N-CAM) (Prag et al. 2001), obstructing their 
ability to facilitate axonal growth.  In this way AGIM in the injured adult CNS prevent 
axonal regeneration by causing growth cone collapse through RhoA/ROCK signalling, and 
the lack of permissive growth-substrate molecules inhibits any regeneration which does 
occur.             
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1.2.3  Surviving neurons fail to switch to an active growth state 
After axotomy the segment of the axon still attached to the neuron retracts from the 
injury site, the resulting slight shrinkage allowing the plasma membrane to seal the newly 
created gap (Spira et al. 1996), whereas the distal axon, disconnected from the soma, 
gradually degrades, a process termed ‘Wallerian degeneration’.  At this point most 
axotomised PNS neurons, such as dorsal root ganglia (DRG), tend to readily form growth 
cones, whereas CNS neurons, such as Retinal Ganglion Cells (RGC) sometimes do not 
(Verma et al., 2005).  Most CNS neurons do form growth cones and enter a relatively well 
characterized phase of attempted outgrowth for between 1 and 3 days post injury.  If CNS 
axons have not begun to regenerate by this timepoint, the vast majority become 
quiescent - a process termed ‘abortive regeneration’ (Berry et al. 1996, 2008).  It is shortly 
after this abortion of regeneration that many CNS neurons begin to die (Berry et al. 2008).  
The initial failure of some CNS neurons to even form a growth cone has been interpreted 
as indicating the differential regenerative responses inherent to CNS and PNS neurons 
(Gumy et al. 2010), particularly as the PNS contains the full complement of AGIM found 
within the CNS (Berry et al. 2008) and yet exhibits spontaneous and often successful 
regeneration.           
 The concept of inherent differential responses between CNS and non-CNS neurons 
has important connotations, making it apparent that, in addition to neuronal death and 
the innate inhospitability of the injured adult CNS, the internal growth state of the neuron 
is equally critical in promoting and maintaining  axonal regeneration.  Many studies have 
shown that while certain therapies can result in the majority of a CNS neuronal 
population successfully staving off cell-death, only a tiny proportion of these will typically 
 24 
 
regenerate their axons, and that conversely, certain factors can stimulate axonal 
regeneration whilst having no effect on survival (Cui et al. 1999, Cho et al. 1999, Li et al. 
2009, Pernet and Dipollo, 2003).  This suggests that in addition to keeping neurons alive, 
an active-growth program, such as is present in utero, must also be initiated in order for 
CNS axons to actively regenerate.  Further support for this hypothesis comes from studies 
showing that embryonic, prenatal and even immediately postnatal mammalian CNS 
neurons exhibit considerable regenerative capability, which declines sharply and 
disappears completely by the first few days postnatal (Goldberg et al. 2004).   At least one 
of the events underlying this change was elucidated following the triple discovery that at 
least two molecules present in the CNS switch from being axon-growth promoting in the 
embryo to being strongly growth antagonistic immediately postnatally, that this shift is 
mediated by intracellular cAMP levels, and that these intracellular cAMP levels rapidly 
decline in postnatal neurons.  Both netrin-1 (Shewan et al. 2002) and MAG (Cai et al. 
2001) function chiefly as chemoattractants in the developing CNS but by the first week 
postnatal (in the rat) both are strongly chemorepellent and if present in sufficient 
quantities can lead to growth cone collapse.  This switch from growth promotion to 
growth antagonism has been shown to be in response to cAMP levels falling below a 
certain critical threshold concentration (Shewan et al. 2000, Cai et al. 2001) and coincides 
closely with the fall in postnatal intraneuronal cAMP levels and concomitant loss of 
regenerative capacity (Filbin 2003).  In addition to rendering netrin-1 and MAG growth 
promoting, elevated levels of cAMP, signalling through the cAMP response binding 
element binding protein (CREB) can lead to increased expression of NTF receptors and the 
transcription of several genes related to growth and survival (Gao et al. 2004) (see Figure 
1.2).  Such an active growth state is likely to be characterised by other intra-neuronal/ -
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axonal changes which recapitulate to a certain extent the intracellular environment in the 
embryonic neuron.  These include the increased expression of growth permitting genes, 
such as those encoding the growth associated protein GAP-43 (expressed by regenerating 
but not non-regenerating RGC (Berry et al. 1996, Lorber et al. 2008, Fischer et al. 2004b)), 
the closely related CAP-23 (Bomze et al. 2001), the cytoskeletal associated protein SPRR-
1A (Bonilla et al. 2002) and many of the genes activated by the ERK/MAPK pathway, 
including genes responsible for activating protein synthesis and increased cytoskeletal 
reorganisation/growth (Rossi et al. 2007).  There is also evidence to suggest that 
upregulation of protein synthesis is another prerequisite for axonal regeneration both 
within the axon and within the growth cone itself (Chierzi and Fawcett 2001); inactivation 
of PTEN, a negative regulator of the protein synthesis controlling protein mTOR promotes 
significant axonal regeneration in the ON (Park et al. 2008), whereas the application of 
protein synthesis inhibitors prevent the elongation of severed segments of peripheral 
nerve in vitro (Gaete et al. 1998).          
 It is then apparent that for CNS neurons to switch from quiescence to an active 
growth phenotype requires a) the upregulation of growth promoting genes, b) increased 
intraneuronal cAMP levels and c) increased intra-neuronal and intra-axonal protein 
synthesis, and that the failure to instigate these changes plays a large part in abortive 
axonal regeneration in the adult CNS. 
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1.2.4. The injured CNS is further damaged by inflammatory and immune 
  cells 
 
The inflammatory and immune responses which follow tissue damage are critical to 
survival; clearing the injury site of pathogens and foreign bodies and killing damaged or 
infected cells before they can become cancerous or further spread infection.  
Unfortunately these actions tend to exacerbate CNS injury, damaging axons and killing 
neurons, which are not replaced, as well as secreting factors inhibitory to axonal 
regeneration.  The primary instigators of the inflammatory and immune responses are the 
only immune cells normally present in the CNS, the microglia.  Microglia reside in the CNS, 
interspersed with astrocytes and oligodendrocytes, and are constantly extending 
processes into their surrounding area, probing for pathogens.  CNS injury and the influx of 
foreign bodies and pathogens activate resident microglia, and this microglial activation is 
largely responsible for initiating and maintaining the immune response to CNS injury (see 
Garden and Moller 2006 for review).       
 The majority of subsequent microglia mediated influenced events are antagonistic 
to neuronal survival and axonal regeneration.  Within minutes of CNS injury the pro-
inflammatory cytokines IL-1, IL-6 and TNF-α are released by microglia (Allan and Rothwell 
2001) in response to raised ATP levels (Tanaka and Koike 2002, Inoue 2006).  These 
cytokines (cytokines are hormone-like factors which communicate with other cells, 
usually immune/inflammatory cells, often causing them to migrate) trigger widespread 
microglial activation away from the immediate injury site and cause upregulation of cell 
adhesion factors on nearby endothelial cells, allowing lymphocytes to “roll” along the 
endothelium of blood vessels and enter the compromised CNS area (Dinarello 1994).  
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Activated microglia, along with macrophages, also release IL-8, which summons 
neutrophils into the injury site (Knall et al. 1996).  Microglia, macrophages, neutrophils 
then cooperatively express and/or release numerous molecules which exacerbate CNS 
injury. These include the highly destructive reactive oxygen species’ peroxynitrite   
(OONO-), superoxide (O2
-) and nitric oxide (NO) all of which irreversibly damage lipids, 
proteins, DNA and organelles, killing bacteria and host cells alike (Profyris et al. 2004), 
excitotoxic neurotransmitters such as glutatmate which trigger neuronal apoptosis 
(Sattler and Tymianski 2001) and the cyclooxygenases, enzymes which convert free 
arachidonic acid to various prostanoids such as prostaglandins and prostacyclins which 
amplify inflammation (Lucas et al. 2006) and cause vasodilatation, which can lead to 
harmful local microhaemorrhages (Profyris et al. 2004).  Perhaps more harmful than any 
of these processes is the auto-immune actions of the aforementioned lymphocytes in the 
injured CNS.   The presence of endogenous self-reactive lymphocytes (i.e. responsive to 
self-antigens, not reactive to other lymphocytes) is at first surprising but at least one 
study has suggested that such auto-immunity is necessary in some way to “calibrate” 
naive cells (Stefanova et al. 2002).  These cells include sub-populations which will 
recognise myelin basic protein (MBP) as foreign (Ankeny and Popovich 2009).  These self-
recognising lymphocytes are normally kept in check by regulatory T-cells (Ankeny and 
Popovich 2009) and by the fact that an intact BBB prevents lymphocyte contact with 
MBP.  After CNS injury the BBB is compromised, allowing these anti-MBP lymphocytes to 
“see” large quantities of MBP for the first time.  The result, following the largely 
microglia-mediatedmediated, cytokine induced lymphocyte recruitment into the injured 
CNS described above, is a swathe of secondary damage to myelinated axons (Popovich et 
al. 1997) and oligodendrocytes (Crowe et al. 1997), which results in the demyelination of 
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previously viable axons and substantial neuronal and oligodendrocytic cell death. 
 Complicating the picture somewhat is the evidence that the inflammatory and 
immune responses can have neuroprotective effects.  Activated microglia are known to 
secrete various neurotrophic and gliotrophic proteins including NGF, BDNF, NT-3, and 
GDNF (Garden and Moller 2006, Presta et al. 1995, Elkabes et al. 1996 and Honda et al. 
1999) which support neuronal and glial survival, whereas several studies using the ONC 
model have shown that macrophage influx, induced by lens injury or zymosan injection, 
yields significantly increased post-injury RGC survival and axonal regeneration (Ahmed et 
al. 2010, Lorber et al. 2005, 2009), a process directly attributed to the release of the 
protein oncomodulin by macrophages (Benowitz and Yin 2006, Yin et al. 2006, but see 
Muller et al. 2007 and Cui et al. 2009).         
 Despite these potentially benevolent actions, inflammatory and immune 
responses make up a large part of the series of secondary insults which compound CNS 
injury and further hinder axonal regeneration.   
 
1.2.5  A regeneration-antagonistic glial scar develops at the injury site  
From around 4-5 days post injury, reactive CNS astrocytes and invading meningeal 
fibroblasts begin the formation of a scar in and around the lesion site (Berry et al. 1999a).  
This scar serves to ‘wall off’ the injured CNS areas from their surrounds, and this process, 
which takes place in all mammals as well as in many lower vertebrates, almost certainly 
evolved as a barrier to infection (Tanaka and Ferretti, 2010).  The glial scar is composed of 
extracellular matrix (ECM) components such as collagen, laminin, fibronectin and 
chondrotin sulphate proteoglycans (CSPG) as well as living astrocytes and fibroblasts 
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(Berry et al. 1999a, 2008) and is normally functionally complete by 10-14 days after most 
CNS injuries, although in some CNS tissues the scar may continue to mature and contract 
for months.  Regenerating axons were often observed to halt at the boundary of the glial 
scar and to proceed no further, and it was assumed that the scar presented an 
impassable barrier to axons, physically preventing their progress.  Instead it has been 
shown that the axon growth inhibitory properties of the scar are in fact caused by the 
large amounts of AGIM present within and around the scar, including semaphorins, 
ephrins and CSPG (see Sandvig et al. 2004 and Berry et al. 2008 for review), and not due 
to any physical barrier effect.  Evidence for this includes the observation that 
regenerating RGC axons will successfully dissolve the scar as they progress through it via 
the production and secretion of matrix metalloproteases (MMPs) (Ahmed et al. 2005), 
that axons will display arrested growth at the boundary of the lesion site even in the 
absence of the glial scar (Berry et al. 2008, Sandvig et al. 2004) and that various lower 
vertebrates exhibit robust axonal regeneration through the fully formed glial scar, 
resulting in functional recovery (Tanaka and Ferretti, 2010).  Crucially, robust axonal 
regeneration appears to prevent formation of the glial scar at all (Berry et al., 1996, 
1999b, Logan et al. 2006), and axonal regeneration through the glial scar leads to its 
dissolution (Ahmed et al. 2005).        
 Accordingly, axon regeneration either pre or post scarring does not appear to be 
impeded by the scar itself, providing the influences of AGIM throughout the CNS can be 
overcome e.g. by direct or indirect combinatorial NTF application (Logan et al. 2006, Berry 
et al. 1996, 1999b respectively), thus the actual growth inhibitory actions of the glial scar 
is largely a further example of the importance of overcoming the AGIM in the CNS. 
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1.3  Current CNS axon regenerative therapies 
It is apparent then that any therapy hoping to elicit function CNS regeneration must 
simultaneously prevent neuronal loss by inhibiting necrosis and apoptosis, switch neurons 
and axons into an active growth state, overcome the growth-cone collapsing effects of 
AGIM and provide the growth cone with factors encouraging its adhesion and advance.  
This fact is reinforced by the absence of regeneration in response to the  inactivation of  
individual AGIM, AGIM receptors or even the downstream signalling molecules RhoA or 
ROCK (Fischer et al. 2004a,b, Benowitz and Yin, 2007), and the inefficacy of the 
application of most single NTFs (Logan et al. 2006, Benowitz and Yin, 2007).  To this end 
many, but not all, current therapies are combinatorial, seeking to simultaneously drive 
axonal growth, neutralise/limit the effectiveness of AGIM and maintain neuronal survival, 
often through multiple sub-therapies, each aimed at achieving one or more of these sub-
goals.              
 Thanks to the generally benign influence of NTFs on neuronal survival, growth-
state and growth cone advancement, many such combinatorial therapies revolve around 
multiple-NTF application, often in combination with other sub-therapies.  The application 
of multiple NTF has been shown to enhance neuronal survival whilst encouraging active 
growth (Logan et al. 2006, Ahmed et al. 2006a) and can even enhance the axons’ ability to 
ignore AGIM by initiating regulated intramembraneous proteolysis (RIP) of its sometime-
coreceptor p75NTR, rendering many NgR unable to signal, and effectively blinding the axon 
to a swathe of AGIM (Ahmed et al. 2006a, b).  More commonly, exogenous NTF therapy is 
combined with some means of combating the effects of AGIM, including neutralisation of 
AGIM e.g. by degrading CSPG with the enzyme Chondroitinase (Chi, 2010, Tom et al. 
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2009) or by blockading RhoA/ROCK signalling (Fischer et al. 2004a, b, Ahmed et al. 2009).  
One problem associated with exogenous NTF application is the formation of a 
neurotrophic ‘sink’ when NTF are applied to the lesion site.  This is an area of highly 
concentrated NTF into which axons will readily regenerate (growing ‘up’ an NTF 
chemotropic gradient which mimics in utero axonal pathfinding), but from which they 
subsequently do not exit.  To overcome this, many NTF based therapies involve either 
delivering NTF to the neuronal cell body (Logan et al. 2006) or, increasingly commonly, 
delivering the genes encoding NTF to either the cell body or to the lesion site (Berry et al. 
2001, Gonzalez et al. 2009) where the genes are retrogradely transported to the neuronal 
cell body enclosed within a plasmid or viral construct.  Studies have also combined one or 
more of the above therapies with anti-apoptotic sub-therapies such as forced over-
expression of mitochondrial anti-apoptotic Bcl-2 family members such as Bcl -2 itself 
(Goldberg et al. 2002b), and agents that elevate and maintain intraneuronal cAMP levels 
(Nikulina et al. 2004), provoking significant axonal regeneration in various models of CNS 
injury (see Hanilla and Filbin 2008 for review).       
 It should be noted that several types of therapy shown to yield significant axonal 
regeneration and/or neuronal survival are not combinatorial, although closer inspection 
of their mechanisms of action almost always reveal multiple contemporaneous effects 
which could be considered combinatorial.  These include the two therapies which 
arguably promote among the most robust and successful CNS axonal regeneration; 
intravitreal (ivit) peripheral nerve (PN) grafts and macrophage recruitment by lens 
injury/ivit zymosan injection.  Surgical insertion of a section of living sciatic nerve into the 
vitreous immediately prior to optic nerve crush (ONC) has been shown repeatedly to 
significantly prolong the lifespan of RGC post-axotomy and to promote significant levels 
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of axonal regeneration: up to 10% of the total RGC population have been reported to 
regenerate up to 3-4 mm in the adult (Berry et al. 1996), with greatly increased neuronal 
survival and axonal regeneration lasting up to around 20-30 days post injury.  This 
significantly enhanced RGC survival and robust regeneration has been attributed to 
multiple-NTF secretion by Schwann cells within the PN graft (Berry et al. 1996, 2008).  
Lens injury and/or ivit injection of the yeast extract zymosan has also been shown to lead 
to significant RGC survival and regeneration after ONC (Leon et al., 2000, Fischer et al., 
2001, Yin et al., 2003, Lorber et al., 2005), a process which has now been identified as 
requiring the macrophage derived factor oncomodulin and the sugar mannose (Yin et al. 
2003, 2006, Benowitz and Yin, 2007).  It is also worth noting that the authors of the 
lattermost study suggest that this macrophage derived effect may also partially underlie 
the beneficial effects on ivit PN grafts.        
 
1.4  The discovery of EGFRki mediated RGC axonal regeneration 
The partial success of these various CNS regenerative studies demonstrates that, in order 
to promote extensive axonal regeneration, any putative CNS regenerative therapy must 
combat several, if not all, of the phenomena responsible for CNS regenerative failure 
discussed above.  In apparent contradiction of this, a recent study found that the 
Epidermal Growth Factor Receptor kinase inhibitors (EGFRki) PD168393 and AG1478 
promoted neurite outgrowth on CNS myelin substrates, in the absence of exogenous 
neurotrophic support, and provoked considerable in vivo regeneration of RGC axons in 
the mouse optic nerve (Koprivica et al. 2005).   For a single, known, exogenously applied 
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factor to elicit significant in vivo axonal regeneration was completely unprecedented.  
This study went on to show that EGFRki elicited neurite outgrowth on CNS myelin, two 
myelin derivatives, Nogo-66 and MAG, and CSPG.  The authors suggested that NgR ligands 
such as Nogo-66 and MAG elicited EGFR activation in a calcium dependent manner, 
although neither the NgR ligands nor NgR itself were seen to interact directly with EGFR.  
 From this it was surmised by the authors that a Ca2+ influx caused by NgR-p75NTR 
activation trans-phosphorylates the tyrosine kinase domains of the EGFR, which then 
activates Rho-activated kinase (ROCK) mediated cytoskeletal collapse via as yet unknown 
signalling intermediaries.  It was hypothesised that EGFRki thus exert their CNS axon 
regenerative effects via the blockade of EGFR phosphorylation, thereby inactivating the 
putative signalling pathways downstream from the NgR which ultimately result in 
cytoskeletal rearrangement and growth cone collapse via interactions with Rho-A 
(Koprivica et al. 2005, Erschbamer et al. 2007).       
 The authors speculated that EGFR-transactivation by other, as yet unidentified, 
signalling partners may explain why EGFR ligand binding and subsequent EGFR activation 
(e.g. in response to EGF) does not result in axonal growth inhibition.  Other data showed 
that while Nogo-66-elicited EGFR activation could be blocked with calcium chelators. EGF-
mediated EGFR activation could not, suggesting distinct and separate signalling pathways 
for different EGFR activating events.  Several subsequent studies have also investigated 
this unexpected axogenic effect of EGFRki, lending evidence to the idea that EGFR 
activation plays a crucial role in the inhibitory signalling cascade.  Western blot analysis of 
retinal lysates from rats with regenerating ON shows a significant reduction in pEGFR 
levels compared with animals from a non regenerating group (Ahmed et al. 2006), EGFRki 
were shown to disinhibit CGN neurite outgrowth on CSPG and various myelin derived 
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inhibitory proteins (Schachtrup et al. 2007) and intra-lesion site application of EGFRki led 
to significant recovery of rat locomotor function following spinal cord injury (SCI) 
(Erschbamer et al. 2007). 
 
1.5  Investigating EGFR and EGFRki in the visual system 
 Being that the epidermal growth factor receptor (EFGR) had never before been directly 
implicated in CNS axonal growth cone collapse, or indeed in axonal signalling at all, and 
that never before had any single agent led to such significant in vivo CNS axon 
regeneration, it was decided to further investigate these phenomena.  As the original 
study was based on the ONC model which our laboratory had extensive experience of 
(Berry et al. 1996, 1999, 2001, Ahmed et al. 2006, Logan et al. 2006) it was decided to 
investigate the role of EGFR and EGFRki in the injured rat visual system, using 
regenerating (ONC+PN graft) and non regenerating (ONC) models.  
 
1.6  The visual system 
The adult mammalian visual system consists of the eyes, containing the neural retinae 
which translate incoming light signals into outgoing action potentials, and the optic 
nerves (ON) which contain the axons of the RGC which transmit these action potentials to 
the lateral geniculate nucleus (LGN) and superior colliculus (SC).  The two ON meet at the 
optic chiasm where they split into the optic tracts which then proceed on to these brain 
areas.  The axons within the mammalian ON decussate (cross over) at the optic chiasm to 
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varying degrees, in rats 95-99% of all axons decussate (Thuen et al. 2005).  The retina is a 
complex neural structure which has earned the nickname ‘mini-brain’ due to its 
exceptional level of autonomous signal integration and anatomical complexity.  The 
mammalian retina as shown in Figure 1.5, (note that all retinal figures are from/of rat 
retinae) is comprised of two types of photoreceptors, rods which are sensitive enough to 
detect a single photon but which only supply monochrome (black and white) visual 
information, and cones, which are less sensitive to light but, by existing in several 
subtypes, each of which is responsive to only specific wavelengths of light, allow colour 
vision.  These photoreceptors, the cell bodies of which make up the outer nuclear layer 
(ONL) hyperpolarize in response to appropriate levels and wavelengths of light, leading to 
hyperpolarisation of their partner bipolar cells, the primary interneuron of the retina.  
The bipolar cell in turn stimulates RGC, and if a certain signalling threshold is exceeded, 
an action potential is generated which propagates along the RGC axon to the brain.  
Horizontal and amacrine cells, whose cell bodies (along with those of bipolar cells and 
resident microglia)  make up the inner nuclear layer (INL), play complex roles in 
integrating and sorting visual information including the detection of edges and 
boundaries between objects and the detection of moving stimuli.  Müller glia extend 
longitudinally throughout the retina, extending from the fibre layer overlying the ganglion 
cell layer (GCL) down through each successive layer of the retina.  Astrocytes also reside 
in the innermost fibre layer.  The axons of RGC converge at the optic foramen where they 
pass through the optic disc and become the ON proper as they exit the eye. 
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Figure 1.5.  The layers and cells of the rat retina, stained with DAPI to show nuclei (left) 
and represented diagrammatically (right).  The cell bodies of photoreceptors, bipolar 
and amacrine cells and RGC are located in the outer nuclear layer (ONL), Inner nuclear 
layer (INL) and ganglion cell layer (GCL) respectively.  Inner and outer plexiform layers 
(IPL) and (OPL) are composed of the axons and dendrites passing between bipolar cells 
and RGC (IPL) and photoreceptors and bipolar cells (OPL).  Hyperpolarisation of 
rods/cones leads to hyperpolarisation of bipolar cells, which in turn excite RGC to 
threshold, resulting in an action potentials being sent along the RGC axons of the ON to 
the brain.  Horizontal and amacrine cells play complex roles in integrating and sorting 
visual information including the detection of edges and the detection of moving stimuli.  
Adapted from Berry et al. 2008. 
 
The ON is composed of the axons of RGC, and is populated by the full complement of CNS 
glia, including the axon-myelinating oligodendrocytes, astrocytes, microglia and 
synantocytes (Figure1.6) (Berry et al. 2008). 
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Figure 1.6.  Simplified schematic representation of the uninjured optic nerve.  RGC axons (blue) are 
interspersed between orderly lines of oligodendrocytes (pink) and the intermittently spaced 
astrocytes (yellow-ochre), microglia (black) and synantocytes (green).  For clarity most of the cellular 
processes are not shown, but the examples illustrated demonstrate the pattern of interconnection 
exhibited by each glial type.  Synantocytes are included for completeness but are not studied 
elsewhere in this study, as the extant literature is very sparse, and no studies focussing on 
synantocytic EGFR or its blockade have been published. 
 
Crush or transection divides the axons of the ON into proximal segments, which are still 
attached to the RGC cell bodies in the retina, and distal segments which are not.  The 
distal segments undergo Wallerian degeneration and decay into bulbous and fragmentary 
debris.  Figure 1.7 shows axons in a healthy, uninjured ON contrasted with an ON which 
has been crushed 14 days previously. 
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1.7  The Optic Nerve Crush + Peripheral Nerve graft model 
The ONC+PN model (Berry et al. 1996) involves the crushing of the rat ON within its 
sheath, such that all RGC axons are severed approximately 2mm distal to the optic disc, 
followed by the grafting of a piece of teased but living peripheral (specifically, sciatic) 
nerve into the vitreal body of the eye, through a small incision in the eyes’ caudal surface.  
Figure 1.7.  A comparison of an uninjured (top) and 14 day post injury (bottom) ON.  
RGC axons were visualised through immunostaining for the cytoskeletal intermediate 
filament and axon marker neurofilament 200 (NF 200).  Note the proximal segments of 
ON axons on the left of the injured nerve, which are still attached to their neurons in 
the retina and the swollen, bulb like and fragmentary sections of axons in the distal 
(right hand side) segment of the injured ON.  P= Proximal segment D= Distal segment. 
* denotes centre of the lesion site.  Image is a composite of multiple x 200 
magnification pictures. 
P D 
* 
* 
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The PN is held in place by a small piece of implanted sterispan sponge ((figure 1.8), and 
see materials and methods for detailed description). 
 
 
Figure 1.8.  The ONC+PN model.  The ON is transected 2mm distal to the optic disc, 
axotomizing all RGC.  Immediately afterwards a piece of living peripheral nerve (PN) is 
implanted into the vitreous through an incision in the caudal surface of the eye.  This PN is 
held in place by a piece of sterispon sponge.  NTF secreted by Schwann cells in the PN 
graft lead to prolonged RGC survival and significant RGC axonal regeneration (Berry et al. 
1996). 
 
In animals which have received a PN graft, Schwann cell-derived NTFs promote RGC 
survival and axonal regeneration into and beyond the lesion site, whereas animals 
receiving ONC alone exhibit little to no RGC axonal regenration at all (Berry et al. 1996) as 
can be confirmed by immunohistochemical staining for growth associated protein 43 
(GAP-43), a protein which is only expressed by growing axons (figure 1.9). 
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Figure 1.9.  GAP-43 immunostaining (green) shows the regeneration of RGC axons in the    
ON in response to ivit PN graft.  Animals which received ONC alone (NRM) show little or 
no axonal regeneration beyond the crush site,whereas PN graft recipient animals (RM) 
exhibit robust axonal regeneration into and beyond the lesion site.* denotes crush site.  
NRM = non regenerating model. RM = regenerating model. 
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1.8  General Aims 
To elucidate: 
 
1) The role of EGFR in RGC regenerative failure  
 
2)  The mechanism of action by which EGFRki mediate RGC axonal regeneration 
 
 
 
1.9  Initial Hypothesis 
 
Levels of activated EGFR (pEGFR) on RGC axons within the retina and ON will be elevated 
in non regenerating RGC axons (ONC treatment group) and decreased/absent in 
regenerating RGC axons (ONC+PN graft treatment group).   
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Chapter 2  
 
Materials and Methods  
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Unless specifically stated otherwise all reagents used were purchased from Sigma-Aldrich, 
Poole, UK. 
 
2.1  In Vivo Methods 
 
2.1.1  Animals and Surgical Procedures 
 
All animal procedures were evaluated and licensed by the UK Home Office.  Adult, female 
inbred Fischer f344 rats of 200 – 250 g (Charles River) were used for Optic Nerve Crush 
(ONC) experiments.  All animal surgery was performed by Professor Martin Berry whilst I 
observed and assisted.  Animals were anaesthetized with 4% isofluorane at the beginning 
of the procedure, dropping to 2.5% prior to first incision and 2% mid way through 
procedure.  5% EMLA anaesthetic cream (Astra Zeneca, Loughborough, UK) was applied 
topically to the inside of animals’ ears prior to head immobilization with surgical head 
support.  Additionally, subcutaneous injections of Buprenorphine analgesic (0.03mg/kg) 
were administered twice on the day of procedure and twice per day for the following two 
days if deemed necessary.  To avoid corneal dehydration whilst sedated, animals’ eyes 
were lubricated with Lacri-Lube (Allegan, High Wycombe, UK). 
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2.1.1.1  Optic Nerve Crush Procedure 
 
The ON was accessed intraorbitally as described by Berry et al. (Berry et al. 1988a).  
Briefly; after a midline cutaneous incision over the skull, the skin was reflected up over 
the upper lid, exposing the orbital margin.  Following removal of the superficial fascia, a 
vertical incision was made through temporalis fascia and muscle.  This incision was 
extended rostrally over the orbital margin without damaging the supraorbital vessels.  
The supraorbital neurovascular bundle, comprising of the supraorbital nerve, vein and 
artery, were clamped and incised between the clamped sites so as to expose the 
Harderian gland.  The gland was excised from its capsule and reflected rostrally, exposing 
the superior rectus muscle.  Retractors were inserted between the medial rectus and 
superior rectus muscles to expose the ON within its dural sheath.  In order to avoid retinal 
ischaemia and subsequent retinal necrosis, care was taken not to damage the retinal 
artery which also runs inside the Dural sheath.  To this end the retractor bulbi muscle and 
dural sheath were incised, exposing the ON.  The ON was crushed with blunt forceps 
transecting all axons 2mm caudal to the lamina cribrosa whilst leaving the pia mater 
intact.  After ONC the retractor bulbi and rectus muscles and the Harderian gland were 
returned to their preoperative positions and the skin margins sutured using 4-0 Ethicon™ 
absorbable suture (Johnson and Johnson International, New Jersey, USA).  All animals 
receiving ONC were killed 14 days post injury (DPI) by CO2 narcosis.  
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2.1.1.2  Intravitreal (ivit) Peripheral Nerve (PN) implant procedure 
 
Adult, female Fischer rats were used as donors for ivit PN implants.  After ONC the sclera 
was incised over the caudal surface and the vitreous body accessed through the choroid 
and retina.  2mm sections of teased sciatic nerve were implanted through this incision 
into the vitreous and retained with a plug of absorbable gelatin foam (Sterispon, Allen 
and Hanbury, London, UK).  For efficacy of PN graft see Berry et al. 1996. 
 
2.1.1.3  Intravitreal (ivit) injection procedure 
 
All injections were performed with glass micropipettes, piercing the sclera immediately 
posterior to the corneal limbus - the border between the cornea and the sclera. 
  
2.1.2  Tissue block preparation and sectioning 
 
Rats were killed by CO2 narcosis and tissue was lightly fixed in situ by cardiac perfusion 
with 4% paraformaldehyde (TAAB Laboratories, Berkshire, UK).  Following excision, ON 
and eye tissue was cryoprotected by immersion in increasing sucrose gradients (10%, 
20%, 30% in PBS) until tissue was observed to sink, before embedding in OCT mounting 
medium (R.A. Lamb Laboratory supplies, Eastborne, UK), and frozen rapidly using dry ice.  
Blocked tissue was stored at -800 C.  Parasaggital retinal sections and longitudinal ON 
sections were cut at a thickness of 15 µm using a Bright 5030 Cryostat (Bright, 
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Cambridgeshire, England), mounted onto charged slides (Surgipath, Peterborough, 
England) and stored at - 200C.   
 
2.1.3  Collagen Matrices 
 
Collagen matrices are 3-dimensional net like structures, created by the polymerisation of 
liquid collagen, which can act as growth substrates for cells and cellular processes.  
Collagen matrices have been implanted into injury sites where they encourage healing by 
providing a permissive growth substrate, and more recently, they have been used to 
deliver genes, proteins and pharmacological agents.  This is achieved by either 
impregnating the matrix with mRNA, proteins or drugs, or by having the matrix contain 
replication deficient viral particles containing the genes for desired proteins.  The net 
result is a scaffold like structure that is conducive to cellular and cellular process invasion, 
which can provide an immobilised repository of drugs, proteins, mRNA, DNA, or vectors, 
allowing uptake only by structures invading the matrix.  This both minimises 
inappropriate uptake of materials by cells or structures outside the implant and allows a 
long term, slow release of any drug or protein without the normal problems of diffusion 
and active clearance. 
 
2.1.4  Specific protocol for creation of collagen matrices  
 
All reagents were kept on ice throughout.  28µl of Na2HPO4 were added to 1 ml of 
3mg/ml bovine type II collagen (NutaCon, Leimuiden, Netherlands), mixed well and 
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allowed to stand (on ice) for 5 min.  140µl of collagen were added to 200µl PBS or PBS 
containing pharmacological agent and mixed well.  For each matrix required, 17µl of this 
solution were pipetted into the very bottom of a 0.5ml tube, with care taken not to form 
bubbles.  Tubes were placed, uncapped, into foam tube racks, which were placed into a 
sterile bag, which was in turn placed into a glass freezedrying jar.  The jar was placed in -
80°C freezer for a minimum of 2 hours.  After this time the jar was taken from -80°C 
freezer, placed immediately onto a bed of dry ice, and connected to a lyophilizer.  The jar 
was left overnight (~ 16 hours) and tubes, once removed, were immediate capped and 
placed into -80°C freezer. 
 
2.1.5  Collagen matrix implantation 
 
The ON was accessed intraorbitally as described previously.  After making a careful 
incision into the superior aspect of the dural sheath the ON was transected within the 
sheath.  The sheath was kept intact to ensure the matrix remained in place.  The dry 
collagen matrix was then placed into the space between the cut ends of the nerve.  As the 
matrix absorbed moisture from the wound it swelled, filling the potential space such that 
it was in direct contact with both ends of the transected nerve.  Care was taken to ensure 
the matrix was conveyed directly from sealed tube to the nerve, so as to both maintain 
sterility and to minimize pre-implantation swelling. 
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2.2  In Vitro methods 
 
2.2.1  Retinal dissection and cell culture 
 
Adult male Sprague Dawley rats (200-300g) were killed by CO2 narcosis followed by 
cervical dislocation.  Both eyes were removed and placed in ice cold, sterile, phosphate 
buffered saline (PBS; Gibco, Paisley, UK).  Retinae were removed from eyes under sterile 
conditions and dissociated with a Papain Dissociation System kit (Worthington Biolabs, 
New Jersey, USA).  This kit included the following reagents: Earle’s Balanced Salt Solution 
(EBSS) - which also contained phenol red and bicarbonate, papain, Deoxyribonuclease 
(DNAse), and albumin ovomucoid inhibitor.  Retinae were dissociated for 90 minutes 
(min) in 5ml of EBSS containing 20 units/ml papain and 100 units/ml DNAse 1, at 37°C 
within a humidified incubator at 95% air   5% CO2.  Before incubation, retinae were 
minced slightly in the above solution using ultra-fine surgical scissors in order to increase 
surface area and aid dissociation.  After 90 min, retinae were triturated in a 10 ml pipette 
to break up any remaining tissue fragments, and the mixture centrifuged at 300 g for 5 
min at room temperature (rt).  The supernatant was discarded and the pellet 
resuspended in EBSS containing 1mg/ml ovomucoid inhibitor, 1 mg/ml albumin and 100 
units/ml DNAse 1.  This cell suspension was then carefully layered on top of 2.5 ml of 
albumin ovomucoid inhibitor, with care taken to create and maintain two separate layers, 
and the resulting double layered solution centrifuged at RT for 6 min at 70g.  Albumin 
ovomucoid inhibitor served as a density gradient; intact cells, being larger and heavier 
than cellular and extracellular matrix debris, experienced greater centrifugal forces, 
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resulting in cells being forced through the viscous lower layer whilst smaller debris 
remained above or within the albumin ovomucoid inhibitor.  The resulting pellet was thus 
almost entirely composed of intact cells and largely debris-free.  The supernatant was 
discarded and the cellular pellet resuspended in 1 ml of supplemented Neurobasal A 
(sNBA; for 25ml, 24.2 ml Neurobasal-A, 500μl B27 supplement, 62.5 μl 200mM L-
Glutamine, 125 μl Gentimycin – all from Gibco). 
 
2.2.2  Retinal culture, cell counts and plating 
 
Of the final 1ml cell suspension in sNBA (see above), 25μl was added to 25 μl Trypan Blue 
dye (Gibco), mixed, and 25μl of this mixture injected into one side of a haemocytometer.  
The number of cells observed (using a light microscope at x 40 magnification) to be within 
the 25 small divisions in the centre of the haemocytometer were counted and this 
number doubled (to account for x 2 dilution in cell number due to addition of Trypan 
Blue) and this number multiplied by 1 x 104 to yield the total number of cells in the 1ml 
cell suspension.  Cells were plated onto chamber slides (BD Biosciences,) pre coated with 
poly-D-Lysine (100μg/ml) and Laminin (10μg/ml) at 125,000 per well, in 300μl sNBA.  As 
retinal ganglion cells (RGC) account for 1-3% of all cells in the rat retina, 125,000 cells per 
well equated to approximately 1500 RGC per well.  Cells were allowed 24h to attach to 
the well floor and test reagents were added to the wells after this time.  Unless stated 
otherwise, all cultures were maintained for 72h in the above incubatory conditions before 
being fixed and processed further. 
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2.2.3  Immunohistochemistry and Immunocytochemistry 
 
The mammalian adaptive immune system has the ability to raise antibodies to almost any 
molecule or antigen (ANTIbody GENerator).  When a laboratory animal such as a rabbit is 
co-injected with an adjuvant (a chemical designed to elicit an immune response) and a 
specific protein, the immune system manufactures antibodies specific to this protein.  If a 
B cell responsible for generating this antibody is subsequently isolated and successfully 
hybridized with an immortalized cell, a mono-clonal antibody can be repeatedly collected 
and purified.  This antibody will recognize a single epitope on the target molecule (almost 
always a protein).  When a mixture of antibodies is taken and purified from the host 
animals’ serum, the result is a poly-clonal antibody; a variety of antibodies to different 
epitopes on the same protein.  
Using these antibodies, thin sections of tissue (immunohistochemistry, IHC) or 
cells in culture (immunocytochemistry, ICC) can be probed for the protein of interest.  
This is achieved by coating the tissue/cells in a solution containing these antibodies, 
which then recognize and bind specifically to the target proteins.  In order to prevent 
these antibodies binding aberrantly and non-specifically to other proteins, a blocking 
agent is used immediately before antibody application, typically consisting of a solution 
containing non-specific proteins such as BSA.  The proteins in solution will bind weakly to 
all proteins in the tissue/cell sample and will only be outcompeted by the primary 
antibody at their specific epitope.  In this way, the antibody will bind strongly only to its 
target allowing subsequent washes with relevant buffer to remove all non-bound protein.  
As a result visualization of the remaining antibody specifically labels only the protein of 
interest.  To this end, some antibodies are conjugated to either fluorescent, enzymatic or 
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radioactive compounds which allow for direct or indirect visualization.  More commonly, 
antibodies raised against the first (primary) antibody are themselves conjugated as above.  
These secondary antibodies are raised against the species specific, conserved region of all 
antibodies, such that a secondary antibody raised against an animal will recognize all 
antibodies created by that species, regardless of the primary antibody’s’ target.  
 
Antibodies used in this study are shown below in Table 2.1. 
Epitope Manufacturer 
Catalogue 
No. Species 
Initial  
Conc. 
Dilution  
Factor Marker For 
 
CAII UCL n/a Rabbit 21mg/ml 1 : 400 
 Oligo- 
Dendrocytes 
OX-42 Serotech MCA 275R  Mouse n/a (ascites) 1 : 200 Microglia 
CD-68 Serotech MCA 341 R Mouse n/a (ascites) 1 : 200 Macrophage 
GAP-43 n/a n/a Sheep n/a (ascites) 1 : 2500 
Regen- 
erating 
Axons 
EGFR – 
Phosphorylated ABCAM Ab5652 Rabbit 
0.125 
mg/ml 1:200 pEGFR 
EGFR - 
Phosphorylated Santa Cruz  SC-12351 Goat 200µg/ml 1 : 50 
 Activated 
EGFR 
Β-III-Tubulin Sigma T8660 Mouse n/a (ascites) 1 : 400 
Retinal 
Ganglion  
Cells 
Neurofilament 
200 (Heavy 
Chain) Sigma N0142 Mouse n/a (ascites) 1 : 400  Axons 
Glial Fibrilliary 
Acidic Protein 
(GFAP) Sigma G3893 Mouse n/a (ascites) 1 : 500 
 Astrocytes, 
Müller Cells 
Goat Ig - 
tagged with 
Alexa Fluor 488 
Molecular 
Probes A11055 Donkey 2mg/ml 1 : 500 Goat Ig 
Rabbit Ig - 
tagged with 
Alexa Fluor 488 
Molecular 
Probes A11034 Goat 2mg/ml 1 : 500 Rabbit Ig 
Mouse Ig -
tagged with 
Alexa Fluor 594 
Molecular 
Probes A11032 Goat 2mg/ml 1 : 500 
 
Mouse Ig 
Rabbit Ig -
tagged with 
Alexa Fluor 594 
Molecular 
Probes A11037 Goat 2mg/ml 1 : 500 Rabbit Ig 
 
Table 2.1.  Antibodies used in immunohistochemical and immunocytochemical analyses. 
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2.2.3.1  Immunofluorescence 
 
 
Antibodies can be linked to a variety of functional groups designed to aid their 
visualization, including enzymes, radioisotopes and fluorophores.  Of these, flurophore-
linked antibodies are arguably the most common.  Fluorophores are molecules which 
absorb light of a specific wavelength and emit light of a specific, longer wavelength.  
Fluorescence microscopes differ from conventional light microscopes only in that they 
have two sets of special light filters.  The first set filters the light projected onto the 
sample, ensuring that only light of the wavelength absorbed by the fluorophore reaches 
it.  The second set of filters ensures only light of the wavelength emitted by the 
fluorophore reaches the eyepiece and camera.  As a result, fluorescent labelled 
antibodies can provide very accurate, high resolution protein imagery. 
 
2.2.3.2  Primary IHC protocol for immunofluorescence 
 
Sections were warmed to RT, fixed in 100% ethanol for 1 min, and washed in tris buffered 
saline (TBS, 50ml 1M Tris pH’d to 7.4 with HCl, 30 ml 5M NaCl in 1 L H2o), 2 x 5 min 
followed by 1 x 10 min wash in TBS with 0.1% Triton - X – 100 to permeate the tissue.  
Sections were isolated using a hydrophobic pap-pen (Vector Labs, Peterborough, UK).  
Blocking solution/Antibody Diluting Buffer (ADB); (1% Bovine Serum Albumin,  0.1% Triton 
- X – 100, 5% (various) Serum in TBS) were applied at 95µl per section and slides were 
incubated at RT in an enclosed metal chamber for 30 min.  Sections were incubated 
overnight (16 h) at 40C in ADB containing relevant antibody dilutions within a humidified 
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metal chamber.  Following 5 x TBS washes, Secondary antibody solutions were added at 
95µl per section and slides were incubated at RT in a humidified metal chamber for 60 
min.  Secondary antibody solutions were removed and sections underwent 3 x 5 min TBS 
washes.  Sections were drained of excess TBS and mounted with Vectamount containing 
DAPI (Vector Labs).  Sections were stored at 40C in cardboard slide containers wrapped 
with aluminium foil. 
 
2.2.3.3 Protocol for immunofluorescence IHC using anti-GAP-43 antibody 
 
All washes and blocking steps were carried out in plastic 14ml 5-slide-containers.  Slide-
containers were rocked within larger cylindrical containers, padded with tissue paper on a 
motorized roller.  Sections were washed and rocked for 5 min in TBS, followed by 10 min 
standing at RT in 100% methanol, incubated and rocked in blocking solution (10% NDS in 
TBS) for 1h at RT,  isolated using a hydrophobic pap-pen, incubated in 1/2500 dilution of 
primary GAP-43 AB in ADB (5% NDS, 2% BSA in TBS2T) overnight (16h) at 4
0C in a 
humidified metal chamber, washed and rocked in TBS2T for 1h, followed by washing and 
rocking for 1 hour in ADB and a further wash and finally rocked for 1 hour in TBS2T, all at 
RT (TBS2T, 50ml Tris pH 7.4, 60ml NaCl, 0.5% Tween 20).  Sections were then incubated in 
1 to 500 dilution of secondary AB in ADB overnight (16 h) at 40C in a humidified metal 
chamber, washed and rocked for 2 x 30 min in TBS2T, followed by 1 x 30 min in TBS and 1 
x 5 min in purified H20 (Millicue, Millipore, Watford, UK) all at RT.  Sections were then 
mounted using Vectamount containing DAPI and covered with glass cover slips.  All 
sections were stored at 40C in cardboard slide containers wrapped with aluminium foil to 
avoid signal quenching. 
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2.2.3.4 Specific protocol for immunofluorescence ICC 
 
In order to avoid the use of pipettes which could aspirate and dislodge cells from the well 
surface, chamber slides were quickly and gently inverted to remove solutions.  Similarly, 
Pasteur pipettes were used for the addition of all non-antibody solutions and reagents 
were carefully dripped down one corner of the well.  For antibody solutions which 
required the addition of exact volumes of solution, large diameter pipettes were used.  
When adjacent wells required different antibodies, antibody solutions were removed 
carefully by large diameter pipette as inverting the entire slide could have resulted in 
small quantities of inappropriate antibodies entering wells.  Cells were fixed for 10 min in 
4% PFA and washed 3 x 10 min in TBS.  Following 10 min at RT in blocking solution (3% 
BSA, 5% relevant serum, 0.1% Triton-X-100) within humidified metal container, cells were 
incubated at RT for 1h, then at 4°C overnight in a blocking solution containing relevant 
concentrations of primary antibodies, within a humidified metal container.  Following 3 x 
10 min wash in TBS, cells were incubated for 1 hour at RT in a blocking solution containing 
relevant concentrations of secondary antibodies, within a humidified metal container.  
Following 3 x 10 min TBS washes, chambers were removed from slides using the special 
tool provided by the manufacturer and glass cover slips were mounted over the cells with 
Vectamount containing DAPI. 
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2.2.4  Photography 
 
Images were captured using an AxioCam HRC Camera, an Axioplan 2 microscope with 
Zeiss Neofluar lenses and Axiovision software, (all from Carl Zeiss, Hertfordshire, 
England).  Care was taken to ensure that exposure times for all channels were kept 
constant across all sections including controls.  Image processing was performed using 
Adobe Photoshop (including creation of composite ON images) after contrast and 
brightness level adjustment.  In order to keep such adjustments standard, macros were 
recorded which applied identical values to all images including controls. 
 
2.2.5 RGC counts 
 
Ten fields of view of retinal sections encompassing the RGC layer of the retina were 
randomly selected for each sample from each treatment group.  RGC were classified as 
clearly β-III-tubulin positive cells with round somata, in the ganglion cell layer (GCL) of the 
retina.  The total number of observable RGC was calculate for each of the ten fields of 
view and summed to obtain an overall count for the 10 fields.  The number of RGC which 
co-expressed β-III-Tubulin and pEGFR were counted and summed simultaneously.  The % 
of all RGC expressing pEGFR per treatment group = [Total number of pEGFR positive 
RGC/Total number of RGC] x 100.  These counts were repeated for a minimum of three 
animals per treatment group. 
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2.2.6  In Vitro RGC quantification 
RGC were identified as those cells which both expressed β-III-tubulin and possessed large, 
round somata.  Neurites were defined as processes which emerge from RGC somata and 
were at least the diameter of that cell body in length.  Sampling was achieved by dividing 
the well into 9 sectors as shown below (Figure 2.1). 
 
 
Figure 2.1.  Sampling method. Subdivision of well into 9 sectors.                     
A-D: examples of 4 pictures from random fields of view within a sector. 
 
A pilot study (included in Chapter 4, introduction) was performed on one entire well in 
which the actual mean RGC neurite length was calculated after measuring the longest 
neurite length for every RGC.  Next, sample sizes of 10, 20, 50, 100 and 200 individual 
measurements were taken and the standard error of the mean (SEM) in these sample 
sizes compared, using the actual mean neurite length obtained previously as a baseline.  
A graph of SEM vs sample size was constructed and an optimum number of 36 samples 
per well was obtained (defined as the point at which further increasing sample numbers 
no longer significantly decreased error levels).  This equated to 4 pictures taken at 
random in each of the 9 well sectors.  For each experimental condition 3 wells were used, 
resulting in 108 pictures per treatment group per experiment being sampled. 
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2.3  Statistical analyses 
 
All statistical analyses and post hoc tests were performed using Graphpad Prism 4 (San 
Diego, CA, USA). 
 
2.3.1 One way ANOVAs and t-tests 
 
Unpaired t tests were used to determine if differences in the data from two groups were 
real or coincidental.  When more than two groups were compared a One way Analysis Of 
Variation (ANOVA) test was used.  Bonferronis and Dunnetts post hoc tests were used 
when comparing groups with one another or with controls respectively.  P values, which 
estimate probability that differences observed between groups are coincidental, were 
denoted as * for p <0.05, ** p < 0.01 and *** p < 0.001, which indicate the confidence 
values that are considered to be increasingly statistically significant.  NS denotes no 
significant difference between groups. 
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2.4  Protein assays 
 
Many techniques require the confirmation of sample protein levels in order to return 
accurate results.  Colorimetric protein assays measure protein concentrations by using 
the protein within a sample to catalyse a colour-change reaction such that opacity 
increases linearly with concentration.  The opacity of samples is then compared with that 
of pre-prepared samples of known protein concentration (standards) and sample protein 
concentrations are extrapolated.  Protein assays were performed according to the 
protocol supplied with the BioRad DC Protein Assay (BioRad, Hemel Hempstead, UK) and, 
unless stated otherwise, all reagents were supplied with this kit.  This assay consists of 
two consecutive reactions; a reaction between protein and copper in an alkaline medium 
and a subsequent reduction of the reagent Folin by the protein-copper solution, 
producing a blue solution with maximum and minimum absorbencies of 750 and 405 nm 
respectively. 
  
2.4.1  Specific protein assay protocol  
 
Reagent A’ was formed by adding 20μl reagent S to each ml of reagent A.  A standard 
curve of increasing bovine serum albumen (BSA) in PBS was plotted with values of 
0.2mg/ml to 1.5 mg/ml.  100μl samples or BSA standards were mixed with 500μl reagent 
A’, vortexed, 4ml of reagent B added and this mixture vortexed.  After 15 min incubation 
in a darkroom at RT, absorbencies were read at 750nm using a Victor spectrophotometer.  
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The slope of a concentration vs absorbance graph using BSA standards was used to 
extrapolate sample protein levels from their absorbance values. 
 
2.5  SDS-PAGE and Western blot 
 
Polyacrylamide gel electrophoresis (PAGE) is a technique which separates mixtures of 
proteins by weight for subsequent detection with antibodies.  By passing an electrical 
current through a gel of defined density the negatively charged proteins move towards a 
positively charged anode at a constant rate.  Individual proteins progress through the gel 
at a rate proportional to their molecular weight; larger, heavier proteins move slower 
than smaller, lighter proteins.  In order to make sure that proteins are separated purely 
by size and not by any differences in charge, all proteins must be of equivalent 
electronegativity/weight ratio.  To this end, β-mercaptoethanol and the anionic detergent 
sodium dodecyl sulphate (SDS) are used to respectively a) destroy tertiary structures by 
reducing disulphide bridges, and b) denature and bind to the resulting unrolled, rod-like 
string of amino acids.  The negatively charged SDS binds approximately one molecule to 
every two amino acids, resulting in each protein being maximally negatively charged.  The 
gel in which this migration takes place is known as the resolving gel.  As proteins sizes are 
measured as a function of the distance travelled through this resolving gel, it is vital that 
all proteins enter the gel simultaneously.  To this end a second gel, the stacking gel, is 
poured onto the resolving gel so that the two are continuous.  The stacking gel is made 
using buffers at a considerably lower pH than the surrounding buffers and is of a much 
lower density than the resolving gel.  At the stacking gel-resolving gel interface all 
proteins irrespective of size are concentrated into a band of approximately 20µm, and 
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enter the resolving gel simultaneously.  To create individual wells in which each sample 
can run, a comb is placed in the stacking gel mixture before polymerization.  The forks of 
this comb occupy fixed, rectangular spaces within the gel, forming regularly spaced wells 
at the top of the stacking gel.  Samples are then pipetted into the bottom of these wells.  
Immediately prior to electrophoresis each sample is at the same vertical level within the 
gel and sufficiently dispersed horizontally to facilitate detection in separate wells. 
Following SDS PAGE, a Western blot can be performed.  The gel containing the 
separated proteins is placed next to a membrane of nitrocellulose or polvinylidine 
fluoride (PVDF) and application of electrical current transfers the proteins onto the 
membrane.  This membrane can then be probed with relevant primary antibodies 
followed by secondary antibodies conjugated to various enzymatic, fluorescent or 
radioactive detector compounds.  Commonly, a horse radish peroxidase (HRP) enzyme is 
conjugated to the secondary antibody and used to catalyse a chemiluminescent reaction.  
The photons emitted develop photographic film placed directly above the membrane, 
resulting in a dark band corresponding to the specific protein.  A premade protein ladder 
consisting of prestained proteins of specific sizes is run through the gel and the 
approximate sizes of bands detected are compared to these standards, allowing accurate 
estimation of molecular weight. 
To accurately measure changes in levels of a specific protein between treatment 
groups the same amount of total protein must be added to each well.  This ensures that 
changes in protein titres are a result of a real, biological effect and not a consequence of 
unequal sample volumes.  This is achieved by probing membranes with an antibody to the 
ubiquitious cytoskeltal component β-actin; ratio of β-actin levels between samples will 
indicate relative levels of total protein. 
 61 
 
2.5.1  Tissue preparation and homogenization for SDS-PAGE   
 and Western blot 
 
ON and retinal tissues were homogenized in homogenization buffer (20mM Tris Hal, pH 
7.4, 150mM NaCl, 1mM EDTA, 0,5mM EGTA, 1% NP-40, 1.5% protease inhibitor, all in 
milliQ H2O, ON in 100μl and retinae in 200μl.  Tissue was homogenized, on ice, with 
homogenizer (IKA, Staufen, Germany) for 2 min starting at low speed and then increased 
to maximum rpm.  After 30 min on ice, the homogenate was centrifuged at 13, 000 RPM 
for 30 min at 4°C.  The supernatant was removed and pellet stored at -80°C.  
 
2.5.2  Specific SDS PAGE and Western blot protocol 
 
Resolving gel (12 %, 2.75ml Protogel (IBR stores, University of Birmingham) 1.65ml 1.5 M 
Tris, 2.2ml milliQ H2O, 66μl 10% SDS, 23.1μl 10% APS, 9.9μl TEMED) was poured into a 
single use gel cassette such that the cassette was 3/5ths full.  To prevent air bubble 
formation, (which would inhibit polymerization) 100% ethanol was poured on top of the 
gel.  After the resolving gel had set, the ethanol was removed, the cassette washed with 
milliQ H2O and stacking gel (0.4ml Protogel, 1.85ml 0.5M Tris, 0.75 ml milliQ H2O, 30μl 
10% SDS, 15μl 10% APS, 7.5 μl TEMED) was poured on top of the resolving gel.  A gel 
comb was placed carefully into the top of the stacking gel, the gel was checked to make 
sure no bubbles of air remained, and the gel was allowed to polymerise.  Prepared gel 
cassettes were wrapped in Clingfilm and damp tissue and stored at 4°C until needed 
(typically less than 3 h).  Although resolving gel was normally set at 12% polyaccrylamide, 
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for molecules larger than ~100 kDa an 8% polyaccrylimide gel was used and the remaining 
volume replaced with milliQ H2O.  Stacking gels remained unchanged. 
 Pre-calculated volumes of samples were diluted 1:1 with a sample buffer (125mM 
Tris containing 2% SDS, 10% glycerol, 2.5% Mercaptoethanol)  in Eppendorf tubes with 
pre-pierced lids, centrifuged at 12,000 G for 1 min and boiled for 4 min at 90°C.  Samples 
were centrifuged as before and loaded into the wells using long, ultra-fine pipette tips.  
Empty wells were loaded with sample buffer alone.  First and last wells were loaded with 
10µl of protein ladder (Benchmark, Invitrogen)  
Running buffer (3.03g Tris base, 14.4g glycine, 20 ml methanol, 980 ml milliQ H2O, 
5 ml 20% SDS) was added until wells were submerged.  The powerpack (Powerease 500, 
Invitrogen) was set at 125V, 18mA, 2.1W and gel run for 90 min.  Times were reduced or 
increased when probing for low or high molecular weight proteins respectively.  During 
this time, filter paper and foam blotting pads were soaked in chilled transfer buffer (3.03g 
Tris Base, 14.4g Glycine, 200ml Methanol, 1 ml 20% SDS in 800 ml milliQ H2O).  Following 
SDS PAGE, a PVDF membrane (Immobilon, Millipore) was activated by 1 min immersion in 
methanol followed by 5 min in milliQ H2O and finally for 5 min in chilled transfer buffer.   
The gel was removed from the case, immersed in transfer buffer for 15 min and 
placed within the Western blotting module (X-cell 2, Novex, San Diego, CA, USA) with 
foam pads, membrane and filter paper in the following order, bottom to top: 3 foam 
pads, filter paper, membrane, gel, filter paper, 2 foam pads.  Care was taken to handle gel 
and membrane only with tweezers, so as to avoid contamination with extraneous protein.  
The Western blotting module, containing gel and membrane, was immersed in chilled 
transfer buffer and the outer compartments of the tank were filled with transfer buffer.  
The western blot option was selected on the powerpack and the transfer time set to 2h.  
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Following transfer the membrane was washed 3 x 5 min in TTBS (1.21g Tris, 8.77g NaCl, 
500µl tween, in 1 litre milliQ H2O) and then immersed in blocking solution (5% Marvel 
powdered milk (Premium International Foods, Lincs, UK) in TTBS) for 1 h.  The membrane 
was immersed in the relevant concentration of primary antibody diluted in blocking 
solution within a heat sealed bag then incubated on a rocker overnight at 4°C.  Following 
3 x 10 min washes in TTBS, the membrane was immersed in its relevant concentration of 
HRP-conjugated secondary antibody, diluted in blocking solution within a heat sealed bag, 
then incubated on a rocker for 1 hour at RT.  After 3 x 10 min washes in TTBS, an 
Enhanced Chemi-Luminescence Kit (Amersham Biosciences, Buckinghamshire, UK) was 
used as follows.  1ml of ECL reagent 1 was mixed with 1ml of ECL reagent 2 and pipetted 
evenly over the membrane which was flipped upside down after 30 s so as to coat each 
side evenly and after a further 30 s (1 min in total) blotted gently with filter paper and 
placed within an unsealed translucent bag.  After transfer to the darkroom, the bag 
containing the membrane was secured inside a lightproof metal container and a similar 
sized piece of photosensitive film (Kodak, Hemel Hempstead, UK) placed directly on top 
of the bag.  After relevant exposure time (typically 1, 5 or 15 min) the film was removed 
and placed into an autodeveloper machine (SRX-101A, Konica Minolta, Banbury, UK).  
After ECL, membranes were washed 3 x in TTBS and placed into TTBS within a heat sealed 
bag to be stored at 4°C.  If required, the membrane was stripped in stripping buffer 
(25μM glycine-Hal, pH 2, 1% SDS) for 1h, washed 3 x 10 min in TTBS, blocked in blocking 
solution and underwent another primary antibody incubation and detection cycle as 
detailed above. 
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2.6  Enzyme Linked ImmunoSorbent Assay (ELISA) 
 
The ELISA yields an accurate measurement of the concentration of a specific compound 
within a solution.  In its simplest form, an ELISA consists of a procedure where an 
antibody is added to an unknown concentration of immobilized antigen.  This antibody is 
pre-linked to an enzyme or a fluorescent compound, which is used to catalyse a 
colorometric reaction, giving a linear relationship between concentration of initial 
substrate and final light absorbance levels.  Fluorescent antibodies are used to identify 
initial concentration of substrate in terms of light emitted.  Commonly, for mammalian in 
vitro studies, an enzymatic antibody-sandwich approach is used.  In this case the initial 
solution containing the substrate is applied to a surface (usually a 96 well plate) which has 
been precoated with an antibody specific to the compound of interest.  After incubation 
the solution containing unbound substrate is removed and a second antibody specific to a 
different epitope on the same compound is applied.  The result is a ‘sandwich’ in which 
the compound of interest is trapped between two antibodies.  The second antibody, 
attached to HRP, is used to catalyse a chromogenic (colour creating) reaction with, for 
example, 3, 3, 5, 5’ –tetramethylbenzidine (TMB).  The amount of compound present is 
directly proportional to the amount of TMB catalysed.  Solutions containing a range of 
concentrations of the compound of interest are processed simultaneously.  The 
concentration of compound in each sample is derived by first plotting a standard curve of 
light absorbance versus concentration, using known conventrations of protein standards, 
on a logarithmic scale and then noting the concentration value on this curve which 
corresponds to the absorbance value gleaned from the sample in question.  
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2.6.1  Specific ELISA protocol for NT-3 
 
The NT-3 Emax ELISA system (Promega, Southhampton, UK) was used to assay NT-3 
concentration in conditioned media.  Both protocol and reagents used were supplied with 
this kit.  Briefly: the wells of sterile, 96 well plates (Nunc, Loughborough, UK) were coated 
with polyclonal anti-human NT-3 (20µl antibody + 10 ml carbonate coating buffer (p.H. 
9.7)), 100µl per well, covered with Parafilm and incubated at 4°C overnight (16 hours).  
Following a single wash with TBST (p.H.7.6, 0.05% Tween), 200µl of 1x block and sample 
buffer were added to each well and the plate was incubated without shaking for 1 hour 
(1x block and sample buffer: 34.4ml deionised water, 8.6 ml block and sample 5X Buffer).  
The plate was set up as indicated in figure 2.2. 
 
 
           Figure 2.2. NT-3 ELISA Plate set-up.  Diagram modified     
           from NT-3 Emax instruction manual (Promega) 
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The initial NT-3 standard solution was diluted 1:2000 with block and Sample buffer and 
subsequently diluted 1:2 serially from 300pg/ml (11A + 12A) to 4.7pg/ml (11G + 12G).  
The bottom-most well (H) contained only block and sample buffer.  Following an initial 
dilution of sample (see specific figure in results) in the topmost lane, e.g. A1, samples 
were subsequently serially diluted 1:2 or 1:5 with block and sample buffer, with the 
bottom-most well containing buffer only.  The plate was then sealed with Parafilm and 
shaken on a plate shaker for 6 hours at RT.  After 5 washes in TBST, 2.5µl NT-3 antibody 
was added to 10mls block and sample buffer, mixed well, and 100µl of this solution was 
added to each well.  The plate was then sealed with Parafilm and incubated overnight at 
4°C.  Following 5 washes in TBST, 100µl of HRP conjugated anti-mouse IgG were added to 
9.9 ml Block and Sample buffer, mixed well, and 100µl of this solution added to each well.  
The plate was sealed with Parafilm and incubated with shaking at RT for 2.5 hours.  
During this time TMB-1 (3,3 ‘, 5,5’ –tetramethylbenzidine) solution was allowed to warm 
to room temperature.  100µl of TMB-1 was then added to each well and the plate was 
sealed with Parafilm and shaken at RT for 15 minutes.  After this time 100µl of 1N HCL 
was added to each well, halting the chromogenic reaction, and absorbencies were read 
on plate-reader at 450nm.  Using Microsoft Excel, a standard curve of absorbance vs NT-3 
concentration was prepared for the NT-3 standards.  This graph then allowed the 
correlation of sample absorbencies to relative NT-3 levels. 
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2.6.2  Specific ELISA protocol for GDNF 
 
The GDNF Emax ELISA system (Promega, Southhampton, UK) was used to assay GDNF 
concentration in conditioned media.  Both protocol and reagents used were supplied with 
this kit.  Briefly: the wells of sterile, 96 well plates (Nunc, Loughborough, UK) were coated 
with monoclonal anti-GDNF antibody (10µl antibody + 10mls carbonate coating buffer 
(p.H. 8.2), 100µl per well), covered with Parafilm and incubated at 4°C overnight (16 
hours).  Buffer was emptied from wells and 200µl of 1x block and sample buffer was 
added to each well and the plate was incubated without shaking for 1 hour (1x block and 
sample buffer:  34.4ml deionised water, 8.6 ml Block and Sample 5X Buffer). 
 
 
     Figure 2.3.  GDNF ELISA plate set-up.  Diagram modified     
      from GDNF Emax instruction manual (Promega) 
 
 
Plate was set up as indicated in Figure 2.3.  The initial GDNF standard solution was diluted 
1:2000 with block and sample buffer and subsequently diluted 1:2 serially from 
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1000pg/ml (11A + 12A) to 15.6pg/ml (11G + 12G).  The bottom-most well (H) contained 
only block and sample buffer.  Following an initial dilution of sample (see specific figure in 
results) in the topmost lane, e.g. A1, samples were subsequently serially diluted 1:2 or 1:5 
with block and sample buffer, with the bottom-most well containing buffer only.  The 
plate was then sealed with Parafilm and placed on a plate shaker for 6 hours at RT.  
Following 5 washes in TBST, 20µl anti-human GDNF polyclonal antibody was added to 
10mls block and sample buffer, mixed well, and 100µl of this solution were added to each 
well.  The plate was then sealed with Parafilm and incubated at 4°C overnight.  Following 
5 washes in TBST, 40µl of anti-chicken IgY HRP conjugate were added to 9.96 ml 1x block 
and sample buffer, mixed well, and 100µl of this solution added to each well.  The plate 
was sealed with Parafilm and incubated with shaking at RT for 2 hours.  During this time 
TMB-1 (3,3 ‘, 5,5’ –tetramethylbenzidine) solution was allowed to warm to rt.  100µl of 
TMB-1 were then added to each well and the plate was sealed with Parafilm and shaken 
at rt for 10 minutes.  After this time 100µl of 1N HCL were added to each well, halting the 
chromogenic reaction, and absorbencies were read on plate-reader at 450nm.  Using 
Microsoft Excel, a standard curve of absorbance vs GDNF concentration was prepared 
using the supplied GDNF protein standards.  This graph then allowed the correlation of 
sample absorbencies to relative GDNF levels. 
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2.6.3 Specific ELISA protocol for CNTF 
 
The Duoset Rat CNTF ELISA kit (R and D systems, Inc, MN, USA) was used to assay CNTF 
concentration in conditioned media.  Both protocol and all reagents were supplied with 
this kit.  Briefly: the wells of sterile, 96 well plates (Nunc, Loughborough, UK) were coated 
with 2µg/mL mouse monoclonal anti-CNTF antibody in sterile PBS, (100µl per well), 
covered with Parafilm and incubated at RT, overnight (16 hours).  Following 3 washes 
with PBST (referred to in protocol as “Wash Buffer”) wells were blocked with reagent 
diluent (1% BSA in PBS, pH 7.2. – 7.4, 0.2µm filtered), 300µl per well, incubated for 1.5 
hours at RT.  Following 3 washes in PBST, 100 µL of sample or standard were added to 
each well.  Plate was set up as indicated as in figure 2.4.  The initial CNTF standard 
solution was diluted with reagent diluent such that the topmost wells (11A and 12A) 
contained 2000pg/mL, with subsequent solutions being diluted 1:2 serially from 
2000pg/ml (11A + 12A) to 31 pg/ml (11G + 12G) in sequential wells.  The bottom-most 
well (H) contained only reagent diluent.  Following an initial dilution of sample (see 
specific figure in results) in the topmost lane, (A1), samples were subsequently serially 
diluted 1:2 or 1:5 with reagent diluent, with the bottom-most well containing diluent 
only.   
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      Figure 2.4.  CNTF ELISA plate set up.  Diagram modified from     
       GDNF Emax instruction manual (Promega) 
 
The plate was then covered with Parafilm and incubated for 2 hours at RT.  After 2 
washes in PBST, 100µL of detection antibody (biotinylated goat anti-rat CNTF, 200ng/mL, 
diluted from 36µg/mL in reagent diluent) were added to each well, before the plate was 
covered in Parafilm and incubated for 2 hours at RT.  After 3 washes in PBST, 100µl of 
Streptavidin-HRP (diluted 1 to 200 from original stock concentration in reagent diluent) 
were added to each well, the plate covered in Parafilm, and incubated for 20 min at RT.  
After this 20 minutes 50µl stop solution (2N H2SO4) was added to each well, the plate 
gently agitated, and absorbencies read at 450nm. Using Microsoft Excel, a standard curve 
of absorbance vs CNTF concentration was prepared using the supplied CNTF protein 
standards.  This graph then allowed the correlation of sample absorbencies to relative 
CNTF levels. 
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2.7  RNA extraction, cDNA synthesis and polymerase chain reaction 
 
If protein levels are sufficiently small, such that they cannot be detected directly, it is 
sometimes possible to infer protein expression from the presence of relevant intracellular 
RNA.  RNA encoding a specific protein is normally present only when protein synthesis is 
to follow.  After isolating and removing the RNA from one or more cells, it is then possible 
to convert each of the single stranded RNA molecules into single stranded 
complementary DNA (cDNA) using the enzyme Reverse Transcriptase.  This is the DNA 
sequence which would have originally served as the template for the RNA molecule in 
vivo, assuming the RNA sequence would not have undergone post-translational 
modifications.  The single stranded cDNA corresponding to the protein of interest must 
then be isolated.  This is achieved using a technique known as Polymerase Chain Reaction 
(PCR).  After being treated with an enzyme to degrade any remaining RNA, the cDNA 
mixture is mixed with an excess of primers, which are oligonucleotides specific and 
complementary to the beginning of the cDNA sequence of interest.  These primers attach 
(anneal) to the beginning of the relevant cDNA molecule via normal base pairings.  There 
are forward and reverse primers, each complementary to and binding at the beginning (3’ 
end) of each single strand.  For example, if the entire double stranded DNA sequence 
were to read “GGCCAATT” on one strand and, correspondingly, “CCGGTTAA” on the 
other, the forward primer for the first strand would be complementary to “GGCCAATT” so 
“CCGG...”.  The primer for the second strand, binding at the 3’ end, would be 
complementary to “CCGGTTAA” but reading in the opposite direction, so this primer, the 
reverse primer, would read “TTAACCGG” – see figure 2.5 below. 
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Figure 2.5  cDNA amplification. 1) Primer binds at relevant sequence on cDNA          
molecule of interest (broken box).  2) Polymerases then incorporate supplied                       
free nucleotides (shown in red), generating the complementary strand.                            
3) Subsequent cycles of heating, cooling and annealing repeat this process              
allowing exponential increases in amounts of desired DNA. 
 
 
The enzyme DNA polymerase and an excess of single nucleotides with triphosphate 
groups (DNA Nucleotide Tri Phosphates - DNTPs) are added.  The polymerase catalyses 
base pairing between the original cDNA strand and the single nucleotides, resulting in the 
formation of the full length double stranded DNA molecule coding for the appropriate 
protein.  Once the double stranded DNA molecule has been synthesized, the mixture is 
heated until the DNA denatures into two separate single strands, and then allowed to 
cool.  Each of the two strands then acts as a template for the other, as in normal DNA 
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replication, and together with the polymerase and free nucleotides, rapidly produce two 
complete double stranded DNA molecules.  Once all the above reagents are mixed 
together, the heating and cooling steps can be easily automated, allowing dozens of 
duplications in a single day.  The power of exponential growth is such that 15 cycles will 
turn one strand of DNA into 16,000.  Using PCR it is thus possible to take tiny samples of 
DNA and quickly produce samples large enough to analyse with other techniques, such as 
gel electrophoresis.  DNA (or RNA) samples are electrophoresed through a gel of 
appropriate material and density, commonly 0.7-1% agarose.  The buffer used will contain 
a reporter compound such as ethidium bromide, which will intercalate between the bases 
of nucleic acid and function as a fluorescent marker, emitting visible light which is excited 
by ultraviolet radiation. 
 
2.7.1  Specific protocol for RNA extraction 
 
All reagents and protocols used were supplied with the RNAeasy kit (Qiagen Crawley, UK).  
Primary retinal cultures, consisting of 1.5 x106 cells plated onto small petri dishes, were 
drained of media and washed once with PBS.  Cultures had PBS removed, 1ml 0.1% 
trypsin added and, after gentle manual shaking, were incubated at 37°C for 5 min.  1 ml of 
media was added (to neutralise trypsin) and the cell suspension was centrifuged at 300g 
for 5 min in supplied 1.5ml sample tube.  The supernatant was discarded and 600µl of 
supplied RLT buffer were added (to disrupt cells) and the mixture was vortexed.  
Following 30 seconds homogenization by a rotoshredder at medium speed, 600µl of 70% 
ethanol was added to the cell suspension and the resulting solution was mixed well by 
pipette.  700µl of solution were added to RNAeasy spin columns, set inside sterile 2ml 
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collection tubes and spun at 8000g for 15 seconds.  After discarding flow through, 700µl 
of supplied RW1 buffer was added to spin column, and column + 2 ml collection tube 
were centrifuged at 8000g for 15 seconds.  Flow through was discarded and column + 
tube were centrifuged at 8000g for 2 minutes.  Spin column was placed within a new, 
sterile 2ml collection tube and 50µl of RNAse free H2O pippetted carefully onto centre of 
spin column.  Following a final 2 minute centrifugation at 8000g, the resulting RNA-H2O 
solution was stored in a sealed, sterile, RNAase free 2 ml Eppendorf at -80°C.  Prior to 
freezing, 1-2µl of RNA solution were removed and assayed for concentration using a 
NanoDrop machine (Thermo Scientific, DE, USA). 
 
2.7.2  Specific protocol for cDNA synthesis and PCR 
 
cDNA was synthesized using the reagents and protocol from a High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems, CA, USA).  The following reagents were 
added to a sterile, RNAse free PCR tube and mixed well: 3.2µl of 10 x supplied RT Buffer, 
0.8µl dntps (free nucleotide-bases), 2µl primers (1 µl forward, 1µl reverse), 1µl Reverse 
Transcriptase, 1µl RNAse inhibitor and 24µl RNA.  After centrifugation to ensure no liquid 
remained in the PCR tube cap, the tube was placed in a thermal cycler and a reverse 
transcription program run.  Following testing for concentration on a Nanodrop machine, 
cDNA was stored in a sealed PCR tube at -80°C.  Each 40µl PCR reaction mixture consisted 
of 2µl forward and 2µl reverse primers, 18µl cDNA and 18µl ReddyMix PCR multimix 
(Thermo Scientific, DE, USA), a mixture containing all enzymes and nucleotides required.  
A PCR tube containing each reaction mixture was placed in the thermal cycler and the 
default PCR program run (96oC for 30 sec, 50oC for 30 sec, 72oC for 45 sec, 30 repetitions).  
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In order to visualise PCR products, PCR tube contents underwent gel electrophoresis 
(0.7% agarose gel in Tris/Borate/EDTA (TBE) buffer, with 10mg/mL Ethidium Bromide) for 
30 minutes at 50v.  Gels were photographed with a Multigenius machine (Geneflow, 
Fradly, UK).  For tissue control, rat brain lysate was used and primers for the house 
keeping gene GAPdh were also used to confirm that RNA extraction, cDNA synthesis and 
subsequent PCR had been successfully performed. NTF primer sequences were as follows.   
 
(F=Forward, R= Reverse) 
BDNF-F:  AGA GTG ATG ACC ATC CTT TTC 
BDNF-R:  CTA TCT TCC CCT TTT AAT GGT 
CNTF-F:   TAG GGG ATG GCT TTC GCA GAG 
CNTF-R:   CTA CAT CTG CTT ATC TTT GGC 
 NGF-F:   ATG TCC ATG TTG TTC TAC ACT 
 NGF-R:   TCA GCC TCT TCT TGC AGC CTT 
 NT3-F:    ATG TCC ATC TTG TTT TAT GTG 
 NT3-R:    TCA TGT TCT TCC GAT TTT TCT 
 NT4-F:    ATG CTC CCT CGC CAC TCC TGC 
 NT4-R:    TCA GGC ACG GCC TGT TCG GCT 
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Chapter 3 
The cellular distribution of pEGFR in the retina and optic 
nerve  
  
 77 
 
3.0 Introduction 
3.1 The Epidermal Growth Factor Receptor 
While the NgR and the PTP receptors for myelin derived proteins and CSPG respectively 
were elucidated by identifying the ligands and then searching for relevant receptors, the 
EGFR was well characterised and had been studied extensively in, for example, cancer 
research, for decades prior to its currently implied role in CNS regenerative failure.  The 
170KD EGFR/ErbB-1 (Figure 3.1) is a member of the ERb family of receptors, a sub-family 
of the receptor tyrosine kinase super family of receptors, the functioning of which require 
the phosphorylation of specific sites on their intracellular domains.   
 
 
Figure 3.1.  The Epidermal Growth Factor Receptor (monomer).                    
A. Diagrammatical representation showing all domains and regions.                            
B.  Alternative, ribbon-like diagram of EGFR structure.  Adapted from     
Ferguson, 2008.  
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The 4 known members of the ERB family are Erb-B-1 (EGFR), Erb-B-2, Erb-B-3 and Erb-B-4.  
To date 7 EGFR-specific ligands have been identified: EGF, Transforming Growth Factor 
(TGF) – α, Heparin-Binding EGF-like-factor  (HP-EGF), betacellulin, amphiregulin, 
epiregulin, and epigen (Wells, 1999).  EGFR activation promotes cell survival, mitosis and 
migration, although it is also associated with apoptosis and cytoskeletal reorganization 
(Bazley and Gullick 2005, Oda et al. 2005, Appleton et al. 2010). When activated by 
ligand, EGFR dimerises and undergoes autosphosphorylation , i.e. each monomer 
phosphorylates the tyrosine kinase domains of the other, before being internalized in 
clathrin-coated vesicles.  The mechanisms underlying EGFR activation and signaling are 
complex and the EGFR signaling network is vast; a paper entitled “A comprehensive 
pathway map of epidermal growth factor receptor signaling” (Oda et al. 2005) lists several 
hundred species and interactions as well as 6 distinct G-protein-coupled transactivatory-
pathways.  The huge variety in ligand dependent signaling pathways stems from three 
main sources.  Firstly, EGFR can form heterodimers with each of the other ErbB family 
members (Shankaran  et al. 2006).  Secondly, following activation and internalization, the 
fate of the receptor-ligand complex is determined by both the ligand and by the nature of 
the receptor hetero/homodimer.  Thirdly, this specific species of receptor-ligand complex 
determines which of the numerous intracellular signaling proteins are interacted with, 
which determines the downstream signaling partners and, ultimately, the final 
intracellular effect, e.g. activation of transcription factors, effecting Ca2+ realease, 
initiating the cell cycle etc. (Jorissen et al. 2003, Oda et al. 2005).  The intracellular portion 
of the EGFR has three main signaling domains.  The first, juxtamembraneous, domain 
provides an activation site for protein kinase C (PKC), the second, central tyrosine kinase 
domain, contains the SH1 domain which is required for transphosphorylation of the 6 
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tyrosine residues in the carboxy terminal and the third, the carboxy terminal tail, contains 
the SH2 domain, with the tyrosine residues required for docking of adaptor/effector 
proteins such as SHC, Grb 2 or Phospholipase C-γ, which then link the EGFR to a variety of 
signaling pathways.  The second of the three, the central tyrosine domain, also contains 
the signaling motifs required for receptor internalization and degradation.  
 Following internalization and the initial interaction with intracellular 
adaptor/effector proteins, either the entire EGFR-ligand complex is directed to lyzosomes 
for degradation, or the ligand and receptor dissociate within early endosomes, the 
receptor being recycled to the cell surface whilst the ligand is lysosomally degraded 
(Wiley,2003, Shankaran et al. 2006,Jorrisen et al. 2003).  Figure 3.2 shows the 
dimerisation and conformational changes which take place when an inactive EGFR 
monomer is activated by EGF. 
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Figure 3.2.  Non activated and activated EGFR.  Inactive, non phosphorylated 
monomeric EGFR (left) binds EGF and dimerises (right) causing the tyrosine kinase 
domains on each EGFR monomer to autophosphorylate its partner.  Adapted from 
Ferguson 2008. 
 
In addition to ligand binding, EGFR can also be transactivated, that is activated 
intramembraneously or intracellularly, by non ErbB receptors and/or other signalling 
intermediaries.  Known transactivators of EGFR include the integrins (Yamada and Even-
Ram 2002, Cabodi et al. 2004), rapamycin (Chaturvedi et al. 2009), fibrinogen (Schachtrup 
et al. 2005), and G-protein coupled receptors (Rosengurt 2007,Oda et al. 2005).  Most 
commonly the signaling mechanisms by which EGFR is transactivated involve Ca2+ influx, 
PLC-γ activation or PKC activation, often as downstream consequences of ligand binding 
to non-ErbB-family receptors such as GPCR (Gschwind et al. 2001, Rosengurt 2007).  
 EGFR can be transactivated in the absence of ligand binding by co-clustering with 
other receptors that sequester adaptor/effector proteins which then bind to and initiate 
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phosphorylation of the tyrosine kinase domains of EGFR (Gschwind et al. 2002, Cabodi et 
al. 2004).  Reported interactions include the integrin receptors (Cabodi et al. 2004) and 
members of the cadherin family (Andl and Rustgi 2005).  See figure 3.3 for diagram. 
 
Figure3.3.  Non ErbB receptors (Blue) clustered near EGFR (orange) sequester adaptor\effector proteins 
including Src and Shc which transphosphorylate and thus activate the adjacent EGFR.  Adapted from    
Yamada and Even-Ram, 2002. 
 
EGFR can also be transactivated following the shedding of membrane bound pro- forms 
of EGFR ligands which activate the EGFR in an autocrine manner (Higashiyama et al. 2008, 
Schneider and Wolf 2009).  This EGFR ligand shedding is mediated by the ADAM (A 
Disintegrin And Metalloprotease) family of metalloproteases including ADAM 17, also 
known as TACE (Tumour necrosis factor-α Converting Enzyme) (Higashiyama et al. 2008, 
Schneider and Wolf 2009).  At least two EGFR ligands, epigen and amphiregulin, have 
been shown to be released from the membrane in an ADAM-dependent manner (Sahin 
and Blobel 2007, Kasina et al. 2009, respectively).       
 The ADAM-mediated EGFR ligand shedding which leads to EGFR transactivation is 
often initiated by the binding and internalization of ligand to a receptor such as a GPCR.  
This “outside-inside -outside” signaling cascade has been termed “triple-membrane-
passing-signalling” and is illustrated in figure 3.4. 
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Figure 3.4.  The “triple-membrane-passing-signalling” model of EGFR transactivation.     
Ligand binding to receptor (which does not have to be a GPCR) initiates the recruitment    
of intracellular second messengers, including Ca2+, proteins such as Src and PKC                   
(1)  This results in the activation of one or more of the ADAM family of metalloproteases,   
which cleave membrane bound pro- forms of EGFR ligands, resulting in the release of                        
the mature protein which can act juxtacrinally, paracrinally, or, as shown, autocrinally    
(2) to activate EGFR in the normal manner (3)  Adapted from Wetzker and Boëmer 2003. 
 
 Although the term transactivation is taken to mean “the activation of a receptor 
by any means other than direct ligand binding”, there is a final means of EGFR 
transactivation which is transactivation in the truest sense.  In this model (figure 3.5) 
GPCR sequester adaptor/effector proteins such as Src and cause them to be recruited to 
the cytoplasmic domain of nearby EGFR, phosphorylating the tyrosine residues 
responsible for EGFR activation and subsequent downstream signaling (Wetzker and 
Boëhmer 2003, Keely et al. 2000).   In this case there is no vertical transfer of signal 
through the EGFR at all and potentially even EGFR lacking an extracellular domain could 
be activated in this way.  
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Figure 3.5.  The recruitment of SRC proteins by GPCR           
adjacent to EGFR result in the phosphorylation of             
tyrosine residues  responsible for EGFR activation.        
Adapted from Wetzker and Boëmer 2003. 
 
While many of the aforementioned phenomena which make up the huge EGFR 
activation and signalling network are not specific to neurons (mitogenic signalling 
pathways for example), there have been several studies concerned purely with the 
distribution and function of neuronal EGFR, including studies of EGFR distribution in the 
mammalian CNS (Erschbamer et al. 2007, see Wong and Guilliaud 2004 for review) and 
more specifically within the visual system (Liu et al. 2006, Chen et al. 2007).    
 As the EGFRki mediated axon-regeneration reported by Koprivica et al.(2005) was 
obtained using a visual system in vivo model, and as many of their corroborative in vitro 
results were gleaned from retinal cultures, the visual system is probably the most 
relevant area of the CNS for examining the role of neuronal EGFR.   
 EGFR plays a critical role in much of the developing visual system; EGF and TGF-α 
each cause retinal progenitor cells to generate neurons and glia (Anchan et al. 1991), 
heparin binding EGF-like growth factor (hb-EGF) causes mitosis in both astrocytic and 
multipotent progenitor cells (Kornblum 1999), and EGFR signalling is required for the 
differentiation of many post mitotic neurons and glia from pluripotent precursors (Lillien 
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1995).  In the normal adult mammalian retina EGFR is largely absent from glia (Gomez-
pinilla et al., 1988, Chen et al. 2007, Liu et al. 2006) but is present on a variety of retinal 
neurons (Kramer et al. 2001) including RGC and amacrine cells (Chen et al. 2007).  EGFR 
ligands are spread throughout the adult retina, including TGF-α in the processes of Müller 
glia (Kramer et al. 2001), RGC and in amacrine cells (Chen et al. 2007) and EGF in RGC 
(Kramer et al. 2001, Chen et al. 2007) and in horizontal cells (Chen et al. 2007).  EGFR has 
been suggested to play a role in RGC physiological homeostasis and possibly even in 
assisting the processing of visual information (Chen et al. 2007), but most studies on 
neuronal EGFR have concluded that the EGFR signalling impinges on neurons via glia, 
primarily astrocytes (Liu et al. 2006, Yamada et al.1997, Wagner et al. 2006, Liu and 
Neufeld 2007), but in the retina, also via Müller glia (Bringmann et al. 2009).  Each of 
these studies concerned with the neuronal effects of glial EGFR signalling has concluded 
that this signalling is usually to the detriment of nearby neurons, primarily because 
neither astrocytes nor Müller glia express significant levels of EGFR prior to CNS 
insult/pathology whereupon EGFR is strongly upregulated and activated (Liu and Neufeld 
2003, Liu et al. 2006, Jin et al. 2002).  Thus retinal glial EGFR is associated with, and 
perhaps necessary for, astrogliosis and Müller gliosis, processes known to be strongly 
antagonistic to axonal regeneration and potentially potently neurotoxic (for review see 
Berry et al. 2008).           
 It has previously been shown in ONC models that retinal and ON pEGFR levels are 
significantly lower in those animals with regenerating ON than in those of non-
regenerating ON (Ahmed et al. 2006).  While this study confirmed pEGFR reduction via 
western blot, correlated with GAP-43 staining of ON sections to confirm regeneration, the 
actual cellular distribution of pEGFR was not investigated.  Hence, although it was 
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confirmed that pEGFR levels were modulated by injury and subsequent surgical 
intervention, it was not confirmed whether neurons, axons, glia or all three were the 
predominant source of pEGFR.  At the time of writing it does not appear that any paper 
has published definitive proof of axonal pEGFR or even EGFR, anywhere in the adult CNS.  
Schachtrup et al. (2007) immunostained spinal cord sections for pEGFR and obtained 
what appeared to be axonal staining, but did not perform coimmunostaining using any 
axonal marker so it is possible that this pEGFR is in fact on the processes of glia such as 
oligodendrocytes or astrocytes.         
 In an attempt to further investigate this novel association between well 
characterised receptor and CNS regenerative failure, it was decided to 
immunohistochemically examine the distribution of pEGFR, the activated form of EGFR, in 
the rat visual system, with particular emphasis on axonal pEGFR.   The decision to study 
distribution of the activated from alone was based on both the proposed necessity of 
EGFR phosphorylation for axonal growth antagonism, and the existence of at least one 
previous paper investigating (non-activated) EGFR distribution within the rodent visual 
system (Liu et al. 2006).  The rat visual system itself was chosen due to its relative simple 
cytoarchitecture, ease of access for surgical procedures, and, crucially, because many of 
the results obtained by Koprivica et al. (2005) were obtained from rat retinal cultures and 
the rodent ONC in vivo model.  Similarly, all treatment group animals were to be killed at 
14 days post injury, as this was the timepoint used by that group.    
 If EGFR activation is in fact critical for axonal growth cone collapse, then axons 
regenerating into or beyond a CNS lesion would be expected to have lower levels of 
activated EGFR (pEGFR) compared to non regenerating axons, or possibly no pEGFR at all.  
 86 
 
Additionally, many previous studies have reported glial EGFR to be nearly absent in the 
uninjured visual system but to be strong upregulated following CNS injury.   
3.1.2  Specific Aims 
 To confirm immunohistochemically that regenerating RGC axons   
  exhibit reduced pEGFR levels compared to non regenerating RGC axons 
 
 To determine the distribution of pEGFR in neurons, axons and glia in   
  uninjured, regenerating and non regenerating retinae and ON 
 
3.1.3  Specific Hypotheses 
1) Levels of RGC axonal pEGFR will increase after injury and regenerating axons 
within ON and retinae will exhibit attenuated pEGFR levels compared to non 
regenerating axons  
 
2) Glia in uninjured ON and retinae will express little if any pEGFR, but following 
injury, glia will become strongly pEGFR+  
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3.2 Results 
 
 
3.2.1   Antibody to pEGFR was specific and detected a protein of the correct
  weight 
 
 
Figure 3.6 shows the results of immunostaining for pEGFR using the goat polyclonal anti-
pEGFR antibody SC-12351 at a concentration of 4µg/ml with (A) and without (B) 80µg/ml 
blocking peptide.  This was performed on consecutive 15µm sections of uninjured rat 
retina, using a standard IHC protocol (described in materials and methods section) and 
produced clear and specific staining, whilst sc12351+ blocking peptide yielded no staining. 
 
   
 
Figure 3.6.  Consecutive 15µm sections of uninjured rat retina, stained with 4µg/ml Goat anti 
pEGFR antibody (sc12351, green staining) with (A) and without (B) 80µg/ml blocking peptide.  
Complete absence of staining in the presence of blocking peptide confirmed antibody specificity. 
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Antibody specificity was further confirmed by SDS-PAGE and Western blot on 
retinal lysates (Figure 3.7).  Lysates consisted of homogenized retinae from animals which 
had undergone ONC 14 days prior to death.  A clear protein band was obtained at the 
correct weight of ~170kDa.   
 
 
 
 
Figure 3.7.  Western blot confirmed specificity 
of antibody SC12351. 3 Retinal lysates from 
14dpi ONC animals were subjected to SDS-
PAGE and Western blotting, using polyclonal 
anti pEGFR Antibody  SC-12351. A clear band 
was obtained from all lysates at the predicted 
weight of 170kDa (arrow).  
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3.2.2 RGC axons in the optic nerve did not contain pEGFR 
 
 
Figure 3.8 shows double immunohistochemical staining for pEGFR and the cytoskeletal 
protein Neurofilament 200 (NF), an axonal marker, on 15µm thick uninjured control, post 
injury non-regenerating (NRM), and post injury regenerating (RM) rat optic nerve 
sections.  pEGFR was found not to colocalise with NF in any experimental or control 
group, neither constitutively nor post injury, in any part on the optic nerve.  This strongly 
suggests that all axons in the rat optic nerve are pEGFR―.  Confocal microscopy (Figure 
3.9) confirms this absence of axonal pEGFR.  
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Figure 3.8  Axons did not contain pEGFR.  First panel: Uninjured control ON.  The boxed region (1) is 
reproduced at high power to show that NF + axons (arrow head) were not pEGFR+ (green).  Note rows of 
pEGFR+ glia (arrows).  Similarly, boxed regions within NRM and RM (second and third panels respectively) 
show in high power that NF+ axonal debris (red) was also pEGFR―.  (NRM – non regenerating model, RM – 
regenerating model, NF – Neurofilament 200, axonal marker). 
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Figure 3.9.  Confocal microscopy confirmed NF+ axons (red) did not contain pEGFR (green) in the 
uninjured (A), NRM (B), RM (C) groups.  Images were taken at proximal boundary of lesion site (B, C) or 
equivalent area of uninjured nerve (A).  Scale bar = 10µm.  DAPI stained nuclei are blue. 
 
3.2.3   Astrocytes in the optic nerve were constitutively pEGFR+, and levels 
  of pEGFR along with GFAP, increased after injury 
 
Figures 3.10 and 3.11 show immunohistochemical staining for the astrocyte marker GFAP 
(red) and pEGFR (green).  Colocalisation of GFAP/pEGFR staining (orange/yellow) can be 
observed in uninjured, non regenerating and regenerating groups, indicating pEGFR+ 
astrocytes.  Note increase in both pEGFR and GFAP staining in all post injury images.  Post 
injury astrocyte hypertrophy and upregulated GFAP are consistent with the reactive 
astrogliosis known to occur following CNS injury.  
 
 
 
Figure 3.10.  Confocal imagery confirms that astrocytes were strongly pEGFR+ after ONC (NRM shown).  
pEGFR (green) and GFAP (red) colocalised extensively in these astrocytic cells and processes.                    
DAPI stained nuclei are blue.  Scale bar = 50µm 
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Figure 3.11.  GFAP+ astrocytes showed higher pEGFR levels after injury.  First panel: Representative 
image of an uninjured control ON (top).  The boxed region (1) is reproduced at high power to show 
GFAP+ (red) and pEGFR+ (green) astrocytes in the longitudinal rows of ON glia.  Second and third 
panels: NRM and RM in which boxed regions proximal (1) and distal (3) to the lesion show high 
power views of reactive astrocytes with upregulated GFAP co-localising with increased levels 
pEGFR (yellow-orange, arrowheads).  (NRM – non regenerating model, RM – regenerating model, 
GFAP - astrocytic marker). 
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3.2.4   Oligodendrocytes in the optic nerve were constitutively pEGFR+ but 
  levels did not appear to increase after injury  
 
 
Figures 3.12 and 3.13 show immunohistochemical staining for the oligodendrocyte 
marker Carbonic Anhydrase II (CAII) (red) and pEGFR (green).  Colocalisation 
(orange/yellow) can be observed in uninjured, non regenerating and regenerating groups.  
No increase in oligodendrocytic pEGFR staining was observed after injury.  Lesion sites 
were devoid of oligodendrocytes and the faintly CAII+ and pEGFR+ cells observed there 
were later shown to be phagocytic haematogeneous macrophages which had consumed 
both antigens.  The large scale degeneration of the distal stump, subsequent flooding of 
the area with previously-contained CAII, and the apparent death of many 
oligodendrocytes  made identifying individual oligodendrocytes more difficult but enough 
were observed to confirm that while many oligodendrocytes were pEGFR+,  pEGFR levels 
did not seem to have increased.   
 
 
Figure 3.12. Confocal imagery confirmed that oligodendrocytes were strongly pEGFR+ after ONC 
(NRM shown).  pEGFR (green) and CA-II (red) colocalised extensively in ON oligodendrocytes. DAPI 
stained nuclei are blue. Scale bar = 50µm 
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Figure 3.13.  Oligodendrocytes were pEGFR+.  First panel: Representative image of an 
uninjured control ON.  The boxed region (1) is reproduced at high power to show CAII + (red) 
oligodendrocytes which are constitutively pEGFR+ (green) visible as longitudinal lines of ON 
glia (arrows).   Second and third panels respectively show NRM and RM ON.  There is no 
discernable increase in pEGFR levels in oligodendrocytes (arrowheads) in NRM and RM 
proximal (1) and distal (3) to the lesion.  The lesion (2) was devoid of oligodendrocytes but 
contained pEGFR+ haematogenous macrophages (arrows).  (NRM – non regenerating model, 
RM – regenerating model, CA-II – Carbonic Anhydrase II, oligodendrocytic marker). 
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3.2.5. Quiescent microglia in the optic nerve were constitutively weakly 
  pEGFR+ or were pEGFR― but levels increased significantly upon 
  microglial activation  
 
 
Figure 3.14 shows immunohistochemical staining for the microglial marker OX42 (red) 
and pEGFR (green).  In the uninjured optic nerve, microglia were either very weakly 
pEGFR+ or were pEGFR― and were spindle shaped and uniformly distributed.  After injury 
(NRM, RM) microglia became activated, assuming a rounded, macrophage like phenotype 
and became strongly pEGFR+.  Although activated microglia are phagocytic, and thus 
could potentially become pEGFR+ by consuming cellular debris, much of the pEGFR 
staining is juxtamembraneous, and not just contained within vesicles, suggesting 
membrane bound pEGFR.  pEGFR and OX42 colocalisation appeared most strongly and 
most commonly near the lesion site and in the distal stump, areas containing larger 
amounts of degenerating myelin sheaths and cellular debris (both NRM and RM, panels 2 
and 3). 
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Figure 3.14.  Activated microglia were pEGFR+.  First panel: Representative image of an 
uninjured control ON.  The boxed region (1) is reproduced at high power to show that non-
activated OX 42+ (red; arrowhead) microglia were constitutively weakly pEGFR+ (green) in the 
longitudinal rows of ON glia.  Second and third panels respectively:  NRM and RM ON 
microglia became activated and showed increased levels of pEGFR (arrow heads) proximal (1) 
and distal (3) to the lesion.  The lesion (2) was full of activated microglia and large numbers of 
pEGFR+ haematogenous macrophages.  (NRM – non regenerating model, RM – regenerating 
model, OX-42, microglial marker). 
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3.2.6   Haematogeneous macrophages entering the optic nerve after injury
  were constitutively pEGFR+ 
 
 
Figure 3.15 shows immunohistochemical staining for the macrophage/activated microglia 
marker ED1 (red) and pEGFR (green).  In the uninjured optic nerve macrophages are 
almost completely absent due to the immunoprivileged nature of the CNS, however the 
occasional macrophage may be found on the very boundary of the dural sheath, 
presumably not quite within the blood brain barrier (uninjured, arrow).  After injury and 
subsequent disruption of the blood brain barrier, hameatogeneous macrophages flood 
the lesion site (NRM, 2 and RM, 2) and phagocytose the detritus.  All macrophages 
observed were seen to be pEGFR+.  Although this may be partly due to the consumption 
of pEGFR+ debris, juxtamembraneous staining can be seen, strongly suggesting the 
presence of pEGFR on the cell membrane itself. 
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Figure 3.15.  Invading haematogenous macrophages were pEGFR+.  First panel:  Representative 
image of uninjured control ON (top) in which ED1+ (red; arrowhead) haematogenous macrophages 
were confined to the pia and were constitutively pEGFR+ (green). In NRM and RM (second and third 
panels respectively), macrophages and activated microglia (arrow head) showed increased levels of 
pEGFR and accumulated in the lesion (2), and were also present to a lesser extent in the proximal (1) 
and distal ON segments (3). (NRM – non regenerating model, RM – regenerating model, ED-1, 
Macrophage marker).  Note that this marker also detects activated microglia, so many ED-1+ cells 
outside the lesion site (2) were likely activated CNS-resident microglia. 
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3.2.7 Axons within the retina were exclusively pEGFR―  
 
 
Figure 3.16 shows double immunohistochemical staining for pEGFR (green) and NF (red), 
on 15µm thick uninjured control (u/c), post injury non-regenerating (NRM), and post 
injury regenerating (RM) rat retinal sections.  pEGFR was found not to colocalise with NF 
in any experimental or control group, neither constitutively nor post injury, in any part of 
the retina.  This strongly suggests that all RGC axons in the FL of the rat retina are 
pEGFR―.   
 
 
 
Figure 3.16.  RGC axons did not contain pEGFR.  Representative images of parasagittal sections of 
uninjured, NRM and RM retinae stained for pEGFR and NF.  NF+ (red, closed arrow) axons in the 
FL were pEGFR (green) negative across all groups (DAPI stained nuclei are blue), as evidenced by 
complete lack of yellow-orange staining.  The number of NF+ axons (red ,closed arrowhead) in the 
FL of NRM and RM retinae was reduced compared to U/C  due to RGC death (See table 3.1).  
There was up-regulation of NF in the OPL in both NRM and RM retinae (open arrows). 
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3.2.8  A sub-population of retinal ganglion cells within the retina were 
constitutively pEGFR+ but this proportion remained the same in all 
treatment groups 
 
 
Figure 3.17 shows double immunohistochemical staining for pEGFR (green) and the RGC 
marker β-III tubulin (red), on 15µm thick u/c, (top) NRM (middle), and RM (bottom) rat 
retinal sections.  Confocal imagery (Figure 3.18) confirms β-III tubulin+ and pEGFR+ RGC 
somata.  pEGFR was found to colocalise with β-III tubulin in approximately 30% of RGC, 
across all experimental and control groups, both constitutively and post injury (see Figure 
3.19). 
 
 
 
Figure 3.17.  A sub population of RGC somata were pEGFR+ but axons remained pEGFR―.  
Representative images of parasagittal sections of uninjured, NRM and RM retinae.  A sub-population 
of RGC costained for both β-III-tubulin (red, closed arrowhead) and for pEGFR (green) in all groups, at 
approximately the same frequency.  β-III-tubulin+ RGC dendritic arborisations ramified the IPL (red, 
open arrows).  DAPI stained nuclei are blue. 
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Figure 3.18.  Confocal imagery confirmed pEGFR+ retinal ganglion cells.  Double immunohistochemical 
staining for pEGFR (green, (B)) and the RGC marker β-III tubulin (red, (C)) shows colocalisation (orange-
yellow, (D)).  Scale bar = 10µm.  DAPI stained nuclei are blue (A) 
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Figure 3.19.  Proportion of all retinal ganglion cells which are 
pEGFR+.  Uninjured, NRM and RM retinae contain 
approximately the same proportion of pEGFR+ RGC. 
Proportions are expressed as:(number of pEGFR+ RGC) / (total 
number of RGC)  Error bars represent 95% confidence 
intervals. 
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3.2.9   Retinal astrocytes and Müller glia were constitutively pEGFR+ and 
  levels increased after injury  
 
 
Figure 3.20 shows double immunohistochemical staining for pEGFR (green) and the 
astrocyte and Müller cell marker GFAP (red), on 15µm thick uninjured control (u/c), post 
injury non-regenerating (NRM), and post injury regenerating (RM) rat retinal sections.  In 
the uninjured retina pEGFR staining is limited to the FL, with the end feet of Müller glia 
and the cell bodies of astrocytes being predominantly pEGFR+ ( U/C, open arrowheads).  
Both astrocytes and the end feet of Müller glia are constitutively GFAP+ but upregulate 
GFAP and exhibit increased pEGFR levels after injury (NRM and RM).  Müller glial 
processes also become pEGFR+ and GFAP+ after injury, (NRM and RM). 
 
 
 
 
 
Figure 3.20.  Representative images of parasagittal sections of U/C, NRM and RM retinae.  GFAP 
(red,open/closed arrowhead) and pEGFR (green) are weakly and constitutively co-localised in retinal 
astrocytes (open arrow heads)  and Müller cells (closed arrowheads) in uninjured retinae. Levels of 
both epitopes increase in Müller cell radial processes (closed arrowheads) Müller cell/astrocyte -feet 
(open arrow heads) in the FL of NRM and RM retinae. 
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3.3 Discussion 
3.3.1   All retinal ganglion cell axons, in both the optic nerve and in the 
  retina, were pEGFR― 
 
In light of the original hypothesis that intra-axonal EGFR transactivation is causal in CNS 
axon growth cone collapse, the total absence of pEGFR in RGC axons and growth cones is 
surprising.  While several studies have provided evidence that EGFR is somehow involved 
in the AGIM signalling cascade (Koprivica et al. 2005, Erschbamer et al. 2007, Liu et al. 
2006, Chen et al. 2007) no study to date has demonstrated pEGFR on RGC axons. Previous 
studies (Liu et al. 2006, Chen et al. 2007) have described EGFR on RGC somata but these 
studies did not examine retinal or ON pEGFR.  The consensus of opinion is that 
transactivation of EGFR is required in order to transduce the AGIM signalling cascade 
(Koprivica et al. 2005, Liu et al. 2006, Chen et al. 2007, Schachtrup et al. 2007), as distinct 
to the pEGFR which results following EGFR ligand binding and would result in receptor 
internalisation.  The putative NgR and fibrinogen interactions with EGFR, described in the 
papers by Koprivica et al. (2005) and Schachtrup et al. (2007) respectively, would require 
physical approximation of these molecules and/or signalling intermediaries and EGFR.  
The absence of pEGFR on RGC axons demonstrated here suggests that this interaction 
cannot be taking place intra-axonally, although this does not rule out the possibilities that 
a) EGFR interactions take place in some RGC somata or b) that pEGFR is present only in 
RGC axonal growth cones – which could not be directly visualised with the techniques 
used.   
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Although it is possible that pEGFR― mediated growth cone collapse could occur 
through intermediaries originating from the somata then being anterogradely 
transported to the axon, it is difficult to explain how such a system could limit its effects 
to the growth cone while avoiding cytoskeletal rearrangement at the somata and 
throughout the axon.        
 Conversely, growth cones are now known to synthesise certain proteins directly, 
rather than depend on anterograde transport from the somata (Zheng et al. 2001, Verma 
et al. 2005), so it is possible that EGFR could be synthesised and inserted into the 
membrane within the growth cone itself.  One difficulty in directly observing such an 
event in vivo is the prevalence of pEGFR+ cellular debris and the enormous increase in 
EGFR/pEGFR levels which occurs after CNS injury, primarily as observed in astrocytes and 
their processes (Liu and Neufeld 2007), but also in microglia (Planas et al. 1998), and 
invading macrophages (this study).        
 Nevertheless, the lack of observable axonal pEGFR makes a purely intra-axonal 
role for pEGFR difficult to accept.  The axon regenerative actions of EGFRki are thus 
unlikely to be due to their abrogation of RhoA/ROCK mediated growth cone collapse 
through direct blockade of RGC axonal pEGFR. 
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3.3.2   A sub-population of retinal ganglion cell somata within the retina 
  were constitutively pEGFR+ but this proportion remained the same 
  in all treatment groups 
 
While RGC are known to express EGFR constitutively (Chen et al. 2006), no study to date 
has published observations on RGC pEGFR levels.  In light of the complete absence of 
RGC- axonal pEGFR and considering the putative role of EGFR in the growth cone collapse 
signalling cascade, the near-identical proportions of pEGFR+ RGC in all groups, including 
uninjured control, is surprising.  The significance of this pEGFR+ subpopulation, consisting 
of approximately 30% of total RGC, is unclear.  What is certain is that this ~30% does not 
represent the population of axons which responded to intra-optic nerve EGFRki therapy: 
the proportion of regenerating RGC fibres were estimated by the authors to be around 
0.5% of the total population (Koprivica et al. 2005).  Among the best reported axon 
regeneration rates, in terms of total percentage of all RGC axons regenerating beyond the 
lesion site, are 0.6-10% 3 weeks after intravitreal peripheral nerve graft implant (Berry et 
al. 1996) and 7.5% 4 weeks after a triple combination of C3-transferase-mediated RhoA 
inactivation, application of exogenous, cell-permeable cAMP and simultaneous peripheral 
nerve autografting onto the cut end of the optic nerve (Hu et al. 2007).  It is thus unlikely 
that the ~30% of pEGFR+ RGC represents a specific population with any significantly 
different regenerative potential.          
 While EGFR activation has been linked to enhanced neurite outgrowth and 
neuronal survival of cerebellar granular neurons (CGN) in vitro (Yamada et al. 1997), its 
primary role in the adult CNS appears to be that of a neuromodulator, activating NMDA 
receptors and enhancing long term potentiation in the rat hippocampal neurons (Yamada 
et al. 1997, Abe and Saito, 1992).  Importantly, both these neuronal-specific effects of 
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EGFR signalling are mediated by standard ligand-receptor interactions, EGF binding to and 
directly activating the EGFR.  The mechanism behind EFGR-mediated growth cone 
collapse posited by Koprivica et al (2005). relies on EGFR-transactivation, a completely 
different process, potentially involving different signalling partners, impinging on 
different signalling pathways and thus capable of having distinct effects on neurons and 
axons.  It is known that EGFR signalling in response to ligand binding involves receptor 
dimerisation and internalization, and that the fate of the ligand-receptor complex is 
dictated by the nature of both the dimer (EGFR can hetero-dimerise with other members 
of the ErbB family) and the specific ligand (Shankaran et al. 2006, Bazley and Gullick 2005, 
Wiley 2002, Wong and Guilliard 2004).  Different ligand-receptor complexes can be 
variously degraded in endosomes or dissociate, with the EGFR returning to the membrane 
(Bazley and Gullick 2005, Wiley 2002).  It has also been reported that EGFR can be 
internalised without receptor kinase activation (Wang et al. 2005) and, conversely, that 
EGFR tyrosine kinase domains can in turn be transactivated without receptor dimerisation 
or internalisation, by fibrinogen via β3-Integrin (Schachtrup et al. 2007) and by GPCRs 
(Gschwind et al. 2001).        
 Taking into account this multitude of potential mechanisms and outcomes of EGFR 
signalling, the presence of pEGFR on an unchanging size of subpopulation of RGC somata 
cannot reliably be construed to have any definite relevance to axonal regeneration. 
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3.3.3   Astrocytes in the optic nerve were constitutively pEGFR+ and levels 
  appeared to increase after injury 
 
In response to CNS injury local astrocytes undergo astrogliosis, a series of radical 
phenotypic changes characterised by GFAP upregulation, hypertrophy, mitosis, and, 
critically, increased secretion of various factors inhibitory to axonal regeneration, 
including Semaphorin 3 (Pasterkamp et al. 2001), ephrin-B2 (Bundesen et al. 2003), slit 
proteins (Hagino et al. 2003), and chondroitin sulfate proteoglycans (Rhodes and Fawcett 
2004, Smith and Strunz 2005).  It should be noted that reactive astrocytes also secrete 
fibronectin (Liu and Neufeld 2004a) and laminin (Martinez and Gomes, 2002), two 
components of the ECM which actually facilitate axonal regeneration by providing a 
positive growth substrate but also form part of the post injury glial scar.  EGFR activation 
has been shown to increase astrocytic production of CSPG (Smith and Strunz 2005) and 
EGFR is known to regulate the release of several factors which attract and/or activate 
various other cell types associated with formation of the glial scar.  These molecules 
include monocyte chemoattractant protein (MCP) 1, which encourages monocyte influx 
into the lesion site where they can transform into macrophages (Tanuma et al. 2006), 
monocyte to macrophage differentiation factor, which would enhance this process (Liu 
2006), and cyclooxygenase 2 which attracts and activates microglia (Zhang and Neufeld 
2005) allowing these cells to then take on a macrophage-like role.  Although macrophages 
and microglia clearly have some neuroprotective roles, secreting NTFs, growth factors 
and phagocytosing any infectious agents within the injury site, these cells also contribute 
to axonal damage and death by stripping myelin from injured axons (for review see 
Donnelly and Popovich 2008).  EGFR activation in astrocytes has also been shown to 
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provoke release of damaging reactive oxygen species such as nitric oxide which can 
directly damage and even kill adjacent neurons (Liu and Neufeld 2003).   
  It is then immediately apparent that EGFRki could potentially enhance axonal 
regeneration purely by ameliorating some or all of the above astrocyte-governed 
processes; rendering the lesion site less hostile by limiting the amount of growth 
antagonistic molecules and harmful cellular events, without necessarily having any direct 
effect on axonal or neuronal EGFR. 
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3.3.4   Müller glia and retinal astrocytes were both mostly constitutively 
  pEGFR― but became strongly pEGFR+ after injury 
 
Müller glia in the healthy adult CNS express negligible or no GFAP, and when visible, GFAP 
is only seen in the cells’ endfeet (Jadhav et al. 2009).  The rapid activation of Müller glia in 
response to almost every type of retinal insult is well documented, as is the rapid 
upregulation of GFAP which accompanies this (see Bringmann et al. 2009 for review).  
Upon activation, GFAP becomes visible along the length of the Müller cell (Douglas et al. 
2009, Liu et al. 2006).  Interestingly, antibodies to EGFR (Close et al. 2006) and pEGFR 
(Douglas and Morrison et al. 2009) reveal very similar phenomenology; both forms being 
almost absent from normal adult Müller glia but clearly visible after injury along the full 
extent of the cell as it traverses the various layers of the retina (Close et al. 2006, Douglas 
and Morrison et al. 2009).  At least three studies have linked EGFR activity to Müller cell 
gliosis (Milenkovic et al. 2003, Scherer and Schnitzer 1994, Roque et al. 1992) while 
another has shown that overexpression of EGFR by retinal progenitor cells consistently 
yields Müller glia instead of photoreceptors, interneurons or RGC (Lillien 1995).  It 
appears then, that EGFR activation can elicit or at the very least facilitate Müller gliosis; a 
process linked to neuronal death via processes as diverse as neurotransmitter removal 
deficiency (leading to or aggravating  neuronal excitotoxicity), K+ and H2O dysregulation 
and the formation and release of cytotoxic reactive oxygen species (Bringmann et al. 
2009).  It has long been known that activated Müller glia, along with retinal astrocytes, 
hypertrophy and multiply after intra-orbital optic nerve crush, extending into and filling 
the spaces left by dead neurons and axons (Barron et al. 1986) and that these activated 
Müller glia can help form a glial scar within the ganglion cell fibre layer of the retina, 
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preventing axonal growth (Burke and Smith 1981).  In short, it would seem that the 
appearance of pEGFR+ Müller glia heralds various processes antagonistic to axonal 
regeneration.  One potential means of investigating intra-retinal Müller Glial (and 
astrocytic) pEGFR function might be to directly inject or implant a bolus of EGFRki directly 
into the vitreous body immediately following optic nerve crush injury and to observe 
what effects, if any, this had on RGC survival and axonal regeneration (see Chapter 3).  It 
should be noted that the original study applying EGFRki to crushed optic nerves (Koprivica 
et al. 2005) did so at a considerable distance from the retina, thus it is likely that the RGC 
axon regeneration observed was elicited in spite of any retinal pEGFR involvement.  
Despite this, there remains the possibility that intra optic nerve EGFRki could have 
retrograde effects on retinal cells.  EGFRki, or other molecules released in response to 
EGFRki, could be retrogradely transported by axons, from the optic nerve to RGC cell 
bodies in the retina, and from there local paracrine effects on surrounding glia and 
neurons are possible.  Another possibility is astrocyte-astrocyte signalling via juxtacrine 
interactions, as an unbroken chain of astrocytes exists from the optic nerve to the retina. 
 
3.3.5   Oligodendrocytes in the optic nerve were constitutively pEGFR+ and 
  levels did not appear to increase after injury 
 
A search of the literature yields only one paper directly concerned with oligodendrocytic 
EGFR.  This study (Aguirre et al. 2007) provides strong evidence that EGFR signalling is 
required for both myelination and remyelination after injury, showing how 
overexpression of EGFR yields higher levels of myelin basic protein in focally 
demyelinated areas of the mouse brain. Myelin production after CNS injury can be both 
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beneficial and detrimental.  In many CNS pathologies and injuries a sizeable percentage of 
long tract axons escape transection.  Studies in cat SCI models showed that locomotion 
could still be achieved with only 5-10% axonal survival in the relevant tracts (Blight 1983, 
Blight and Decrescito 1986).  Oligodendrocyte death and axonal debridement by invading 
lymphocytes often results in these surviving axons being completely demyelinated (Crowe 
et al. 1997) and unable to conduct action potentials effectively over any distance.  Thus 
remyelination of these surviving tracts is highly desireable as this could avoid the need for 
the long tract axonal regeneration, pathfinding and reconnection that has so far been 
almost universally elusive in treating CNS pathologies.  Conversely, myelin provides 
arguably the greatest source of axon growth-cone collapsing molecules: Nogo (Chen et al. 
2000, Grandpre et al. 2000, Prinjha et al. 2000), OMgp (Kottis et al. 2002) and MAG 
(McKerracher et al. 1994) are all present in CNS myelin.  Each of these has been shown to 
elicit growth cone collapse, leading to axonal regenerative failure and subsequent 
neuronal loss.  Neutralising Nogo with the antibody IN-1 has been shown to enhance 
functional recovery and significantly increase axonal regeneration at the lesion site 
(Thallmair et al. 1998) and similar experiments with antibodies conjugated to MAG 
greatly enhanced neurite outgrowth in cerebral granular neurons plated in the presence 
of MAG (Irving et al. 2005).  The large amounts of fragmented myelin in the distal stumps 
of both the RM and NRM ON are testament to the fact that Wallerian degeneration in the 
CNS is immensely slow or absent, as by the equivalent time point in PNS injuries (14 dpi) 
almost all axonal and myelin debris has normally been cleared (Vargas and Barres, 2007) –
see general introduction for more detail.  That oligodendrocytic pEGFR levels do not 
appear to change following injury implies that oligodendrocytic pEGFR is, on balance, not 
particularly relevant to axonal regeneration.  Additionally, this may indicate that 
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oligodendrocytes require ongoing EGFR activity in order to maintain myelin production or 
other, unidentified, cellular processes. 
 
3.3.6  Quiescent microglia in the optic nerve were constitutively weakly 
 pEGFR+ or were pEGFR― but became strongly pEGFR+ upon activation 
 
Non-activated microglia being largely pEGFR― and activated, post injury microglia 
becoming strongly pEGFR+ agrees with the results of at least one previous study of 
microglial EGFR expression (Planas et al. 1998).  This group found that while quiescent 
microglia in the uninjured rat brain express very low levels of, or do not express EGFR, all 
microglia observed 4 days post ischaemic brain injury were strongly EGFR+ and suggested 
that EGFR signalling is required for microglial activation. Being that activated microglia are 
largely responsible for initiating and maintain the immune response to CNS injury (see 
Garden and Moller 2006 for review), this ties EGFR directly into the ongoing conundrum 
of whether the inflammatory and immune responses are beneficial or detrimental overall 
to CNS axonal regeneration (see general introduction for details). Thus both microglial 
activation and macrophage activity can be either conducive to, or inhibit neuronal 
survival and axonal regeneration, depending on the exact nature of the CNS injury. 
 Despite the potentially beneficial actions of activated microglia, putatively 
requiring or at least facilitated by pEGFR, numerous studies prior to and separate from 
those involving EGFRki have shown another EGFR antagonist, Decorin, to be profoundly 
conducive to axogenesis both in vitro and in vivo, and that these effects are at least 
partially mediated by microglia (Davies et al. 2006).  Decorin is a small leucine rich 
proteoglycan, abundant in ECM, which is a natural antagonist of scar formation (see 
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Hocking et al. 1998 for review).  Tumour suppression studies describe how Decorin binds 
to EGFR, causing it to be internalised and degraded (Csordas et al. 2000, Zhu et al. 2005) 
and, more importantly, abolishing the activation of remaining EGFR (Csordas et al. 2000).  
Within the CNS Decorin has been shown to degrade, and/or suppress the production of, 
various axon growth inhibitory molecules, including the CSPGs versican, neurocan, NG2 
and brevican, reduce astrogliosis, prevent or attenuate glial scar deposition, significantly 
reduce post injury macrophage influx and massively increase cultured PNS dorsal root 
ganglia neuron (DRGN) neurite outgrowth on CSPG and CNS myelin substrates (Tang et al. 
2003, Davies et al., 2004, Logan et al. 1999, Minor et al. 2008).  As Decorin potently 
inactivates EGFR, this is strong circumstantial evidence that microglial (and astrocytic) 
pEGFR plays an important role in many processes antagonistic to CNS repair.  A recent 
study has also provided evidence that one member of the CSPG family, versican, actually 
signals directly through EGFR as a ligand (Xiang et al. 2006), suggesting another 
mechanism by which blocking pEGFR could potentially benefit the regenerating CNS.  It 
should be noted however that this study actually found a specific domain of versican (the 
G3 region) to signal through the EGFR, and also found the results of this signaling to be 
neuritogenic for cultured hippocampal neurons, although the authors point out that two 
different isoforms of versican, V1 and V2 have different axon growth inhibitory 
properties, and thus much depends on the specific isoform/version of versican.  
Nevertheless, the direct activation of EGFR by a CSPG should not be overlooked as a 
potentially novel source of axonal growth inhibition, nor discounted when considering the 
actions of broad-spectrum EGFR antagonists such as Decorin or EGFRki. 
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3.3.7   Haematogenous macrophages entering the optic nerve after injury 
  were constitutively pEGFR+ 
 
The literature for EGFR signalling in macrophages/monocytes appears remarkably sparse.  
A PubMed search for either ‘EGFR macrophage’ or ‘EGFR monocyte’ yields only two 
directly relevant papers.  The first confirms macrophage EGFR expression and posits EGFR 
signalling to be involved in macrophage chemotaxis and mitosis (Lamb et al. 2004) and 
the second simply confirmed the presence of EGFR+ macrophages in a melanoma model 
(Scholes et al. 2001).  Nevertheless, this supports the present study’s findings that 
macrophages express EGFR, and if EGFR is required for/involved in macrophage migration 
then invading macrophages would be expected to exhibit pEGFR.  If attenuation of EGFR 
activation by EGFRki could limit macrophage numbers and reduce their influx into the 
injured CNS then this could potentially lead to a reduction in the secondary damage to 
axons associated with phagocytic leukocytes in SCI models of CNS injury.  How such an 
attenuation of macrophage ingress would affect ONC models of CNS injury and 
regeneration is another matter, considering the proven beneficial effects of intravitreal 
macrophage recruitment described above. 
 
3.4   Interim Conclusions 
That all RGC axons observed in both the optic nerve and the retina were found to be 
pEGFR― implies that the axonal regenerative effects of EGFRki are unlikely to be a result 
of direct interaction with neuronal/axonal EGFR.  It is possible that pEGFR could be 
present in axonal growth cones alone, as the antibody used to identify axons was raised 
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against the heavy chain Neurofilament, NF-200, which is only present in the consolidated 
axon and therefore does not allow visualisation of the newly grown axon or the growth 
cone itself.  Endogenous EGFR signalling would presumably result in detectable levels of 
axonal pEGFR as ligand-receptor complexes are endocytosed and travel to either the 
nucleus or endosomes.  That this was not observed suggests an absence of pEGFR within 
RGC growth cones.  The near ubiquity of glial pEGFR and the abundance of literature 
describing various glial EGFR-mediated, regeneration-antagonistic processes strongly 
suggest that the primary means by which EGFRki effect axonal regeneration is to partially 
neutralise the inhibitory impact of the CNS lesion itself.  By reducing astrogliosis EGFRki 
could attenuate CSPG deposition, prevent or reduce the interaction between astrocytes 
and fibroblasts crucial to the formation of the glial scar in the ON.  Suppressing Müller 
glial activation via EGFR blockade could prevent the neuronal death associated with 
Müller cell dysfunction following activation.  Preventing or abrogating EGFR-mediated 
microglial activation, as shown prominently in studies involving decorin, can have wide 
reaching benefits including abrogated production of ROS, reduced recruitment of MBP-
sensitised lymphocytes (and hence reduced axonal and neuronal myelin debridement) 
and lower levels of excitotoxic glutamate.  If the migration and mitosis of macrophages is 
in fact primarily EGFR mediated then EGFRki could also potentially directly reduce 
macrophage numbers recruited.  That one therapeutic target could attenuate or abolish 
so many potentially noxious processes appears promising but this is tempered somewhat 
by the fact that in the original study using EGFRki in an ONC model (Koprivica et al. 2005) 
no effect on RGC survival was found and, crucially, only 0.5% of the total RGC population 
regenerated axons across the lesion site and into the distal segment of the ON in vivo.  
Compared with the ~10% of the total RGC population which has been reported to 
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regenerate > 4 mm into the distal section of the crushed ON following intravitreal PN 
graft (Berry et al. 1996) this is not particularly impressive.  However, the the mitosing 
Schwann cells contained within the intravitreal PN graft, which is undergoing Wallerian 
degeneration, supply a wealth of neurotrophic factors which strongly support RGC 
survival for weeks after axotomy (Berry et al. 1988, 2008, Logan et al. 2006), whereas, as 
mentioned, EGFRki do not appear to enhance RGC survival.  That a subpopulation of RGC 
will regenerate in the (apparent) absence of exogenous NTF support is both unusual and 
potentially important, possibly pointing to a novel mechanism by which at least some RGC 
can be disinhibited.  More importantly, if EGFRki are actually capable of rendering the 
CNS environment significantly less hostile to axonal growth, there is much potential for 
future combinatorial therapies involving EGFR blockade along with exogenous growth 
stimuli.          
 That no difference was observed in pEGFR levels between the RM and NRM does 
not necessarily reflect a real equivalence in pEGFR levels, rather it highlights that at best, 
semi-quantitative nature of immunohistochemical studies.  SDS-page and Western 
blotting would establish whether or not any real differences in pEGFR levels existed but 
animal numbers and the need for mutually exclusive tissue preparation (fixation versus 
non fixation) prohibited these extra experiments in this case.  Previously our laboratory 
has published studies involving larger scale experiments and included groups of RM and 
NRM animals to be used as tissue donors for SDS-PAGE and Western blot, and obtained 
results showing that pEGFR levels are in fact significantly lower in the RM compared to 
the NRM (see Ahmed et al. 2006, Figure 3A).  It is also likely that such a clear discrepancy 
could not come about from merely differences in any extant axonal pEGFR, such a clear 
difference would very likely reflect differences in glial expression of EGFR.  This is also 
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circumstantial evidence that suppressing pEGFR may be conducive to axonal 
regeneration.           
 As the in vivo immunohistochemical results obtained in this Chapter have 
highlighted a discrepancy between the proposed mechanism of action of EGFRki-
mediated axonal regeneration as suggested by Koprivica et al. and the actual distribution 
of pEGFR in the rat visual system, namely the complete absence of axonal pEGFR, it was 
decided to examine the actions of one of the EGFRki used by Koprivica et al., AG1478, in 
primary retinal cultures, to attempt to ascertain whether or not EGFRki can elicit RGC 
neurite outgrowth in an inhibitory environment and, if so, to attempt to elucidate the 
mechanisms underlying this effect.       
 Finally it should be noted that while this study is the first to examine pEGFR 
distribution in the visual system, Chen et al. (2007) studied the distribution of EGFR, not 
discerning between EGFR and pEGFR, and that the main findings of that study confirm 
those of the present study; namely that EGFR is not present on RGC axons, is present on 
at most a subpopulation of RGC somata and is weakly present on/absent from astrocytes 
and Müller glia pre-injury but strongly present after ONC.  
 128 
 
Chapter 4 
An investigation of the In Vitro effects of the EGFRki 
AG1478 on primary retinal cultures and the RGC-5 cell line 
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4.0 Introduction 
Having shown all RGC axons and the majority of RGC somata to be pEGFR―, the question 
arose of exactly how EGFRki elicited the in vitro neurite outgrowth and in vivo axonal 
regeneration reported by Koprivica et a(2005).  The original mechanism suggested by 
these authors implicated the EGFR as a critical part of the intraneuronal/axonal inhibitory 
signalling cascade initiated by the NgR, based on the evidence that preventing the 
activation of (or more specifically the phosphorylation of) EGFR disinhibited neurite 
outgrowth in vitro.  In light of the lack of axonal pEGFR this explanation was considered 
unsatisfactory; it was difficult to see how EGFR signalling could play such a direct intra-
axonal role.  While previous studies have shown that blocking single receptors for AGIM 
can elicit significant axonal regeneration and functional recovery (e.g. Grandpre et al. 
2002, Fabes et al. 2007), these studies use spinal hemisection injury models, usually 
severing a dorsal tract and leaving its ventral counterpart intact.  At least one study has 
shown that, without any therapeutic intervention whatsoever, considerable functional 
recovery can result from spontaneous ‘rewiring’ of injured dorsal corticospinal (CST) 
tracts via collateral sprouting from uninjured ventral CST tracts (Weidner et al. 2001).  
Conversely, the literature does not contain any reports of functional recovery-level RGC 
axonal regeneration in response to antagonism of any single receptor.  As such, the 
significant regeneration associated with neutralisation of specific receptors in each of the 
aforementioned studies is likely to represent an enhancement of existing neural plasticity.  
As such, it is unlikely that the neutralisation of any one single receptor, including EGFR in 
its putative axon growth inhibitory role, would actively drive RGC axonal regeneration 
following complete ON transection – there being no other population of axons to which 
 130 
 
RGC axons could laterally connect.  Previous studies have shown the neutralisation of NgR 
alone to be largely insufficient for RGC regeneration in vivo (Fischer et al. 2004a, but see 
Chen et al. 2009) whereas similar neutralisation of the small GTPase Rho A (Fischer et al. 
2004b), which transduces signals from multiple receptors,  yields greater, if still marginal, 
levels of axonal regeneration.  However, when NgR inactivation is combined with any 
growth promoting therapy such as NTF support, significant regeneration is often reported 
(Fischer et al. 2004b, Chen et al. 2009, Ahmed et al. 2005).  It is thus likely that the growth 
promoting effects of EGFRki such as AG1478, as reported by Koprivica et al(2005), result 
from more than just the indirect intraneuronal blockade of NgR signalling via EGFR 
antagonism, and the purpose of this study was to determine the nature of this proposed 
stimulus to RGC neuritogenesis/axogenesis.       
 The previous Chapter showed that, while all RGC axons and most RGC somata 
were pEGFR―, many retinal and ON glia were pEGFR+, and pEGFR levels increased after 
ONC.  This implied that the effects of EGFRki such as AG1478 could be significantly or 
even primarily glially mediated.  Considering the numerous, neurite outgrowth 
antagonistic, glially mediated processes linked to EGFR signalling (see discussion, previous 
Chapter), this was considered a promising line of investigation.  However, 
contemporaneous with this work, it was found by others in our laboratory that 90% siRNA 
knockdown of EGFR failed to disinhibit RGC neurite outgrowth in primary retinal cultures 
exposed to CNS Myelin Extract (CME) (then-unpublished findings of Dr M. Douglas and Dr 
Z. Ahmed, since published in Douglas et al. 2009), and that subsequently treating these 
EGFR knockdown cultures with AG1478 still resulted in disinhibited neurite outgrowth.  
This was strong evidence that the neuritogenesis elicited by AG1478 was not primarily 
due to its blockade of EGFR.  These developments warranted further investigation of the 
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in vitro effects of AG1478.  To this end, it was decided to confirm first hand that AG1478 
could in fact disinhibit primary culture-RGC neurite outgrowth in a growth inhibitory 
environment.  Ideally, this required an effective, replicable, non neurotoxic neurite 
outgrowth inhibition assay.  Many research groups have used CSPG and CME in 
outgrowth inhibition assays, but the former is difficult to purify and expensive to 
purchase, whereas it is difficult to accurately assess relative protein levels in the latter.  
The synthetic recombinant Nogo-P4 peptide was selected as a potential candidate 
inhibitory ligand due to both its soluble nature - which allows the titration of specific and 
easily replicable concentrations of the compound into culture media - and its well 
understood NgR-dependent signalling properties.  If a concentration of Nogo-P4 could be 
found which significantly inhibited RGC neuritogenesis without causing neuronal death, it 
could then be ascertained whether this inhibition could subsequently be neutralised by 
AG1478.  As primary retinal cultures require the sacrifice of an animal and can be prone 
to relatively large inter-experimental variation, it was decided to also model Nogo-P4-
inhibited and AG1478-disinhibited primary retinal culture experiments using the 
immortalised neuronal RGC-5 cell line.  If successful, this would provide an inexpensive, 
highly replicable, neurite outgrowth-inhibitory assay.  It is also worth noting that the 
literature does not appear to contain any studies having made use of Nogo-P4 peptide in 
such an assay; so successful inhibition of RGC neurite outgrowth with Nogo-P4 would 
represent a potentially novel neurite outgrowth inhibition assay.    
 Having confirmed the efficacy of AG1478 in disinhibiting neurite outgrowth, the 
next step would be to establish the nature of the hypothesised off target effect(s).  The 
most obvious candidates for driving neurite outgrowth are NTFs, including the NTs, 
and/or any compound which could mimic their effects.  If AG1478 could elicit NTF 
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release, autocrinally from RGC or paracrinally from retinal glia, these factors could be 
detected by ELISA analysis of collected conditioned culture media.  Additionally, if both 
primary retinal cultures and the RGC-5 cell line were found to respond to AG1478, and if 
subsequent ELISAs on conditioned media detected NTF release, this would point to 
AG1478-stimulated autocrine NTF release as a primary drive of neuritogenesis, as RGC-5 
cultures contain no glia.  As mentioned, some effects of NTF can be elicited in the absence 
of NTF, normally by receptor crosstalk.  Accordingly, it was decided to investigate reports 
that the adenosine A2A receptor could, in the absence of any exogenous NTF, 
transactivate Trk receptors, effectively enabling A2A agonists, including adenosine, to 
function as NTFs (Jeanneteau and Chao, 2006).  To ascertain whether this A2A-dependent 
event contributed to the putative disinhibitory effects of AG1478, it would be 
investigated whether the potent and specific A2A receptor antagonist ZM21385 could 
neutralise or diminish the AG1478-stimulated effects.   
 Attention was then turned to the experimental end-point measurement criteria, in 
terms of discerning and measuring the effects of Nogo-P4 and AG1478 on neurite 
outgrowth.  The mean number of neurites produced per neuron were considered to be a 
separate factor from that of actual mean neurite length, as each of these values are more 
or less significant for different types of neuron.  For neurons normally possessed of a 
single long axon, including RGC, longest neurite length is arguably a more relevant 
indicator of regenerative success than neurite number.  Following axotomy by ONC, RGC 
must regenerate their single axon (ignoring any axonal branching closer to the target 
area) to the relevant brain region.  For other neurons such as bipolar cells, which connect 
intricately with several relatively nearby targets, neurite number becomes more relevant 
as a regenerative correlate.  Also, whilst both neurite outgrowth and elongation both 
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require the parent neuron to enter an active growth state, exogenous signalling 
molecules local to the growth cone can elicit axonal elongation without necessarily 
involving or even travelling to the somata (Twiss and Van Minnen, 2006) thus probably 
not affecting the formation of new neurites.  Conversely while neurons can enter an 
active growth state, and attempt to create several neurites, a potently growth 
antagonistic extracellular environment can attenuate growth cone advance to the extent 
where these new neurites barely extend away from the cell body at all and may collapse 
back to the somata completely.  This is commonly seen in the ON in vivo - during the first 
12 – 96 hours after axotomy; RGC sprout multiple neurites which generally extend very 
little distance through the growth-antagonistic CNS environment.  For these reasons it 
was decided to measure and analyse both mean longest neurite length and mean neurite 
number.  In order to detect any effects on neuronal survival, one further measurement 
criteria was included: the mean number of RGC.  The number of RGC in each treatment 
group was standardised as much as possible initially (see methods) and monitored during 
data analysis.           
 In order to accurately measure RGC neurite outgrowth in vitro it was first 
necessary to ascertain the sample size required for accurate representation of the 
neuronal population.  Equating this to the number of photographs taken per culture-slide 
well, a pilot study was performed which compared the standard error of the mean (SEM) 
of the entire population (i.e. every RGC in that well, as measured by photographing the 
entire well - 209 pictures) with SEMs from samples of 10, 20, 50, 100 and 200 pictures.  
SEMs were calculated for the “longest neurite” parameter (see figure 4.1).  The optimum 
number of pictures to be taken per well was deemed to be around 40, as an ideal 
compromise between time-effectiveness and an acceptably low SEM, and as wells were 
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subdivided into 9 quadrants for quantification (see methods for details) it was decided to 
take 36 pictures per well, as this number allows 4 pictures per quadrant.  It should be 
noted that 3 wells were used per condition, per experiment, so the actual number of 
pictures taken per treatment group would in fact be at least 108, further minimising any 
sampling error. 
 
Figure 4.1.  Standard Error of the Mean (SEM) of Longest Neurite parameter vs sample size (number of 
pictures taken) taken from a randomly chosen PDL/Laminin coated  chamber slide well.  One entire well 
was photographed such that every RGC was photographed and the SEM for the “longest neurite” 
parameter was calculated for the entire RGC population.  This SEM was compared with those obtained from 
sampling 10, 20, 50, 100 and 200 pictures.  The optimum number of pictures to be taken was deemed to be 
around 40, as an ideal compromise between time-effectiveness and an acceptably low SEM. 
 
In this way, the specific experimental conditions, parameters, sample number and 
treatment groups were selected and investigations begun into the in vitro mechanisms of 
action of AG1478. 
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4.1  Specific Aims 
 To establish an assay which would inhibit neuritogenesis in the RGC-5 cell line and
  in primary retinal cultures without causing significant neuronal death, using the 
  recombinant Nogo-P4 peptide 
 
 To attempt to rescue RGC-5 and RGC neurite outgrowth from the above Nogo-P4 
  assay using the EGFRki AG1478, and so confirm that EGFRki can disinhibit RGC 
  neurite outgrowth in vitro 
 
 If possible, to establish whether or not the Adenosine A2A receptor mediates any
  of the putative EGFRki disinhibitory effects by attempting to disrupt above rescue
  experiments with the  concomitant addition of the A2A receptor antagonist 
  ZM21385 
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4.2 Results 
 
To establish the effects of AG1478 on RGC neurite outgrowth it was necessary to have an 
assay which simulated the growth antagonistic environment of the CNS.  To this end the 
recombinant Nogo-P4 peptide was used to create a RGC neurite outgrowth inhibition 
assay.  A dose-response pilot experiment was performed using primary retinal and RGC-5 
cultures.  These cultures were exposed to media containing Nogo-P4 at concentrations of 
4-40µM.  The number of neurons (specifically β-III-tubulin+RGC in the case of primary 
retinal cultures), longest neurite length per neuron and number of neurites per neuron 
were measured, averaged and analysed.  It is of paramount importance in a neurite 
outgrowth inhibition assay to inhibit neuritogeneis without cytotoxicity, primarily because 
neurons undergoing necrosis and apoptosis would not extend neurites, thus neurons in 
the early stages of necrosis or apoptosis could be mistakenly counted as merely 
possessing no neurites.  As such, an appropriate concentration of Nogo-P4 would be one 
at which neurite outgrowth was maximally inhibited whilst avoiding any significant 
neurocytotoxicity. 
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4.2.1  Nogo-P4 inhibited RGC neuritogenesis at concentrations above 
  25µM  
 
Primary adult rat retinal cultures were exposed to 25, 30 and 35µM concentrations of 
recombinant Nogo-P4.  Each of these concentrations dramatically reduced the mean 
number of neurites per RGC (Figure 4.2).  The mean number of neurites per RGC for the 
PDL – laminin control was 0.63± 0.08 whereas RGC in the 25, 30 and 35µM treatment 
groups had mean neurite numbers of 0.08± 0.04, 0.16± 0.08 and 0.12 ± 0.05 respectively. 
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 Figure 4.2.  Nogo P4 peptide significantly reduced RGC neuritogenesis. Nogo P4   
 peptide inhibited RGC neurite number at concentrations of 25, 30 and 35µM.    
 Error bars represent 95% confidence intervals.  n = 4 for all groups.      
  *** = p value of <0.001. 
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4.2.2  Nogo-P4 attenuated RGC neurite length 
Primary adult rat retinal cultures were exposed to 25, 30 and 35µM concentrations of 
recombinant Nogo-P4.  Each of these concentrations dramatically reduced the mean 
longest neurite length per RGC (Figure 4.3).  The mean length of the longest neurite per 
RGC for the PDL – laminin control was 28.1± 5.4 µm whereas RGC in the 25, 30 and 35µM 
Nogo-P4 treatment groups had mean longest neurites of 2.2 ± 2.1 µm, 4.2 ± 2.4 µm and 
4.2± 2.3 µm respectively. 
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  Figure 4.3.  Nogo P4 peptide significantly reduces RGC longest-neurite length.   
   Nogo P4 peptide inhibited RGC neurite outgrowth at concentrations of 25, 30  
   and 35µM.  Error bars represent 95% confidence intervals.    
   n = 4 for all groups.   *** = p value of <0.001. 
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4.2.3  Nogo-P4 was cytotoxic to RGC at 30µM and 35µM but not at 25µM  
Primary adult rat retinal cultures were exposed to 25, 30 and 35µM concentrations of 
recombinant Nogo-P4.  30 and 35 µM concentrations of Nogo-P4 significantly reduced 
RGC numbers compared to PDL – laminin only controls whereas 25µM Nogo-P4 did not 
(figure 4.4).  The mean number of RGC per field of view was 2.23± 0.3 for the PDL-laminin 
control group and 1.88± 0.28, 1.58± 0.28 and 1.70± 0.26 for the 25µM, 30µM and 35µM 
groups respectively.  As 25µM Nogo-P4 was non-cytotoxic yet still significantly inhibited 
neurite number and neurite length (figures 4.5 and 4.6 respectively), it was decided that 
all future neurite outgrowth inhibition assays would use Nogo-P4 at a maximum 
concentration of 25µM. 
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 Figure 4.4.  Effects of NogoP4 peptide on RGC survival in vitro.  Nogo P4    
 peptide was toxic to RGC at 35 and 30µM but not at 25µM.  Error bars     
 represent 95% confidence intervals.  n = 4 for all groups.        
 *** = p value of <0.001. 
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4.2.4  Nogo-P4 peptide did not affect RGC-5 cell survival 
The RGC-5 cell line has been used to replicate primary cultured RGC in vitro.  Here, it was 
shown that concentrations of Nogo-P4 up to and including 40µM had no effect of RGC-5 
cell number (figure 4.5).  Concentrations of 4, 10, 20 and 40µM Nogo-P4 peptide did not 
significantly affect the mean number of RGC-5, indicating that Nogo-P4 peptide at up to 
40µM was not cytotoxic to RGC-5 cells.  Mean number of RGC-5 per field of view for PDL – 
Laminin control was 3.4 ± 1.2 and no treatment group significantly differed from this.   
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Figure 4.5.  Nogo P4 peptide had no effect on survival of the RGC-5 cell line.                      
Concentrations of Nogo P4 up to and including 40µM did not alter RGC-5 number.                   
Error bars represent 95% confidence intervals.   n = 5 for all groups. 
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4.2.5  Nogo-P4 peptide did not affect the mean number of RGC-5 neurites   
Mean RGC-5 neurite number (i.e. mean number of neurites per cell) was not affected by 
concentrations of Nogo-P4 up to and including 40µM (figure 4.6).  Mean number of 
neurites per RGC-5 for the control PDL – laminin group was found to be 3.12 ± 0.4.  No 
treatment group exhibited a mean significantly different to this value.  
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4.2.6  Nogo-P4 peptide did not affect RGC-5 longest neurite length  
Concentrations of Nogo-P4 up to 40µM did not affect the mean length of RGC-5 longest 
neurite.  Mean longest neurite per cell was 100 ± 17 µm for the PDL – laminin control 
group and none of the treatment groups’ neurite outgrowth deviated significantly from 
this value (Figure 4.7).  This result combined with the lack of effect on neurite number 
Figure 4.6.  Nogo-P4 peptide had no effect on RGC-5 neuritogenesis.   
  Concentrations of Nogo-P4 up to and including 40µM did not alter the number    
  of neurites per RGC-5 cell.  Error bars represent 95% confidence intervals.   
  n = 5 for all groups.  
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(Figure 4.8) indicated that Nogo-P4, in concentrations up to 40µM, had no significant 
effect on RGC-5 neuritogenesis.  Almost all RGC-5 cells were observed to possess 
multiple, extensive neurites, irrespective of treatment group. 
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4.2.7  100nM AG1478 abolished the neurite number inhibitory effects of 
Nogo-P4 in primary retinal cultures and this effect was partially attenuated 
by the Adenosine A2A receptor antagonist ZM21385  
 
Mean number of neurites per RGC for PDL – laminin control was 0.497± 0.05,   mean 
number of neurites per RGC for Nogo, AG1478, Nogo+AG and Nogo+AG+ZM groups were 
0.23 ± 0.04, 0.61 ± 0.09, 0.53 ± 0.07 and 0.36 ± 0.09 respectively (Figure 4.8).  25µM 
Nogo-P4 significantly inhibited RGC neuritogenesis (red column) whereas 100nM AG1478 
elicited a modest but statistically significant increase in RGC neurite number (blue 
column).  Nogo+AG treated RGC (red and black column) exhibited similar neurite 
Figure 4.7.  Nogo P4 peptide had no effect on RGC-5 neurite length.     
Concentrations of Nogo-P4 up to and including 40µM did not alter the length       
of RGC-5 cell neurites.  Error bars represent 95% confidence intervals.        
n = 5 for all groups. 
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outgrowth to PDL-laminin control, indicating that AG1478 completely abolished the 
growth inhibitory effects of Nogo-P4.  Interestingly 50nM ZM21385 significantly 
abrogated the disinhibitory effects of AG1478 on Nogo-P4 mediated neurite outgrowth 
inhibition (green column). 
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Figure 4.8.  Effects of treatments on mean RGC neurite number.  25µM Nogo P4 
peptide significantly reduced RGC neurite number (red column), whereas 100nM 
AG1478 promoted a slight but significant increase in neurite number (blue column).  
Nogo-P4mediated neuritogenic inhibition was abolished by AG1478 (red striped 
column), and this abrogation was itself partially attenuated by the addition of 
50nM of the adenosine A2A receptor antagonist ZM21385 (green column).  Error 
bars represent 95% confidence intervals.  n = 4 for all groups except NAZ, wherein n 
= 3.  * = p value of <0.05, ** = p value of <0.01, ***= p value of less than 0.001 
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4.2.8  100nM AG1478 abolished the RGC neurite outgrowth inhibitory 
  effects of Nogo-P4 and significantly enhanced mean longest neurite 
  length  
 
Mean longest neurite length per RGC for PDL – laminin control was 19.11 ± 2.5µm,   mean 
longest neurite length per RGC for Nogo, AG1478, Nogo+AG and Nogo+AG+ZM groups 
were 8.01 ± 1.6µm, 28.92 ± 6.6µm, 21.21 ± 3.6µm and 15.14 ± 5.1µm respectively (Figure 
4.9).  25µM Nogo-P4 significantly inhibited RGC longest neurite length (red column) 
whereas 100nM AG1478 elicited a modest but statistically significant increase (blue 
column) compared to PDL – laminin control.  Nogo+AG treated RGC (red and black 
column) exhibited similar mean neurite length to PDL-laminin control, showing that 
AG1478 completely abolished the growth inhibitory effects of Nogo-P4.  ZM21385 did not 
significantly abrogate the ability of AG1478 to rescue Nogo-P4 mediated neurite 
outgrowth inhibition (green column), a result at odds with the inhibitory effect of ZM on 
“mean neurite number” parameter (see Figure 4.8).  Figure 4.9b shows representative 
images of RGC neurite outgrowth in each treatment group. 
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Figure 4.9.  Effects of various treatments on RGC neurite length.  25µM Nogo P4 
peptide significantly reduced RGC neurite outgrowth (red column), whereas 100nM 
AG1478 promoted a significant increase in neurite length (blue column).  Nogo-P4 
 mediated neuritogenic inhibition was abolished by AG1478 (red striped column).   
50nM ZM21385 (green column) did not prevent AG1478 from disinhibiting RGC in 
the presence of Nogo-P4.  Error bars represent 95% confidence intervals. 
n = 4 for all groups except NAZ, wherein n = 3.  ***= p value of less than 0.001. 
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Figure 4.9b.  Representative images of RGC neurite outgrowth.  Β-III+RGC 
(red) in primary retinal cultures exhibit inhibited neurite outgrowth in the 
presence of Nogo-P4 (B) compared to untreated control cultures (A).  
AG1478 elcits modestly increased neurite outgrowth (C) compared to 
control (A) and abrogates the outgrowth inhibitory effects of Nogo-P4 (D).  
The adenosine A2A receptor antagonist ZM21385 may partially reduce the 
extent of this AG1478-mediated rescue of Nogo-P4 inhibition (E) (see figures 
4.8 and 4.9 and accompanying text for details).  Scale bar = 40µm apart from 
(B) where scale bar = 20µm. 
 
4.2.9   RGC survival was not affected by 25µMNogo-P4, 100nM AG1478 nor
  50 nM ZM21385  
 
Mean number of RGC per field of view for PDL – laminin control was 2.86 ± 0.3.  Mean 
number of RGC for AG1478, Nogo-P4, AG+Nogo and AG+Nogo+ZM treatment groups 
were 3.07 ± 0.33, 2.58 ± 0.36, 2.37 ± 0.25 and 2.72 ± 0.44 respectively.  None of these 
values were significantly different from control (figure 4.10).  From this it can be seen that 
no treatment group caused RGC cell death. 
A B 
C D 
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 Figure 4.10.  Effects of various treatments on RGC survival.  RGC survival    
 was not affected by any of the treatment groups.  No treatment group   
 exhibited any significant difference in RGC number compared to    
 PDL Laminin control.  Error bars represent 95% confidence intervals.    
  n = 4 for all groups except NAZ, wherein n = 3.  
 
 
4.2.10  Conditioned media collected from primary retinal cultures did not 
   contain detectable amounts of CNTF, NT-3 or GDNF 
 
Conditioned media were taken from all primary retinal cultures used to generate figures 
4.8 – 4.10.  This media was concentrated (see Chapter 2 for details) and these samples 
were used in ELISAs for CNTF, NT-3 and GDNF (Figure 4.11).  No CNTF, NT-3 or GDNF was 
detected in the conditioned media of any of the treatment groups.  Relevant NTF 
standards supplied with ELISAs confirmed that the assays were performed correctly; 
ensuring that absence of signal did in fact reflect absence of NTF. 
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Figure 4.11.  Combined results of ELISAs for CNTF (blue column), NT3 (red column) and GDNF 
(green column) on concentrated conditioned media from primary retinal cultures exposed to 
various treatments.  No CNTF, NT3 or GDNF was detected in the conditioned media from any of the 
treatment groups, but this may be due to insufficient concentrating of conditioned media (see text 
for details).   n = 4 for all groups except NAZ wherein n = 3.  Standards are recombinant versions of 
respective NTF protein supplied with respective ELISA kits and show that all reagents were working 
correctly allowing lack of signal for any treatment group to be reliably inferred as reflecting a lack 
of the appropriate NTF in the conditioned media assayed.  The ‘top standard’ group shows the 
highest detected concentration of these recombinant protein standards. 
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4.2.11  Previous experiments detected NTF in the conditioned media from 
   AG1478 treated primary retinal cultures 
 
Although Figure 4.11 shows that no NTFs were detected in the conditioned media of 
primary retinal cultures exposed to AG1478 in the present experimental series, Drs Z. 
Ahmed and M. Douglas previously detected physiologically relevant levels of NGF, BDNF 
and NT-3 in similarly treated retinal cultures.  Having obtained express permission, Figure 
4.12 shows the levels of NTF they detected in conditioned media from AG1478 and non-
AG1478 treated cultures.  NT-3, BDNF and NGF were all present in AG1478 treated 
culture media but absent in non AG1478 treated control culture media.   
 
  
Figure 4.12.  ELISA results for NGF, BDNF and NT-3 in             
conditioned media from AG1478+CNS Myelin Extract treated retinal          
cultures.  NGF, BDNF and NT-3 were all found to be            
present at physiological concentrations in AG+Myelin              
treated cultures.  Untreated control cultures were found           
not to contain NGF, BDNF or NT-3. Experimental result and           
figure courtesy of Dr Zubair Ahmed and Dr Mike Douglas,         
University of Birmingham. 
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4.2.12  PCR on control retinal culture lysate detected BDNF and NT-3 
 
Following RT-PCR to obtain DNA, PCR was performed on lysate from the cells in 
untreated, control, retinal cultures, using forwards and backwards primers for BDNF, 
CNTF, NGF, NT-3, NT-4 and the housekeeping gene GAP-dh (Figure 4.13 ).  Clear bands 
visualised at the correct size for BDNF and NT-3 indicated that the RNA for both these 
neurotrophins was expressed by cells within control retinal cultures, and thus strongly 
suggested that the proteins BDNF and NT-3 were expressed.  No bands were detected for 
CNTF, NGF or NT-4.  Although this result could suggest that these factors were not 
present in control retinal cultures, the fact that no band was detected in either AG1478 
treated culture lysates (Figure 4.14) nor in whole rat brain lysate (Figure 4.15) strongly 
suggested that one or both of the primers for each of these failed to function. 
   
 Figure 4.13. PCR results from untreated retinal culture lysate, using primers for BDNF,  
  CNTF, NGF, NT-3, NT-4 and the house keeping gene GAP-dh.  Bands for CNTF, NGF 
   and NT-4 were not observed, whereas clear bands were observed for both NT-3 and 
  BDNF as well as the housekeeping gene GAP-dh.  Arrow indicates molecular weight   
   band signifying 1000 base pairs. 
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4.2.13  PCR on AG1478 treated retinal culture lysate detected BDNF and 
   NT-3 
 
Following RT-PCR to obtain DNA, PCR was performed on lysate from AG1478 treated 
retinal cultures, using forwards and backwards primers for BDNF, CNTF, NGF, NT-3, NT-4 
and the housekeeping gene GAP-dh (Figure 4.14).  Clear bands at the correct size for 
BDNF and NT-3 indicated that the RNA for both these neurotrophins was expressed by 
cells within AG1478 treated retinal cultures, and thus strongly suggested that the proteins 
BDNF and NT-3 were expressed.  Again, no bands were detected for CNTF, NGF or NT-4, 
suggesting that one or both of the primers for each of these failed to function. 
.    
    
 
Figure 4.14.  PCR results from AG1478 treated retinal culture lysate, using 
primers for BDNF, CNTF, NGF, NT-3, NT-4 and the house keeping gene GAP-dh.  
Bands for CNTF, NGF and NT-4 were not observed, whereas a clear band was 
observed for both NT-3 and BDNF as well as the housekeeping gene GAP-dh.  
Arrow indicates molecular weight band signifying 1000 base pairs. 
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4.2.14  PCR on whole rat brain lysate detected BDNF and NT-3 
 
Following RT-PCR to obtain DNA, PCR was performed on whole rat brain lysate, using 
forwards and backwards primers for BDNF, CNTF, NGF, NT-3, NT-4 and the housekeeping 
gene GAP-dh (Figure 4.15).  Clear bands at the correct size for BDNF and NT-3 indicated 
that the RNA for both these neurotrophins was expressed by cells in the rat brain, and 
again strongly suggested that the proteins BDNF and NT-3 were expressed.  That, once 
again, no bands were detected for CNTF, NGF or NT-4 suggested that one or both of the 
primers for each of these failed to function, particularly as the rat brain is known to 
contain both NGF and NT-4.  Note the increased brightness of the band signifying BDNF 
(red box) compared to that seen in the culture lysate groups. 
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Figure 4.15.  PCR results from control rat brain lysate, using primers for BDNF, CNTF,  
 NGF, NT-3, NT-4 and the house keeping gene GAP-dh.  Rat brain is known to contain  
 each of the above proteins and as such absence of predicted bands for individual  
 DNA stretches strongly suggested that the relevant primer did not function correctly.   
 CNTF, NGF and NT-4 Primers appeared not to function correctly, whereas a clear  
 band was obtained for BDNF, NT3 and the housekeeping gene GAP-dh.  Arrow  
  indicates band signifying 1000 base pairs. 
 
 
4.2.15  Immunocytochemistry confirmed the presence of NGF in RGC 
 
As NGF was not detected by PCR, yet was detected by ELISA by others (see figures 4.11-
4.12) it was decided to attempt to visualise NGF immunocytochemically on RGC in AG-
treated and non-AG treated retinal cultures using a well characterised antibody to NGF.  
NGF was detected on β-III-tubulin+ RGC somata and neurites both without (A) and with 
(B) 100nM AG1478, and no signal was observed in the no primary control (C) (Figure 
4.16). 
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Figure 4.16.  Immunocytochemistical staining for the RGC marker β-III-Tubulin (red) and NGF (green) in   
Nogo-P4 treated cultures without (A) and with (B) 100nM AG1478.  (C) No primary antibody control for 
NGF antibody.  NGF is present both before and after AG1478 exposure, in both somata and neurites. DAPI 
stained nuclei are blue.  Scale bar = 20µm. 
 
 
 
 
 
 
 
 
 
A 
B 
C 
 155 
 
4.3  Discussion 
 
4.3.1  Nogo-P4 dramatically inhibited RGC neuritogenesis  
While Nogo-P4 significantly inhibited cultured primary RGC neurite outgrowth at 
concentrations of 25, 30 and 35µM, concentrations above 25µM proved cytotoxic, 
making it difficult to differentiate between genuine neurite growth inhibition and a lack of 
neurites due to ongoing apoptosis/necrosis.  At 25µM Nogo P4 attenuated mean RGC 
neurite number as effectively as at 30µM and 35µM but without causing significant cell 
death (mean of 0.08 neurites per RGC compared to 0.63 neurites per RGC in the 
untreated control group).  It appears that only one previous study (Wang and Zhu, 2008) 
has used recombinant Nogo-P4 to inhibit neurite outgrowth and, while this study also 
found Nogo-P4 to be antagonistic to neurite outgrowth at as little as 4µM, these neurons 
were derived from one day postnatal neuronal precursor cells taken from the rat spinal 
cord. Additionally the precursor cells were allowed to differentiate in the presence of 
Nogo P4 and/or differentiated neurons were exposed to the peptide at 3 days post 
plating; making these cells effectively postnatal day 3 neurons.       
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4.3.3  Nogo-P4 was cytotoxic to RGC at 30µM and 35µM but not at 25µM  
Nogo-P4 caused significant RGC death at concentrations of 30 and 35µM, reducing mean 
number of RGC per field of view from 2.23 for the untreated control group to 1.58 and 
1.70 respectively.  The 25µM Nogo-P4 treated group exhibited mean number of RGC per 
field of view of 1.88; not significantly different from the untreated control.  It is possible 
that at concentrations of above 25µM the Nogo peptide itself became cytotoxic to RGC, 
although there does not appear to be any direct link between NgR signalling and RGC cell 
death (in fact at least one study has suggested that NgR signalling can in fact be 
neuroprotective by sequestering P75NTR and rendering it unable to initiate apoptosis; 
Dupuis et al. 2008).  It is also possible that severely restricting neurite outgrowth 
prevented dissociated RGC from establishing contact with adjacent glia, thus denying RGC 
contact-dependent NTF support and/or that Nogo-P4 above 25µM somehow affected 
glial survival or function (glial cell numbers were not investigated in any of these 
experiments).  Nevertheless, it was found that 25µM Nogo-P4 strongly inhibited RGC 
neurite outgrowth and elongation without causing significant RGC death.  This formed the 
basis of a RGC neurite outgrowth inhibitory assay which was subsequently used to 
examine the effects of the EGFRki, AG1478, on RGC neurite outgrowth. 
 
4.3.4  Nogo-P4 drastically attenuated RGC neurite length 
While 25, 30 and 35µM Nogo P4 inhibited RGC mean longest neurite length equally well 
(no significant difference was seen in mean longest neurite length between any of the 
three), only 25µM Nogo-P4 did so without causing significant RGC death - mean longest 
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neurite length of 2.2µm compared to 28.1µm for untreated control group.  Along with the 
aforementioned non-cytotoxic blockade of neuritogenesis, this showed the potential of 
Nogo-P4 to form the basis of an excellent in vitro neurite outgrowth inhibition assay. 
 
4.3.5  Nogo-P4 peptide did not affect RGC-5 cell survival 
 
While primary RGC began to die in significant numbers at concentrations of Nogo-P4 
above 25 µM, RGC-5 survival was entirely unaffected by Nogo-P4 peptide at 
concentrations of up to 40µM.  This is not unexpected; while 1.07nM staurosporine is 
enough to cause significant RGC death in vivo (Maass 2007), up to 316 nM staurosporine 
has been used to differentiate RGC-5 cells, with no reduction in cell number reported (J. 
o’ Neill, unpublished data, Wood et al. 2010).  That RGC-5 cells in vitro were impervious to 
a potent cytotoxin, present at levels 316 times higher than those required to kill primary 
RGC in vivo, highlights the fundamental difference between the two cell types and further 
illustrates the unsuitability of RGC-5 for use in a Nogo-P4 based assay. 
 
4.3.6  Nogo-P4 peptide did not affect the mean number of RGC-5 neurites   
 
In contrast to its effects on primary culture RGC, Nogo-P4 peptide failed to inhibit RGC-5 
neuritogenesis, at concentrations of up to 40µM.   That the mean neurite number per 
RGC-5 cell was not significantly affected by Nogo-P4, even at levels which proved 
cytotoxic for neurons in primary culture (see above), suggests that RGC-5 cells are an 
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unsuitable cell line for use in a Nogo-P4 based inhibitory assay.  It is possible that, as an 
immortalised cell line, the potent growth inhibitory effects of Nogo-P4 seen with primary 
RGC are mediated by a signalling pathway which has been disrupted by the original 
transformation of the cells via the ψ2 E1A virus (Krishnamoorthy et al. 2001) and thus 
that the signalling cascade beginning with NgR and its coreceptors is interrupted before it 
reaches the actin cytoskeleton.  Alternatively, if RGC-5 cells do not express NgR, the 
receptor through which Nogo-P4 signals, then Nogo-P4 would be impotent.  Recent work 
within our lab, however, has repeatedly detected NgR on RGC-5 cells via 
immunocytochemistry (O’Neil, unpublished data), so this is unlikely.  Another possibility is 
that the effects of Nogo-P4 are being countered by other factors; it is known that 
sufficient levels of NTF can overcome the neurite outgrowth inhibitory effects of myelin 
derived proteins via Regulated Intramembraneous Proteolysis (RIP) of the NgR coreceptor 
p75NTR (Ahmed et al. 2006b) so it is possible that RGC-5 cells, which grow continuously in 
the absence of glia or extraneous NTF support, generate their own NTF, which could 
potentially neutralise any neurite inhibitory and potentially cytotoxic effects.   
 
4.3.7  Nogo-P4 peptide did not affect RGC-5 longest neurite length  
 
Concentrations of Nogo-p4 up to 40µM did not affect the mean length of longest neurite 
per RGC-5 cell.  As an immortalised cell line, it was perhaps unsurprising that almost all 
untreated control RGC-5 cells possessed multiple, extensive neurites in the absence of 
extraneous NTF. These cells, if not differentiated, divide continuously, and once 
differentiated, continuously extend neurites.  The fact that neurites extended completely 
 159 
 
unchecked for over 100µm, through an environment containing significant levels of an 
axon growth inhibitory peptide that is cytotoxic to putatively equivalent primary neurons, 
requires an explanation.  As discussed above, it is possible that the immortalisation 
process altered signalling cascades impinged upon by NgR, such that signalling through 
NgR and its coreceptors do not effect changes on the cytoskeleton, and/or that RGC-5 
produce their own NTFs which abrogate the effects of Nogo-P4 via RIP. 
 
4.3.8  100nM AG1478 abolished the RGC neurite outgrowth inhibitory 
  effects of Nogo-P4, and this effect was partially attenuated by 
 50 nM ZM21385  
 
When exposed to 100nM AG1478 alone, the mean number of neurites per RGC was 
modestly but significantly higher than PDL-laminin control values; 0.61 to 0.49 
respectively.   That an EGFRki could elicit significant RGC neurite outgrowth in the 
absence of AGIM implied some sort of growth stimulatory mechanism of action for 
AG1478.  The mean number of neurites per RGC for Nogo-P4 treated cultures was 0.23, 
showing the continued effectiveness of Nogo-P4 as a neurite inhibitory agent.  
Interestingly, AG1478 completely abrogated this effect: retinal cultures exposed to both 
25µM Nogo-P4 and 100nM AG1478 exhibited neurite outgrowth at very similar levels to 
PDL – laminin control cultures, 0.53 neurites per RGC compared to control value of 0.49.  
This again suggested either a neurite outgrowth inhibitory role for EGFR, potentially as a 
required part of the inhibitory signalling cascade and/or, again, some novel mechainism 
of action for AG1478.  Interestingly 50nM ZM21385 significantly abrogated AG1478-
mediated rescue of Nogo-P4 mediated neurite outgrowth inhibition; mean number of 
neurites per RGC for the Nogo+AG+ZM21385 group was 0.36, not significantly different to 
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PDL-Laminin control, significantly lower than AG and Nogo+AG mean values and not 
significantly different from the 25µM Nogo-P4 treatment group.   This synthetic 
compound, ZM21385, a potent, selective, Adenosine A2A receptor blocker, was included 
in these experiments to investigate whether the A2A receptor played a role in AG1478 
mediated neurite outgrowth, following reports that the A2A receptor could strongly 
enhance neurite outgrowth and neuronal survival via transactivation of the Trk receptors 
(Jeanneteau and Chao 2006).  That pharmacological blockade of a single receptor couldn 
significantly erode the neuritogenic capabilities of AG1478 implied that the adenosine 
A2A receptor played a part in whichever signalling pathway(s) AG1478 affected; either as 
an inhibitor of EGFR signalling or as part of some other off target signalling pathway, 
possibly involving Trk receptors. 
 
4.3.9   100nM AG1478 abolished the neurite outgrowth inhibitory effects of
  Nogo-P4 and significantly enhanced longest neurite length  
 
Mean longest neurite length per RGC for PDL – laminin control was 19.11µm.  Mean 
longest neurite length per RGC for Nogo-P4 treated retinal cultures was significantly 
lower at 8.01µm, again highlighting the efficacy of Nogo-P4 as a neurite outgrowth 
inhibitory agent.   AG1478 treated cultures exhibited mean longest neurite length per 
RGC of 28.92µm, significantly higher than PDL – laminin control cultures, demonstrating 
that AG1478 could elicit significant RGC neurite extension.  Once again AG1478 
completely ameliorated the neurite outgrowth inhibitory effects of Nogo P4 – mean 
longest neurite value for AG+ Nogo group was 21.21µm, near identical to PDL-laminin 
control values, implying that EGFR signalling was antagonistic to neurite elongation 
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and/or that AG1478 enhanced neurite extension via some other means.  While the 
Nogo+AG+ZM treatment group showed a trend towards decreased mean longest neurite 
outgrowth, with a mean longest neurite length of 15.14µm, this was not significantly 
different from the AG+ Nogo group nor from control cultures.  It should be noted that this 
value of 15.14µm is significantly lower than that of the AG1478 alone treatment group 
and, given that the SEM was notably larger for this group than for any other (due to an 
accidentally destroyed chamber slide, the n number for AG+Nogo+ZM group was one less 
(n = 3 instead of at least 4) it is possible that a real effect would be found if more 
experimental repeats were performed. 
 
4.3.10  RGC survival was not affected by 25µMNogo-P4, 100nM AG1478 or 
50 nM ZM21385  
 
Neither 25µMNogo-P4, 100nM AG1478, 50 nM ZM21385 nor any combination of the 
three, significantly affected RGC survival, in the form of mean RGC number per field of 
view.  This showed that any antagonistic effects on neuritogenesis and neurite elongation 
elicited by these compounds, either in concert or singly, were not a result of RGC death. 
 
4.3.11  Conditioned media collected from primary retinal cultures did not 
   contain detectable amounts of CNTF, NT-3 or GDNF 
 
Once the retinal cultures used to obtain the above neurite outgrowth data were ready to 
be fixed and to undergo immunocytochemical staining, the conditioned media was 
carefully aspirated from the living cells and stored appropriately.  Media was spun at for 
 162 
 
10 minutes at 20,000 RPM and supernatant disgarded such that an approximate 
concentration factor of x 10 was achieved.  This concentrated media was then probed 
using ELISAs designed to detect CNTF, NT-3 and GDNF.  No trace of any of these three 
NTFs was found in any of the treatment or control groups.  Absorbance readings from 
wells containing various dilutions of the standards provided with ELISAs (relevant 
concentrations of the recombinant NTF in question) proved that all ELISAs were 
performed correctly and that lack of signal did in fact reflect lack of NTF.  In terms of 
relevance to in vitro RGC neurite outgrowth and survival, perhaps the most commonly 
used exogenous NTFs are CNTF and BDNF, the former for neurite outgrowth and the 
latter for RGC survival.  Previous experiments performed by our group (see below) 
screened conditioned media from AG1478 treated retinal cultures for NGF, NT-3, and 
BDNF, finding physiological concentrations of each in the media from AG1478 treated 
cultures, and finding none in the media from control cultures (see Douglas et al. 2009 for 
data and discussion).  For this reason it was assumed that the experiments described here 
should also have found similar levels of these NTFs so it was decided to ascertain if other 
NTFs, namely CNTF and GDNF, were present in conditioned media from AG1478 treated 
cells.  When neither of these NTFs were detected, the ELISA for NT-3 was performed on 
samples of the same media.  These too detected no NTF, suggesting that the conditioned 
media used latterly in the above experiments was not adequately concentrated (see 
section below). 
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4.3.12  Previous experiments detected NTFs in AG1478 treated retinal 
  cultures 
 
Although the above experiments detected no NTFs in the conditioned media of primary 
retinal cultures exposed to AG1478, previous experiments, specifically performed by Dr Z 
Ahmed and Dr M Douglas, detected physiologically relevant levels of NGF, BDNF and NT-3 
in similarly treated retinal cultures.  NT-3, BDNF and NGF were all present in AG1478 
treated culture media but absent in non AG1478 treated control culture media (see 
Douglas et al. 2009).  The concentration regime followed by Douglas et al. included the 
culturing of large numbers of whole retinal cultures, each split in half in two large petri 
dishes and treated with 5 hour pulses of AG1478, and the collection of up to 5 ml of 
media per experiment.  These cultures were treated identically to the cultures used to 
generate neurite outgrowth data, except that larger populations of cells were used: the 
entire dissociated retina being split into two populations of around 1.5 million cells.  After 
multiple repeats, upwards of 25 mls of media from each group were concentrated down 
to around 1 ml and ELISAs were performed on this concentrated medium.  The 
experiments performed as part of this study, used only the conditioned media from the 
actual cultures of ~125,000 cells used to generate the in vitro data shown above, and as 
mentioned, involved concentrating these media by a factor of 10.  Although the 
difference in concentration between the two sets of experiments is only x 2.5 ( x 10 vs x 
25) the relatively small volume of media collected by myself compared to that obtained 
by  Ahmed and Douglas could have prevented me from detecting NTFs due to their 
relatively low abundance.  However, each of the ELISAs used was sensitive enough to 
detect picograms of NTF; and the levels detected by Ahmed and Douglas were on the 
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order of tens of nanograms.  This is a difference of around 3 orders of magnitude, which 
should have been easily enough to overcome these differences in volume and 
concentration of media. 
 
4.3.13  RT-PCR on control retinal culture lysate detected BDNF and  
 NT-3 mRNA 
 
As ELISAs failed to detect NTF it was decided to attempt NTF mRNA detection in whole 
retinal culture lysate using RT-PCR.  Following total RNA extraction and conversion to 
DNA, sets of NTF-specific forward and reverse primers (oligonucleotides) were used in an 
attempt to detect and amplify BDNF, NGF, NT-3 and NT-4 and the housekeeping gene 
GAP-dh .  Clear bands at the correct size for BDNF and NT-3 mRNA indicated that the RNA 
for both these neurotrophins was expressed by cells within control retinal cultures, 
strongly suggestding that the proteins BDNF and NT-3 were expressed.  No bands were 
detected for CNTF, NGF or NT-4 mRNA.  Although this could suggest that these factors 
were not present in control retinal cultures, the fact that no band was detected in either 
AG1478 treated culture lysates nor in whole rat brain lysate strongly suggests that one or 
both of the primers for each of these failed to function.  The detection by PCR of NT-3 
mRNA in retinal lysates when no NT-3 was found via ELISA suggests either a) that NT-3 
was present in amounts too small to detect with ELISA, b) that NTFs were being 
synthesized but not secreted or c) that the original RNA was transcribed but no protein 
was produced.  By extension, it is possible that the other NTFs which were screened for 
and not detected by ELISA, namely CNTF and GDNF, were not detected for similar 
reasons.  That NGF, another NTF detected with ELISAs on retinal culture conditioned 
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media by Ahmed and Douglas, was detected immunocytochemically in retinal cultures 
(see below,) lends credence to the idea that collected media contained insufficient 
amounts of NTF for detection by these methods. 
 
 4.3.14  RT PCR on AG1478 treated retinal culture lysate detected BDNF and
    NT-3 mRNA 
 
As in the control group, clear bands at the correct size for BDNF and NT-3 mRNA indicated 
that the RNA for both these neurotrophins was expressed by cells within AG1478-treated 
retinal cultures, suggesting that the proteins BDNF and NT-3 were expressed.  Once again, 
no bands were detected for CNTF, NGF or NT-4, implying that one or both of the primers 
for each of these failed to function.   As in the control group, the detection by PCR of NT-3 
mRNA in retinal lysates when no NT-3 was found via ELISA suggests that NT-3 may have 
been present in conditioned media in amounts too small to detect with ELISA. 
 
4.3.15  RT PCR on whole rat brain lysate detected BDNF and NT-3 mRNA 
 
The whole rat brain lysate group was included as a tissue control.  As the brain contains 
large amounts of nearly every NTF known (with the possible exception of CNTF, but see 
Yang et al. 2008 for recent evidence of CNTF in the adult rat subventricular zone), any 
failure to detect the mRNA of a specific NTF in whole brain lysate could more reliably be 
said to be due to experimental error.  As the predicted bands for CNTF, NGF and NT-4 
mRNA were not obtained from rat brain lysate, whilst those bands representing BDNF 
and NT-3 mRNA were obtained, it is likely that the specific primers for CNTF, NGF and NT-
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4 mRNA failed to function.  There is then strong evidence that the lack of corresponding 
bands for both the AG-treated and the control retinal lysates reflect this primer failure. 
 
4.3.16  Immunocytochemistry confirmed the presence of NGF in RGC 
 
As ELISA and PCR failed to verify the presence of NGF in AG1478 treated RGC it was 
decided to attempt to visualise this NT immunocytochemically.  NGF was observed on all 
RGC in both the control and the AG-treated primary retinal cultures.  At least one other 
study has immunocytochemically detected NGF on RGC in primary culture (Agarwal et al. 
2007), which suggests that either NGF was synthesised but not released by RGC or that 
NGF was released but was not detected via ELISA.  As others have detected NGF in AG-
treated-RGC conditioned media (Douglas et al. 2009) the latter explanation seems likely.  
It should be noted however that the aforementioned study did not detect NGF (nor BDNF, 
nor NT-3) in the conditioned media taken from non-AG-treated, control cultures.  
Although it is possible that AG1478 elicits the release of previously synthesised NGF from 
RGC, it is perhaps more likely that AG1478 stimulates NGF release from glia.  To this end 
co-immunocytochemical staining using antibodies raised against retinal glial markers, 
such as GFAP, as well as anti-NGF antibodies, would confirm the presence or absence of 
glial NGF in such cultures. 
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4.3.17  Interim Conclusions 
 
The purpose of this series of experiments was to investigate the actions of AG1478 in 
vitro, in an attempt to confirm the EGFRki-meditated neurite outgrowth disinhibition 
reported by Koprivica et a (2005).  To this end a neurite outgrowth inhibitory assay was 
designed.  Based on the synthetic Nogo-P4 peptide, this assay was intended to serve as an 
in vitro model of the inhibitory environment within the adult mammalian CNS.  With this 
in place it was then possible to investigate the putative RGC neurite outgrowth 
disinhibitory effects of AG1478.  Preliminary experiments with Nogo-P4 on primary retinal 
cultures and the RGC-5 cell line yielded interesting results.  Primary RGC were significantly 
affected by concentrations of Nogo-P4 above 25µM, with neurite number and length 
being drastically attenuated.  Unfortunately 30µM and 35µM Nogo-P4 caused moderate 
but significant RGC death, making it very difficult to confidently ascribe attenuated 
neurite number and/or length to outgrowth inhibition, as opposed to ongoing/impending 
RGC death.  At a concentration of 25µM Nogo-P4 inhibited neurite number, longest 
neurite length and, importantly, did not cause significant RGC death.  Accordingly, this 
concentration of Nogo-P4 was used in subsequent experiments involving AG1478, serving 
as a novel inhibitory assay.          
 In an attempt to create an inexpensive, reliable and easily replicated in vitro 
neurite outgrowth inhibitory assay, RGC-5 cells were exposed to varying concentrations 
of Nogo-P4, including the 25-35µM range which had dramatically affected primary RGC.  
RGC-5 cells were completely unaffected by the Nogo-P4 peptide up to and including 
concentrations of 40µM; no effect on survival, neurite number or neurite length was 
observed.  For this reason RGC-5 cells were deemed unsuitable for a Nogo-P4 based 
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inhibitory assay and all subsequent experiments were performed on primary retinal 
cultures.  Nevertheless, it should be noted that this easily replicable, non cytotoxic Nogo-
P4 mediated RGC neurite outgrowth inhibition assay is, as far as can be seen, entirely 
novel and could prove very useful for future studies on inhibitory mechanisms.  
 Previously, conditioned media taken from AG1478 treated primary retinal cultures 
has been shown to promote considerable RGC neurite elongation and a concomitant 
increase  in average neurite number when added to otherwise untreated primary retinal 
cultures (Douglas et al. 2009), although this is somewhat at odds with the findings of 
Koprivica et al(2005) ,who observed no effect of AG1478 on control cultures.  One 
possible explanation for this is that the former study plated retinal cultures onto PDL + 
Laminin coated wells whereas Koprivica et al(2005) plated their cultures on PDL alone.  It 
is possible that the modest but significant enhancement to neurite outgrowth in response 
to AG1478 is masked by the relatively less growth-permissive nature of PDL.  In any case, 
the present study found that AG1478 effected a small but significant increase in RGC 
neurite outgrowth, both in terms of mean neurite length and mean number of neurites, 
on otherwise untreated cultures plated on PDL+ laminin.  Crucially, AG1478 completely 
abrogated the effects of Nogo-P4; Nogo-P4 + AG1478 treated cultures exhibited mean 
neurite number and mean neurite length values which were near identical to those of 
control cultures.  This result confirmed that AG1478, an EGFRki, was capable of rendering 
primary RGC invulnerable to the effects of Nogo-P4, an analogue of a potent myelin 
derived neurite outgrowth inhibitory factor, present and active in the CNS.  Interestingly 
the addition of the adenosine A2A receptor antagonist ZM21385 to AG+ Nogo treated 
cultures was found to partially restore the neurite inhibitory actions of Nogo-P4.  RGC in 
AG+Nogo+ZM treated cultures exhibited a small but significant decrease in mean neurite 
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number, and there was a similar trend for mean neurite length, although this trend did 
not reach statistical significance.  This implies that the A2A receptor is involved in the 
events underlying AG1478-mediated neurite outgrowth.  ZM21385 was included in these 
experiments to investigate the previously reported phenomenon of transactivation of Trk 
receptors, the receptors for the neurotrophins, by the A2A receptor (Lee et al. 2002, Chao 
et al. 2006).  Douglas et al. (2009) showed that the pan-Trk blocker K252a and Trk-Fc 
proteins completely blocked the neuritogenic effects of AG1478, showing the 
neuritogenic effects of AG1478 to be Trk mediated.  Similarly, it would follow that 
blockading the A2A receptor, which primarily transactivates only Trk-B, would produce a 
similar but smaller effect.        
 Having confirmed that AG1478 could elicit significant enhancement of otherwise 
untreated primary RGC neurite outgrowth and, more importantly, ameliorate the 
outgrowth inhibitory actions of Nogo-P4, it was decided to attempt to uncover the 
mechanisms by which it did so.  Previous work had already shown the in vitro 
neuritogenic effects of AG1478 to be Trk dependent (Douglas et al. 2009) and had 
detected significant levels of the NT (BDNF, NGF and NT3) in AG-treated retinal culture 
media which was not present in untreated culture media.  The present study used ELISA 
to assay conditioned media for GDNF, CNTF and NT-3.  This media was collected from the 
cultures used to generate the in vitro neurite outgrowth data and stored separately by 
treatment group.  No trace of GDNF, CNTF or NT-3 was found in the media from any 
treatment or control group.  CNTF and GDNF were initially assayed for due to the Douglas 
et al (2009) study having performed ELISAs for, and finding the NTs BDNF, NGF and NT3.  
When neither CNTF nor GDNF were detected in conditioned media, the assay for NT-3,  
one of the NTs already confirmed to be released by retinal cultures in response to 
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AG11478 (Douglas et al. 2009), was performed.  When no NT-3 was detected, where 
another study had detected it in substantial amounts, it was suspected that the apparent 
lack of CNTF and GDNF may not have reflected an actual lack of these NTFs and instead 
might represent either experimental error (unlikely as all standards returned perfect 
absorbance readings) or perhaps insufficient concentrating of media (unlikely as the 
sensitivity of each specific ELISA would have meant that even picogram levels of protein 
would be detected).  For details on differences in media-concentrating methodology see 
above discussion of this result.  The ultimate reasons for this discrepancy thus remain 
unknown, but it should be noted that the presence or absence of CNTF and GDNF in AG-
treated retinal cultures is still to be determined due to the results obtained in the present 
study being inconclusive.        
 The failure to detect NTF release by ELISA led to an attempt to detect NT-3, NT-4, 
NGF, BDNF and CNTF mRNA in AG-treated retinal culture lysates via RT PCR.  That NT-3 
and BDNF were both strongly expressed by both control and AG-treated retinal cultures 
suggests that the negative results obtained from ELISAs were inaccurate and supports the 
NTF release described by Douglas et al(2005).  Unfortunately NT-4, NGF and CNTF mRNA 
were not detected but this is almost certainly due to primer malfunction as the same 
absence of band or blurred multiple band was observed in the rat brain control group.  
Once again, it should be noted that CNTF has been described as being absent from the 
brain, or present in only a sub population of cells in the SVZ, so it remains a possibility 
that the lack of CNTF mRNA observed does in fact reflect a real lack of CNTF, as the tissue 
control (brain) may be inappropriate for this particular NTF.  That NGF was detected 
immunocytochemically on both control and AG-treated primary RGC further reinforces 
the idea that the absence of NTF observed in ELISAs of conditioned media did not 
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accurately reflect actual NTF levels.       
 One of the overall goals of this study was to elucidate the mechanism of action by 
which AG1478 both promotes considerable axon regeneration in vivo, and elicits neurite 
outgrowth and neutralises the outgrowth inhibitory actions of compounds such as Nogo-
P4 (as above), myelin (Douglas et al. 2009, Koprivica et al. 2005) and CSPG (Koprivica et al. 
2005) in vitro.  The authors of the original study using EGFRki to facilitate neurite 
outgrowth, Koprivica et al (2005), did not put forward a specific hypothesis as to the 
events underlying these effects other than to implicate the EGFR as being a vital 
component in the NgR mediated inhibitory signalling cascade, and implied that the effects 
of AG1478 were as a direct result of EGFR blockade.  The authors also demonstrated that 
a calcium influx was required for the phosphorylation of EGFR, showing that calcium 
chelators prevented EGFR phosphorylation.  It should be noted however that this paper 
did not directly show that calcium chelators neutralised the outgrowth-inhibitory actions 
of myelin, its derivative proteins, not CSPG.   The authors concluded that EGFR 
transactivation was “required but not sufficient” for the transduction of NgR mediated 
outgrowth inhibitory signalling.  Douglas et al (2009), having showed that AG1478 effects 
NTF release from primary retinal cultures, suggested that this NTF support could induce 
the destruction of the p75NTR coreceptor, a key signalling partner of NgR, via RIP.  They 
further showed that AG1478 treated cultures to exhibit significantly raised levels of 
cAMP.  Raised levels of this intracellular secondary messenger are known to enhance in 
vivo axonal regeneration and in vitro neurite outgrowth (see Hannilla and Filbin, 2007 for 
review) and have been shown to actually switch the effects of at least one myelin derived 
protein, MAG, from axon-growth antagonistic to growth promoting (Cai et al. 2001).   
 A search of the existing literature also revealed at least two additional potential 
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pathways through which AG1478 could also be exerting its beneficial effects.  Regarding 
the first, a recent study demonstrated that AG1478 could strongly inhibit the activity of 
the calcium sensing receptor (CaR) (Tomlins et al. 2005), showing that the blockade of 
EGFR transactivation by AG1478 largely neutralised downstream CaR signalling.  Another 
study, roughly contemporaneous with the first (Davies et al. 2006), reported that the CaR 
could signal through Rho and ROCK, causing actin stress fiber assembly and altered 
cellular morphology.  These are processes which, in a growth cone, lead to filopodial 
retraction and growth cone collapse.  It would thus seem that there is a possibility that 
AG1478 could actively prevent growth cone collapse.  One caveat associated with this 
hypothesis is that both studies used non neuronal cells (primary rat fibroblasts and 
Human Embryonic Kidney (HEK 293) cells, respectively) which may not respond to EGFR, 
CaR or Rho/ROCK signalling in a manner identical to neurons – one obvious difference 
being that these cell types maintain an ability to respond to mitogenic signalling pathways 
whereas primary culture neurons are effectively terminally differentiated.  Regarding the 
second potential pathway through which AG1478 could be exerting its neuritogenic 
effects, three drugs very similar to AG1478, genistein and the tyrphostins B44 and  51, 
were shown to strongly inhibit phosphodiesterase (PDE) activity.  As cAMP is hydrolysed 
by certain PDE subtypes, this results in higher levels of intracellular cAMP (Ho and Chik 
1995, Nichols and Morimoto, 1999).  It is noteworthy that the latter study was concerned 
specifically with PDE4 – a subtype of PDE strongly associated with RGC.  The 
supplementary material from Koprivica et al. (2005) contains a table listing the results of 
a high throughput study on the effects of over 400 compounds on in vitro neurite 
outgrowth in the presence of myelin, arranged by magnitude of effect on neuritogenesis.  
This table shows that this study tested both genistein and tyrphostin B44 and found the 
 173 
 
former compound to exhibit no significant neurite outgrowth and the latter to elicit 
modest but apparently unremarkable outgrowth.  This table also shows that alongside 
AG1478 and two other tyrphostins, A23 and A46, the PDE4 inhibitor etzolate 
hydrochloride elicited significant neurite outgrowth.  It would appear then that this is 
another means by which AG1478 could elicit neurite outgrowth – by raising cAMP levels 
within RGC via the inhibition of PDE-mediated cAMP hydrolysis.  This hypothesis is 
supported by the raised cAMP levels found in AG-treated primary retinal cultures 
reported by Douglas et al. (2009).       
 Having identified potential mechanisms by which AG1478 could be exerting its 
neuritogenic effects, and having ratified the in vitro findings of Koprivica et al(2005) and 
Douglas et al (2009), namely that the EGFRki AG1478 promotes and disinhibits primary 
RGC neurite outgrowth, it remained to confirm the effects of EGFRki in vivo. It was thus 
decided to investigate the effects of the irrereversible EGFRki PD168393 on the 
regeneration of RGC axons following ONC.  Along with AG1478, Koprivica et al(2005) also 
tested the in vitro effects of the EGFRki PD168393, showing the two compounds to elicit 
comparable neurite outgrowth.  PD168393 is an irreversible EGFRki (as opposed to 
AG1478 which is reversible and will dissociate in time) and, as in vivo axonal regeneration 
is measured on the timescale of days or weeks, PD168393 was accordingly selected by 
Koprivica et al(2005) over AG1478 for their subsequent in vivo investigations of intra-
optic nerve post-ONC axonal regeneration, due to this requirement for long term EGFR 
blockade.  While Koprivica et al (2005)applied PD at the lesion site in the injured ON, it 
was decided to investigate the effects of intravitreal (i.v.) PD168393 on intra-optic nerve 
RGC axonal regeneration. 
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Chapter 5 
 
Examining the effects of Intravitreal Injections of the 
EGFRki PD168393 on RGC axonal regeneration and 
survival 
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5.1  Introduction 
 
The previous Chapter confirmed that the EGFRki AG1478 was capable of disinhibiting and 
actively driving RGC neurite outgrowth in vitro.  The next step was to investigate the 
mechanisms of action of EGFRki in vivo.  Subsequent to Koprivia et al. (2005) study, at 
least one paper has reported in vivo axonal regeneration in response to EGFRki; 
Erschbamer et al. (2007) delivered PD168393 intrathecally and reported significant 
recovery of locomotor function and enhanced performance in several other functional 
recovery paradigms in the weight drop-injured rat spinal cord.  As it did not appear that 
any group had studied the effects of ivit EGFRki on axotomised RGC, it was decided to 
attempt to recapitulate the regeneration seen by Koprivica et al (2005) by delivering 
PD168393 directly to RGC somata within the retina itself.       
 If PD168393  were to be successful in eliciting RGC axonal regeneration in the ON 
whilst being present only in the retina this would refute any hypothesis that revolved 
around  EGFRki acting directly on growth cones  within the ON.  Additionally, RGC 
regeneration in response to ivit PD would strongly suggest that the regenerative effects of 
intra-ON PD168393 reported by Koprivica et al (2005) were largely not a result of 
rendering the ON a less growth inhospitable environment.  In other words, this would 
suggest that EGFRki do not achieve the greater part of their effects on axonal 
regeneration via the abrogation of various EGFR-dependent cellular processes/events. 
Conversely, if ivit PD168393 is found to have no effect on axotomised RGC this will 
constitute strong evidence that the effects of such EGFRki are mostly mediated by cells 
and structures in the ON - chiefly growth cones, glia and invading immune/inflammatory 
cells – making the retrograde transport of EGFRki to RGC somata, a potential hypothesis 
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outlined in Chapter 3, unlikely to be relevant.      
 In order to accurately compare and statistically analyse any differences in 
regeneration between treatment and control groups it was necessary to quantify the 
number of axons regenerating past the lesion site as well as the total distance 
regenerated by each axon.  To this end, distance intervals of 250µm past the centre of the 
lesion site, up to 1.75 mm, were to be marked on composite photomicrographs of post 
experiment GAP-43 stained ON sections.  The number of axons crossing each interval 
(represented by a line drawn across the photomicrograph, perpendicular to the long axis 
of the nerve) would be counted and the results tabulated.  In this way numbers of axons 
regenerating increasing distances from the crush site could be quantified – i.e. if one 
treatment potentiated a small number of axons regenerating long distances whereas 
another treatment encouraged larger numbers of axons to cross the lesion site but not 
progress as far, this would be detected, measured statistically and represented on a bar 
graph as ‘number of fibres crossing 0.25mm, 0.5mm etc”.  Were this to be applied to an 
intra-ON experiment this could potentially discriminate between strongly stimulated 
axonal elongation (potentially few fibres, advancing well into the distal segment of the 
ON) and a general abrogation of the inhibitory elements of the CNS environment (many 
fibres regenerating across the lesion but for relatively short distances).   
 Although the primary focus of this series of experiments was to examine the 
effects of ivit PD168393, it was also decided to investigate the effects of combined ivit 
PD168393 and Nogo-P4.  As mentioned briefly in Chapter 2, Douglas et al. (2009) 
observed that AG1478 in the presence of CME actually results in a supra-normal growth 
stimulus to RGC in primary retinal cultures, i.e. AG+CME yields superior neurite 
outgrowth to AG1478 treatment alone.  If this is a real phenomenon, one possible 
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explanation is that CNS myelin contains a compound which, along with the putative NTF 
release caused by AG1478, enhances axonal regeneration.  One such candidate is Inosine, 
and this matter is discussed in the discussion section of this Chapter.  Another possibility 
is that AG1478/PD168393 could effectively change the growth antagonistic properties of 
a myelin derived protein to growth promoting.  Douglas et al. (2009) showed that AG1478 
treated cultures exhibit significantly raised levels of cAMP, and raised levels of this 
intracellular secondary messenger have been shown to render MAG an actively growth 
promoting agent (Cai et al. 2001).  As CNS myelin is absent from the rat retina, it was 
decided to investigate whether a similar synergistic effect could occur with ivit PD168393 
and Nogo-P4.  Additionally, as several previous studies by our group have generated 
accurate and reliable data as to the behaviour of axotomised RGC axons in sham-ivit 
injected, but otherwise untreated animals, and as the aforementioned treatment groups 
consisted of a) ivit PD alone and b) ivit PD+Nogo P4, it was thought sensible to have the 
third group receive ivit Nogo-P4 alone.  Such a group would function as a control for the 
PD+Nogo-P4 group, as well as being a treatment group in its own right.  As the literature 
does not appear to contain any examples of ivit delivered Nogo-P4, this group also 
represents a novel application of this peptide.        
 In order to have a positive control, ON sections from a regenerating ONC+PN 
group retina, from a previous set of experiments, were to be stained with GAP-43 and 
would undergo the same quantification procedure detailed above.  As ivit PN grafts are 
known to result in significant numbers of fibres crossing the lesion site and penetrating 
into the distal ON, this will provide a benchmark level of axonal regeneration with which 
to compare any regeneration obtained with ivit PD, Nogo-P4 or both. 
 Koprivica et al (2005) demonstrated that intra-ON PD168393 did not affect RGC 
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survival, despite producing significant numbers of regenerating RGC axons.  If EGFRki such 
as AG1478 and PD168393 do in fact cause NTF release from local glia, intra-ON PD could 
potentially have supplied an NTF gradient up which growth cones could grow, reminiscent 
of the original target seeking behaviour of these axons in utero, a process which would 
not necessarily directly influence survival. Additionally, any NTF released in the ON would 
have to be retrogradely transported through RGC axons to the somata if they are to have 
any effect on cell signalling cascades and transcription.  As the present study will be 
injecting PD directly into the vitreal body, any NTF release by local retinal glia will be 
effectively juxtacrinally supplied to the RGC somata.  Such direct delivery of multiple NTFs 
to RGC somata has been repeatedly demonstrated to promote RGC survival (see Berry et 
al. (2008) for review and references within) and it is thus possible that ivit PD168393 will 
significantly enhance RGC survival where intra-ON PD did not.  To quantify this effect, the 
eyes from treated animals will be appropriately processed before being sectioned, 
stained with Haemotoxilin and Eosin (H & E), and the surviving RGC counted.  In this way 
the mean number of surviving RGC per animal per group will be established and 
subsequently statistically analysed.        
 It is almost impossible to accurately measure the exact in vivo concentration of an 
injected drug, in terms of exposure of specific populations of cells.  It is then important to 
have an indicator of a drugs efficacy, irrespective of whether or not the desired effects 
are observed.  In the case of PD168393 the indicator will be EGFR phosphorylation levels 
in the GCL and the FL.  pEGFR levels will be measured by staining retinal sections with an 
anti-pEGFR antibody and fluorescent secondary antibody and by analysing subsequent 
photomicrographs using the histogram function within the image analysis program 
ImagePro.  By defining the GCL and the FL as an “area of interest”, Imagepro will measure 
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the mean pixel intensity of multiple stretches of retina, remove from this value the 
equivalent value for unstained control retina and calculate average pixel intensity per 
treatment group.  In this way it will be possible to confirm whether or not PD168393 did 
in fact inhibit EGFR phosphorylation, preventing spurious conclusions being drawn 
regarding the efficacy of PD.  If pEGFR levels are not shown to be significantly attenuated 
in retinae receiving PD, then it must be assumed that the EGFRki did not reach or did not 
affect ganglion cell and axonal EGFR.  Conversely if pEGFR levels are shown to be 
significantly attenuated whilst no regeneration is observed, this will strongly suggest that 
retinal pEGFR alone is irrelevant to axonal regeneration.  A third and final possibility is 
that PD168393 will be found not to inhibit RGC EGFR phosphorylation but nevertheless to 
promote significant axonal regeneration.  This would strongly suggest that EGFR such as 
PD promote RGC axonal regeneration via entirely off-target effects, i.e. that despite their 
designation as EGFRki, PD and AG are exerting their effects on some other molecular 
target, and that the EGFR itself is largely irrelevant. 
 
5.1.1  Specific Aims 
 To attempt to elicit in vivo RGC axonal regeneration by injecting the  
 vitreous body of ONC recipient rats with the EGFRki PD168393 
 
 To ascertain if concomitant intravitreal injection of PD168393 and   
 Nogo-P4 will elicit synergistic RGC axonal regeneration 
 
 To examine the effects of ivit Nogo-P4 on RGC survival and regeneration after ONC 
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5.2  Results 
5.2.1  Intravitreal PD168393 did not elicit RGC axonal regeneration 
 
Ivit injection of 100nM PD168393 failed to enhance RGC axonal regeneration 14 days 
after ONC.  GAP-43 staining showed that the vast majority of axons did not advance 
beyond the lesion site (Figure 5.1) and that the minority that did so failed to progress 
further than 0.25 mm (Figure 5.5, red-brown column).  In terms of the mean number of 
axons crossing the lesion site, no significant difference was found between the PD treated 
group and the Nogo-P4 and Nogo+PD treatment groups (figure 5.5).   
 
Figure 5.1.  GAP-43 staining showed the absence of significant RGC axon regeneration beyond the crush site 
following ivit PD168393 treatment.  * denotes centre of crush site.  Inset shows high power (x400) image of 
the single furthest regenerating/spared axon.  P= Proximal section D= Distal section. 
 
* 
* 
P D 
P 
* 
* 
D 
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5.2.2  Intravitreal Nogo-P4 peptide did not affect RGC axonal regeneration 
Ivit injection of 25µM Nogo-P4 peptide failed to influence RGC axonal regeneration after 
14 days after ONC.  GAP-43 staining again showed that the vast majority of axons did not 
advance beyond the lesion site (Figure 5.2) and that the minority that did so failed (with 
one exception) to progress further than 0.25 mm (Figure 5.5, purple column).  In terms of 
the mean number of axons crossing the lesion site, no significant difference was found 
between the Nogo-P4 treated group and the PD168393 and Nogo+PD treatment groups 
(figure 5.5).   
 
Figure 5.2.  GAP-43 staining showed the absence of significant RGC axon regeneration beyond the crush site 
following ivit Nogo P4 treatment.  * denotes centre of crush site.  Inset shows high power (x400) image of 
the single furthest regenerating/spared axon.  P= Proximal section D= Distal section. 
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5.2.3  Intravitreal PD168393 + Nogo-P4 peptide did not affect RGC axonal 
regeneration 
 
Ivit injection of 100µM PD168393 + 25µM Nogo-P4 peptide failed to influence RGC axonal 
regeneration 14 days after ONC.  GAP-43 staining showed that the vast majority of axons 
did not extend beyond the lesion site (Figure 5.3) and that the minority that did so failed 
(with few exceptions) to progress further than 0.25 mm (Figure 5.5, green column).  In 
terms of the mean number of axons crossing the lesion site, no significant difference was 
found between the PD+Nogo treated group and the PD168393 and Nogo-P4 treatment 
groups (figure 5.5). 
 
Figure 5.3.  GAP-43 staining showed the absence of significant RGC axon regeneration beyond the crush site 
following ivit PD168393 +Nogo P4 treatment.  * denotes centre of crush site.  Inset shows high power 
(x400) image of single furthest regenerating/spared axon.  P= Proximal section D= Distal section. 
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5.2.4  No treatment group elicited significant axonal regeneration  
Figures 5.1 - 5.3 show that neither PD, Nogo-P4 nor PD+Nogo-P4 treatment promoted 
axonal regeneration, as qualified by GAP-43 staining.  Figure 5.4 shows an example of 
significant axonal regeneration achieved with an ivit PN graft, as shown by GAP-43 
staining, with large numbers of axons crossing the lesion site and extending up to ~2 mm 
into the distal section of the nerve. 
 
Figure 5.4.  Example of axonal regeneration seen in response to ivit PN graft.  Axons regenerated up to 
~2mm past crush site 14 days after ONC + PN implant.  Note large number of axons crossing lesion site 
(white box) and extending up to ~ 2mm distally (white arrows).  * denotes centre of crush site.                   
P= Proximal section D= Distal section. 
 
 
Quantification of the mean number of axons extending up to 1.25 mm beyond the crush 
site for each treatment group, followed by statistical analyses, showed that neither PD, 
Nogo-P4 nor PD+Nogo-P4 treatment significantly differed from one another (Figure 5.5).  
In contrast, ONC + PN treatment was shown to yield statistically significant increases in 
mean numbers of axons extending up to and well beyond 1.25 mm distally.  Figure 5.5 
shows the mean number of axons extending 0.25, 0.5, 0.75, 1 and 1.25 mm past the 
* 
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* 
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lesion site, with means and statistical analyses for number of axons crossing each of these 
distances.  No statistically significant difference was found between PD168393, Nogo-P4 
nor PD+Nogo-P4 treatment groups for any of these distances, while each distance interval 
contained statistically significantly more PN-treatment group axons crossing it (figure 5.5, 
blue column). 
 
 
Figure 5.5.  Ivit PD168393 did not elicit significant RGC axon regeneration.  Number of axons 
regenerating up to 1.25 mm past the crush site were not significantly different between PD alone, 
Nogo-P4 alone and Nogo-P4+PD treatment groups.  In each group numbers of regenerating axons 
were negligible compared to the number of axons seen to regenerate in response to ivit PN graft.  
n = 4 for each group.  ***= p value of <0.001.  Error bars signify 95% Confidence Intervals. 
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5.2.5  Intravitreal PD168393 significantly attenuated retinal pEGFR staining  
In order to confirm that the injected PD168393 was in fact bioactive, retinal sections from 
each treatment group were immunohistochemically probed for pEGFR and, using the 
histogram function within the image analysis program ImagePro, relative pEGFR staining 
intensity was measured in the FL, GCL and IPL.  Subtracting the mean background pixel 
intensity for unstained retina, obtained from control tissue exposed to secondary but not 
primary antibodies, the relative mean pixel intensity was calculated for each treatment 
group (Figure 5.6).  Both the PD168393 and the PD168393+Nogo treated groups exhibited 
significantly lower pEGFR staining intensity compared to the Nogo treated group. 
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Figure 5.6.  PD168393 reduced pEGFR staining intensity in the FL, 
GCL and IPL layers of the retinae.  Units are mean pixel brightness 
values as measured with image anaylsis software histogram 
function. n = 4 for all groups   Error bars are 95% confidence 
intervals.  
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5.26  Intravitreal PD168393 did not enhance RGC survival 14 days post ONC 
Ivit PD168393 did not promote RGC survival 14 days after ONC.  No significant difference 
was found in mean surviving RGC number between PD168393, Nogo-P4, PD+Nogo-P4 or 
ONC-alone treatment groups (Figure 5.7).  Mean number of RGC per field of view for 
uninjured control was 56 ± 4.3, compared to between 31 ± 7.6  and 35 ± 4.5 for the 
treatment groups and previously collated ONC alone data (inter-treatment group 
differences were not statistically significant).   
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Figure 5.7.  PD168393 did not affect RGC survival 14 days after ONC.  Mean  
numbers 14 days after ONC were unaffected by ivit application of PD168393, 
Nogo-P4 or PD+Nogo-P4.  Mean was calculated by averaging retinal ganglion cell 
counts over multiple fields of view of GCL. n = 4 for all groups   ***= p value of 
<0.001.  Error bars = 95% confidence intervals. 
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5.3  Discussion 
5.3.1  Intravitreal PD168393 did not elicit RGC axonal regeneration 
Chapter 3 showed all RGC axons in both the retina and the ON to be pEGFR―, with only a 
subpopulation of RGC somata being pEGFR+.  By contrast the majority of glia in both the 
retina and ON were shown to be predominantly pEGFR+ and to exhibit enhanced pEGFR 
levels following ONC.  That ivit injections of the EGFRki PD168393 failed to elicit RGC 
axonal regeneration suggests that its primary mechanism of action is not the blockade of 
neuronal EGFR, as hypothesised by Koprivica et al (2005).  Although there is always the 
possibility with any in vivo drug application that the compound did not reach the target 
area, (or having done so, failed to impact on target cells), the significant attenuation of 
pEGFR staining intensity in the GCL and other layers of the retina (discussed in detail 
below) strongly suggests that RGC EGFR phosphorylation was indeed inhibited.  As ivit 
application of PD168393 yielded no significant RGC axonal regeneration whatsoever, 
while Koprivica et al(2005) observed considerable regeneration in response to intra-ON 
PD168393, it would appear that the events underlying this regeneration occur in the ON 
and not in the retina.  The results and discussion sections from Chapters 3 and 4 provide 
evidence for multiple different potentially beneficial actions of EGFRki specifically within 
the ON.  First and foremost are the myriad of EGFR-dependent cellular processes which 
are antagonistic to axonal growth, including astrogliosis, astrocytic CSPG deposition, 
fibroblast-astrocyte interactions leading to scar formation and the astrocytic and 
microglially mediated recruitment of immune cells into the lesion site, which debride and 
further damage axons (see Chapter 3 discussion for details).  If the abrogation or 
attenuation of these intra ON processes even partially underlies EGFRki-mediated 
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regeneration, then this would absolutely require EGFRki within the ON – the presence of 
ivit EGFRki would be largely irrelevant.         
 Secondly, there is considerable evidence to suggest that some glia may respond to 
EGFRki by releasing NTFs (Chapter 4, results and discussion).  While this has been shown 
to be true in AG1478 treated mixed retinal cultures in vitro (Chapter 4, results and 
discussion, Douglas et al. 2009), it is likely that this effect would be more pronounced in 
the ON in vivo, due to the larger numbers of glia involved (including oligodendrocytes 
which are absent from the retina), the irreversible nature of PD168393 (as opposed to the 
reversible EGFR blockade instigated by AG1478), and the juxtaposition of ON glia and 
axonal growth cones.  It is important to note that this is based on the assumption that the 
actions of PD168393, both on and off target, are identical to that of AG1478, which is by 
no means certain – the latter is a Tyrphostin, a reversible kinase inhibitor which achieves 
its EGFR blockade by competing locally for ATP, whereas the former binds directly and 
irreversibly to EGFR at Cys 773.  Nevertheless, Koprivica et al (2005) reported that PD and 
AG both elicited similar neurite outgrowth in vitro and Douglas et al (2009) demonstrated 
NT3 upregulation in RGC somata following ivit PD injection, suggesting that both EGFRki 
are having similar effects.         
 Thirdly, it is possible that the immunohistochemical investigation of ON pEGFR 
localisation shown in Chapter 3 failed to localise pEGFR on axonal growth cones, as the 
axonal antigen, NF-200, detected by the anti-axonal antibody used, is expressed only by 
consolidated section of the growing axon and not by the growth cone itself.  This is 
considered unlikely as no pEGFR― NF colocalisation was observed at all, requiring all 
pEGFR to be in the growth cone itself, signifying a complete lack of retrograde and 
anterograde transport of pEGFR to and from the somata, making it impossible for EGFR  
 189 
 
to interact with the nucleus and thus affect protein synthesis/transcription.  While 
considered unlikely, it should be noted that it is still technically possible that EGFR 
transactivation could be taking place within the growth cone, and that subsequently the 
putative role for EGFR in the NgR signalling cascade put forward by Koprivica et al (2005) 
could still hold true, providing that all interactions took place within the growth cone. 
     
5.3.2  Intravitreal PD168393 + Nogo-P4 peptide did not affect RGC axonal 
regeneration 
 
It has been observed that, while RGC axon outgrowth in vitro is inhibited by the presence 
of CME, RGC exposed to both CME and AG1478 exhibit synergistic neurite outgrowth, 
above and beyond PDL-Laminin controls (Douglas et al. 2009).  Taking into account the 
evidence that AG1478 causes raised levels of intra-RGC cAMP (Douglas et al. 2009), and 
that high levels of cAMP can cause MAG to switch from being neurite outgrowth 
inhibitory to being actively growth promoting (Cai et al. 2001), it was decided to 
investigate whether dual ivit injections of the CNS myelin derivative Nogo-P4 peptide and 
PD168393 could elicit this synergistic axonal outgrowth in vivo, there being no CNS myelin 
within the rat retina.  That no regeneration was observed in this study might have 
suggested that Nogo-P4 peptide does not provide the same synergistic boost to RGC 
outgrowth as CME, but being that ivit PD168393 injections alone failed to promote axonal 
regeneration, this cannot be asserted.  It is probable that some other, as yet unidentified, 
factor in CME is responsible for this counter-intuitive growth stimulatory in vitro effect, 
and this factor may be required for the unprecedented in vivo RGC regeneration originally 
reported with EGFRki by Koprivica et al. in 2005. 
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5.3.3  Intravitreal Nogo-P4 peptide did not affect RGC axonal regeneration 
Numerous previous in vivo experiments performed by our group featured control groups 
which received ivit saline/appropriate vehicle, meaning the levels of RGC axonal 
regeneration associated with such controls were well documented after large numbers of 
experimental replicates.  Additionally, as one treatment group consisted of PD+ Nogo-P4, 
a Nogo alone group allowed the ascription of any observed effects of RGC regeneration in 
the dual treatment group to either PD or the combination of PD+Nogo, as opposed to the 
Nogo peptide itself.  This group therefore functioned both as a negative control and as a 
treatment group, examining the effects of ivit injected Nogo-P4 peptide on RGC axonal 
regeneration.  Taking into account Nogo-P4’s growth antagonistic effects, the lack of 
significant difference in mean number of regenerating axons between both of the PD 
treated groups and this Nogo-P4 group demonstrates that no regeneration took place in 
any treatment group. 
 
5.3.4  No treatment group elicited significant axonal regeneration  
 
When compared to a ONC + ivit PN graft treated ON, all three treatment groups  
exhibited statistically significantly less axonal regeneration at measured checkpoints of 
0.25, 0.5, 0.75, 1.0 and 1.25 mm distal to the crush site, with PD treated RGC regenerating 
no better than those exposed to Nogo-P4.  The best ON regeneration reported to date, in 
terms of total percentage of all RGC axons regenerating beyond the lesion site is, as 
mentioned previously, 0.6-10% at 3 weeks after intravitreal peripheral nerve graft implant 
(Berry et al. 1996) and 7.5% at 4 weeks after a triple combination of c3-transferase 
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mediated Rho inactivation, application of exogenous, cell-permeable cAMP and 
simultaneous peripheral nerve autografting onto the cut end of optic nerve (Hu et al. 
2007).  In comparison, the intra-ON, PD168393-mediated, in vivo axonal regeneration 
reported by Koprivica et al (2005). was estimated by the authors as being ~0.5% of the 
total population of RGC, and the number of fibres regenerating in each of the three 
treatment groups in the present study was effectively zero.  It is thus apparent that, even 
where effective, in vivo delivery of EGFRki does not elicit as effective an RGC regenerative 
response as an ivit PN graft. 
 
5.3.5  Intravitreal PD168393 significantly attenuated retinal pEGFR staining  
Levels of pEGFR immunofluorescence in the FL, GCL and IPL were significantly lower in Ivit 
PD – treated groups, demonstrating that PD168393 both reached the target cells and 
acted upon EGFR in those layers.    This is a critical result, providing strong evidence that 
PD168393 was bioactive within the PD treated retina and hence that the observed 
ineffectiveness of ivit PD as an in vivo RGC regenerative agent was a valid result and not a 
consequence of failed drug-delivery.  Although there are numerous, more direct, and 
more reliably quantitative methods of determining phosphoprotein levels (SDS-PAGE with 
densitometry for example) these would have required the partial or total destruction of 
the retinae being analysed, which would have made it impossible to perform RGC survival 
counts.  Had in vivo regeneration been observed then there would have been justification 
for experimental repeats followed by one or more of these techniques for directly 
quantifying protein levels.  As no such regeneration occurred, and because the above 
indirect method using immunofluorescence pre-empted the likely results of any such 
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study, additional experiments to this end were deemed to be superfluous and an 
unjustifiable use of further animals. 
 
5.3.6   Intravitreal PD168393 did not enhance RGC survival 14 days post 
  ONC 
 
RGC survival was unaffected by ivit delivery of PD168393, Nogo-P4 or PD+Nogo.  This 
agrees with the findings of Korpivica et al (2005), who found PD to have no effect on RGC 
survival despite its reported regenerative effects.  In contrast, ivit injections of even single 
NTFs have been shown to promote significant RGC survival.  Ivit BDNF and CNTF were 
shown to promote 2-3 fold increase in RGC survival up to 4 weeks post ONC (Mey and 
Thanos 1993), ivit BDNF and, to a lesser extent, NT-4 (but not NT-3) were reported to 
delay RGC death by up to 3 days and significantly increase RGC survival rates up to 14 
days post ONC, and ivit CNTF was shown to encourage RGC axonal regeneration into an 
implanted segment of PN (Cui et al. 1999).  That intra-ON application of PD168393 (as 
performed by Koprivica et al.(2005) did not enhance RGC survival does not necessarily 
rule out the previously mentioned hypothesis that EGFRki such as PD and AG elicit local 
(i.e. intra ON) NTF release; it is possible that levels of NTF released are insufficient to 
significantly promote survival once retrogradely transported back to the RGC somata.  
More difficult to account for, working under the assumption that PD provokes local 
release of NTF, is the fact that ivit PD, which was shown to significantly reduce pEGFR 
levels in and around RGC somata, still failed to promote RGC survival.  Douglas et al. 
(2009) showed that RGC in retinae receiving ivit PD but not vehicle, upregulated NT-3, 
but, as discussed above, NT-3 appears to be ineffective at promoting RGC survival/axonal 
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extension.  It is then very likely that the in vivo effects of PD168393 are not exclusively 
mediated by NTF release, as such a pathway would almost certainly affect RGC survival. 
 
5.37  Interim conclusions 
 
Chapter 3 of this study showed that all RGC axons in both the retina and the ON were 
pEGFR―. Chapter 4 and Douglas et al. (2009) both show the EGFRki PD168393 and 
AG1478 to have a demonstrable neuriteogenic effect and to effect the release of NTF in 
vitro. Koprivica et al. (2005) demonstrated significant in vivo RGC regeneration using only 
intra-ON PD168393.  The present study (specifically this Chapter) also found that ivit 
PD168393, whilst effectively reducing EGFR phosphorylation, had no effect on in vivo RGC 
survival or axonal regeneration.       
 Taken together these results strongly suggest that the blockade of neuronal EGFR 
is not the primary means by which EGFRki exert their axogenic/neuritogenic effects, and 
points towards EGFR not being an integral part of the inhibitory signalling cascade.  The 
original in vivo post-ONC regeneration reported by Koprivica et al (2005) cannot be 
explained in terms of intra-RGC pEGFR, as all intra ON axons were pEGFR― and any 
pEGFR+ RGC somata, being in the retina, were almost certainly too far away from the area 
of ON exposed to PD168393 to be directly affected by the treatment, particularly as 
PD168393 in that case was largely contained within a gelfoam cuff placed around the 
injury site on the ON itself.  Additionally, as shown above, ivit PD168393, whilst 
demonstrably affecting RGC EGFR phosphorylation, elicited no RGC survival or axonal 
regeneration whatsoever.         
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 As mentioned previously, there are numerous processes antagonistic to axonal 
growth associated with almost every cell type found in the ON, glial or otherwise, 
(including invading inflammatory/immune cells) which depend either partially or wholly 
on EGFR signalling (for details see Chapters 3 and 4 discussion).  The abrogation of any 
one of these processes, e.g. astrocytic CSPG secretion, would render the ON a less growth 
inhibitory environment for regenerating axons, so it is immediately apparent that the 
inhibition or reduction of EGFR phosphorylation on almost the entire non-neuronal cell 
population could indirectly enhance axonal regeneration, even in the absence of 
extraneous NTF support.  There is also reason to believe that EGFRki may provoke the 
release of NTF from local glia (Douglas et al. 2009), which, in concert with the 
aforementioned reduction in axon growth antagonistic stimuli, could potentially explain 
the intra-ON regeneration obtained with PD168393 (Koprivica et al., 2005).  
Unfortunately there are at least two caveats associated with this hypothesis.  Firstly many 
of the same cell types within the ON are also present within the retina (with the 
important exception of oligodendrocytes), so paracrine/juxtacrine release of NTF by 
retinal glia in response to EGFRki should also stimulate growth, when in fact it does not.  
Secondly, while ivit PD168393 yielded no in vivo axonal regeneration through the growth 
inhibitory environment of the ON, dissociated primary retinal cultures , in which the exact 
same population of cells were exposed to AG1478 and to levels of Nogo-P4 peptide 
proven to inhibit RGC neurite outgrowth, did exhibit disinhibited neurite outgrowth.  This 
difference is likely to be at least partially a result of the difference in growth substrates 
between the two models: retinal cultures were plated on PDL + Laminin coated chamber 
slides, a surface known to be permissive to neurite outgrowth, whereas axons in vivo 
have no option but to grow in, around and through various growth inhibitory proteins and 
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cellular debris, in the presence of numerous other noxious influences such as 
inflammatory and immune interference.  Although the difference in growth substrate 
almost certainly plays a part, it is unlikely that the failure of in vivo axons to respond to 
ivit PD is entirely a consequence of this: the fact remains that Intra-ON PD elicits axonal 
regeneration, whereas intra-retinal PD does not.        
 One hypothesis put forward to explain both these phenomena is that a factor 
present in CNS myelin is capable of acting in concert with EGFRki such as PD and AG and 
provoking a supra-disinhibitory stimulus, i.e. PD/AG, in concert with this unknown factor, 
provokes levels of outgrowth above and beyond that associated with the mere 
abrogation of inhibitory stimuli - the interplay between EGFRki and unknown agent 
actively driving axonal regeneration as opposed to simply disinhibiting it.  This hypothesis 
is based on the observations that 1) retinal cultures exposed to both CME and AG1478 
exhibited supra-disinhibtory levels of neurite outgrowth – the combination of CME and 
AG appeared to actively drive growth in a manner reminiscent of that seen in response to 
exogenously delivered NTF (Douglas et al. 2009), 2) neither the mouse nor the rat (nor 
the human) retina contains CNS myelin and 3) this effect was not seen with recombinant 
Nogo-P4 peptide (see Chapter 4).  It should be noted that while Koprivica et al (2005) also 
used CME as an inhibitory agent and did not report any such synergistic effects, this study 
did not include details about the nature of the CME used and it is unlikely that the CME 
contained the exact complement of compounds at exactly the same relative 
concentrations as the CME used by Logan et al (2006) to outline the above hypothesis.  It 
is therefore possible that a factor present in myelin in vivo and in the CME used by 
Douglas et al. (2009) could act in concert with EGFRki to promote synergistic 
neuritogenesis and axonal regeneration, potentially including NTFs.  One potential 
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candidate for this unknown factor is Inosine.  This purine nucleoside is a breakdown 
product of Adenosine and has been implicated as being involved in at least two different 
pathways which could potentially aid axonal regeneration.  Firstly, inosine has been 
shown to activate MST3b, a protein kinase critical to axonal outgrowth (Irwin et al. 2006) 
and secondly, Inosine has been reported to serve as a ligand for the adenosine A2A 
receptor (Nascimento, 2010) which in turn has been shown to transactivate Trk receptors, 
resulting in growth and axogenic responses similar to that obtained with conventional 
NTF-therapy (Jeanneteau and Chao, 2006).  Chapter 4 of the present study showed how 
the A2A receptor antagonist ZM21385 partially inhibited the growth promoting effects of 
AG1478 on primary retinal cultures, an effect potentially attributable to either (or both) 
of these two pathways, and recent work from within our laboratory has shown that CME 
contains physiologically relevant levels of Inosine (Ahmed et al. unpublished data).  If 
Inosine and/or other compounds contained within CNS myelin are in fact necessary for 
EGFRki-mediated axonal regeneration, this would explain why intra-ON but not ivit 
PD168393 promoted growth because, again, neither rat nor mouse retinae contain CNS 
myelin.         
 Whether or not the presence of CNS myelin is required for EGFRki to elicit in vivo 
axonal regeneration, the fact remains that ivit PD168393 failed to produce such an effect.  
Having confirmed that AG1478 stimulated neuritogenesis and disinhibited RGC growth in 
vitro (see Chapter 4) and having shown ivit PD168393 to be ineffective, it was decided to 
investigate the effects of intra-ON PD168393, in an attempt to confirm the original in vivo 
findings of Koprivica et al (2005) 
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Chapter 6 
Examination of the effects of Intra-ON implantation 
of collagen matrix implanted with the EGFRki PD168393 
on RGC survival and axonal regeneration  
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6.0  Introduction 
Chapter 3 of this study showed that activated EGFR was not present in RGC axons, either 
before or after injury.   This contradicts the hypothesis of a purely intra-axonal role of 
pEGFR in abortive intra-ON axonal regeneration.  Chapter 4 confirmed that at least one 
EGFRki, AG1478, could stimulate RGC neurite outgrowth in the presence of otherwise 
outgrowth-precluding conditions in vitro - concentrations of Nogo-P4 peptide sufficient to 
largely abolish neurite outgrowth were rendered impotent following administration of 
AG1478.  Chapter 5 showed that ivit injections of the EGFRki PD168393 suppressed 
retinal pEGFR levels but neither promoted RGC axonal regeneration nor enhanced RGC 
survival.  Taken together these results showed that while ivit application of an EGFRki did 
not elicit in vivo RGC axonal regeneration, in vitro models did indeed show a significant 
growth promoting effect on previously inhibited RGC.   Furthermore, while the 
mechanisms underlying these in vitro effects were at least partially uncovered - including 
the release of putatively glially derived NTFs - the mechanisms underlying the in vivo 
regeneration reported by Koprivica et al.(2005) as well as those underlying the 
regenerative failure seen in ivit experiments, remained to be elucidated. The observation 
by Koprivica et al (2005) that considerable in vivo RGC axonal regeneration resulted from 
the intra-ON application of PD immediately suggested that EGFRki were exerting their 
axonal regenerative effects in or around the ON lesion site itself.  It was therefore decided 
to chronically expose the ON lesion site of ONC-recipient rats to the EGFRki PD168393 in 
an attempt to a) confirm the efficacy of intra-ON EGFRki therapy and b) elucidate the 
means by which PD, and putatively by extension other EGFRki, achieve such regeneration.  
In planning this experiment the primary goal was to expose the axons and cells in and 
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around the ON lesion site to relevant concentrations of PD168393 for the duration of the 
experiment, 14 days.  To deliver intra-ON PD for 14days, Koprivica et al (2005) wrapped 
sections of soluble-PD-saturated gelfoam around the ON lesion site, replacing sections 
with fresh PD-saturated sections every 3 days.  Each gelfoam replacement required 
surgery to expose and then reseal the lesion site, as well as the associated anaesthesia 
and recuperation of animals.  When planning the in vivo experiments described in this 
Chapter it was decided that this level of invasive surgery was unacceptable, in terms of 
surgical logistics, potential distress to animals and, crucially, the potentially experiment-
confounding inflammatory and immune responses to each and every surgical 
intervention.  Although various long-term in vivo drug-delivery techniques were 
appraised, the chosen method of intra-ON PD168393 delivery was that of collagen matrix 
implantation.            
 Collagen matrices have been used for decades to enhance wound healing in 
tissues as varied as skin and muscle (Carlson and Longaker, 2004), bone (Bonadio, 1999) 
and, crucially, in the mammalian CNS (Berry et al. 2001, Gonzalez et al. 2009, Yang et al. 
2010).  In many circumstances collagen matrices (referred to in the literature as, 
variously, scaffolds, matrices, lattices or frameworks) are seeded with cells such as 
Schwann cells or fibroblasts (see Carlson and Longaker 2004 for review) which secrete 
desired factors, or with genes encoding desired proteins (Berry et al. 2001) or with 
replication deficient viruses containing such genes (Gonzalez et al. 2009).  The latter two 
studies reported successful implantation of collagen matrices into the rat ON lesion site 
which promoted significant axonal and cellular invasion, resulting in the uptake of 
genes/virions by RGC and relevant glia.  The dual advantages of such a structure is that it 
provides a positive growth substrate along which axons can advance whilst allowing 
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compounds required to affect invading cells/axons to be effectively immobilised within its 
structure.  This immobilisation of factors/viruses/plasmids has itself three key 
advantages.  The immobilisation of bioactive agents prevents both their active clearance 
and their passive diffusion, which ensures the maintenance of a relatively fixed 
concentration of compound within the matrix whilst conserving the stock of compound, 
allowing long-term bioactivity.  This immobilisation also effectively renders the compound 
in question accessible only to cells/axons abutting or invading the matrix itself, a 
particularly desirable effect when seeking target-cell specific actions.  Finally, when 
implanted as a lyophilised, dry bolus such collagen matrices expand as they absorb tissue 
fluids, swelling to fill the lesion site.  In the case of ON lesions, this ensures that the matrix 
is in physical contact with both the proximal and the distal ends of the severed ON, 
ensuring a continuous growth substrate for axons across the entirety of the lesion site 
(Berry et al. 2001).  The 14dpi timepoint was selected for several reasons.  Firstly, by 14 
dpi sufficient numbers of control group RGC will have died (~70%) to make any effects on 
RGC survival more salient in treatment groups.  Secondly, 14 days is sufficient time for 
any regenerating axons to invade and cross the lesion site, allowing for the verification of 
long tract regeneration.  Thirdly, for exactly these two reasons, all IHC results from 
Chapter 3 are from 14dpi animals thus setting all subsequent in vivo experiments to end 
at the same time period allows a more valid comparison of results. Finally, the in vivo 
intra-ON experiments performed by Koprivica et al (2005)were concluded at 14dpi, thus 
by using the same time point in the present study all experimental results could be 
compared and contrasted with those of the former.    
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 In order to allow close comparison of the effects of intra-ON PD168393 on RGC 
survival and axonal regeneration with those of the ivit PD therapy detailed in Chapter 5, 
identical analytical methodology was followed.  Full details for each of these are given in 
the introduction to Chapter 5.  Briefly:,to establish extent of axonal regeneration, 
distance intervals of 250µm past the centre of the lesion site, up to 1.75 mm, were 
marked on composite photomicrographs of post experiment GAP-43 stained ON sections.  
The number of axons crossing each interval (represented by a line drawn across the 
photomicrograph, perpendicular to the long axis of the nerve) were counted and the 
results tabulated.  To quantify RGC survival, eyes from treated animals were appropriately 
processed before being sectioned, H & E stained, and the surviving RGC counted.  In this 
way the mean number of surviving RGC per animal per group were established.  To 
confirm that PD effected EGFR phosphorylation blockade, the immunofluorescence of 
each pEGFR immunostained lesion site of each animal was compared to that of the 
adjoining proximal and distal sections of ON, with the prediction that the lesion 
site/matrix would exhibit significantly less pEGFR staining, reflecting an abrogation of 
EGFR phosphoylation.  This was done under the assumption that PD would not affect 
pEGFR levels in any areas outside the immediate surrounds of the matrix.  Finally, to 
provide a useful comparison in terms of numbers of axons surviving and regenerating, 
sections of ON from PN-graft recipient rats from previous experiments were stained for 
GAP-43 and the extend of regeneration ascertained, while the respective retinae were 
sectioned, H & E stained and counted to provide RGC survival values.  As the mean 
numbers of axons regenerating and the mean numbers of surviving RGC at 14dpi in this 
model have long been established by repeated experiments performed by our research 
group, the values obtained in the present study could immediately be checked against 
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these figures, lending extra validity to comparisons of the extent of regeneration and RGC 
survival between PN graft and PD-matrix models.     
 Taking into account the provenance of previous collagen matrix implantation 
studies, the effects of intra-ON PD168393 reported by Koprivica et al (2005), including 
significant axonal regeneration without increase in RGC survival, and the results of ivit PD 
injection, it was predicted that considerable axonal regeneration would be observed in 
the PD-matrix group, that pEGFR levels would be attenuated in the lesion site of PD-
matrix group animals, and that no effect would be found on RGC survival.  It was not 
known to what extent, if any, the collagen matrix alone would promote axonal 
regeneration.  
 
6.1.1  Specific Aims 
 To promote in vivo RGC axonal regeneration using the EGFRki   
  PD168393 (contained within a collagen matrix) and so confirm the  
  in vivo results of Koprivica et al (2005). 
. 
 To obtain more robust RGC axonal regeneration than reported  
 by Koprivica et al.(2005) due to the combination of permissive growth  
   substrate and constant source of PD168393 provided by the  
   implanted collagen matrix 
 
6.1.2  Specific Hypotheses 
1) RGC axons will regenerate into and through the implanted PD-impregnated 
collagen matrix  
 
2) RGC survival will likely not be affected by the presence of PD168393 
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6.2 Results 
Due to time constraints and accidental tissue destruction during tissue processing for IHC, 
several of the analyses comprising this final results section are less complete than 
intended.  Specifically, several of the below results relying on ON tissue sections were not 
fully obtained in triplicate – the minimum required for statistical analysis.  Where this was 
the case it has been stated explicitly so as not to mislead.  Unless stated otherwise, n = 3 
or more, as in all previous experiments.  Additionally, several results refer to and show 
data derived from, ivit PN graft treated animals.  These data were included to serve as an 
example of substantial RGC survival and axonal regeneration with which to compare any 
EGFRki-initiated regeneration, but, as these experiments were performed prior to all 
other experiments listed below, using a different strain of rat and did not involve any 
experimental manipulation of the ON beyond ONC, the results should not be directly 
compared.   
 
6.2.1  RGC axons invaded lesion sites containing PD-matrix 
 
GAP-43 staining showed that in PD-matrix implanted ON, many RGC axons advanced into, 
and often beyond, the lesion site (Figures 6.1-6.3).  Many axons entered the PD-matrix 
and regenerated until they abutted the distal section of the ON, although most failed to 
exit the matrix and enter the distal ON segment.  In terms of the mean number of axons 
crossing the lesion site, statistical analysis was impossible due to the results for the 
control matrix group consisting of only 2 animals (n = 2).  Nevertheless, it can be seen that 
 204 
 
all 3 PD-matrix-implanted ON exhibited considerable regeneration (Figures 6.1-6.3 and 
6.6).  Figure 6.6 shows the number of axons crossing various distances distal to the centre 
of the lesion site.  The ivit PN group data were taken from a previous experiment and was 
included as an example of definite in vivo regeneration.  This group did not receive any 
intra-ON treatment whatsoever beyond ONC. 
 
 
Figure 6.1.  PD-matrix was invaded by axons which crossed the lesion site and progressed through the 
matrix and its border abutting the distal ON segment.  Upper image shows GAP-43+ axons (green), lower 
image shows GFAP+ Astrocytes (red).  ON sections are consecutive.  Note the extent of axonal and astrocytic 
invasion of the matrix/lesion site.  The collagen matrix has expanded such that it contacts both ends of the 
ON.  The boundaries of the lesion site are traced in white.  *=Approximate centre line of lesion.  P= Proximal 
segment, D= Distal segment. 
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Figure 6.2.  GAP-43+ axons (green) entering the lesion/PD-matrix of second PD-matrix implanted ON.  No 
GFAP staining available due to the accidental destruction of tissue.  The Collagen matrix has expanded such 
that it contacts both cut ends of the ON.  The boundaries of the lesion site are traced in white.  
*=Approximate centre line of lesion.  P= Proximal segment, D= Distal segment. 
 
 
Figure 6.3.  Third replicate of PD-matrix implanted ON.  GAP-43+ axons (green, upper image) and GFAP+ 
astrocytes (red, lower image) have partially invaded the lesion site/PD-matrix . ON sections are consecutive.  
The collagen matrix has expanded such that it contacts both cut ends of the ON.  The boundaries of the 
lesion site are traced in white.  *=Approximate centre line of lesion.  P= Proximal segment, D= Distal 
segment. 
 
 
P D 
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6.2.2  RGC axons did not invade lesion sites containing control-matrix 
GAP-43 staining showed that almost no axons entered the control-matrices, with very few 
axons crossing into the matrix/lesion site and no axons whatsoever progressing further 
than the centre of the lesion (figures 6.4, 6.5, 6.6).  As mentioned above, time constraints 
and experimental error resulted in only 2 complete control-matrix results, which 
precludes the use of statistics to determine the significance of differences in regenerating 
axon numbers.  Despite this, a qualitative comparison of the number of axons entering 
and subsequently traversing the lesion site in the PD- and control-matrix groups (figures 
6.1 – 6.3) strongly suggests that intra ON PD168393 promoted RGC axon regeneration. 
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Figure 6.4.  Control matrix implantation elicited no regeneration into or beyond the lesion site.  
Upper image shows GAP-43+ axons (green) failing to enter lesion site.  Lower image shows GFAP+ 
astrocytes (red) showing the approximate boundaries of the lesion site (traced on upper image in 
white).  Few astrocytes can be seen invading the lesion site.  ON sections are consecutive.  The 
collagen matrix has expanded such that it contacts both cut ends of the ON.  The boundaries of the 
lesion site are traced in white.  *=Approximate centre line of lesion.  P= Proximal segment, D= Distal 
segment. 
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Figure 6.5.  Control matrix implantation elicited no regeneration into or beyond the lesion site.  
Upper image shows GAP-43+ axons (green) failing to enter lesion site.  Partial GFAP+ astrocyte 
influx/sparing within the lesion site is visible (red, lower image).  ON sections are consecutive.  The 
collagen matrix has expanded such that it contacts both cut ends of the ON.  The boundaries of the 
lesion site are traced in white.  *=Approximate centre line of lesion.  P= Proximal segment, D= 
Distal segment. 
 
6.2.3   PD-matrix promoted axonal regeneration, albeit less than ivit PN 
  graft 
 
Figure 6.6 shows the mean number of axons that regenerated increasing distances from 
the centre of the lesion site.  PD-matrix (blue) and ivit PN graft (green) groups 
regenerated axons up to and including 1.25mm distal to the centre of the lesion site.  
Several PD-matrix group axons were also observed to have exited the lesion site and to 
have entered the distal ON section (Fig 6.2, 6.3).  Although a small number of axons were 
seen to cross the proximal boundary of the lesion site and enter the control-matrix, no 
P D 
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axons were observed to extend further than 0.25mm distal to the proximal boundary of 
the lesion (Figures 6.4 and 6.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6.  Mean number of axons regenerating past the proximal boundary of the lesion site  
and distances of 0.25 – 1.25 mm distally.  ivit PN graft (green) and intra-ON PD-matrix (blue) 
implantation resulted in considerable axonal regeneration.  Intra-ON control matrix 
implantation (brown) did not promote axon regeneration. 
 
The following rationale were used to translate the values for regenerating axon numbers 
shown in Figure 6.6 into the percentages of total axonal population regenerating per 
treatment group shown in figure 6.7: 
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Average diameter of adult albino rat ON = 504.8µm (Melo et al. 2006) 
Average diameter of adult albino rat ON axon = 0.77µm (Foster et al. 1982) 
So in any ON section taken at or around midline of ON, number of axons in 
section = Diameter of ON/Diameter of axon = 504.8/0.77 = 655.6. 
Therefore any one section of uninjured ON taken near ON midline should 
contain ~650 axons. 
Regenerating axons are defined as being GAP-43+ and extending beyond the 
proximal boundary of the lesion site.  
Thus: 
Percentage of total RGC axon population regenerating in each 15µm-thick ON 
section=  
(No. regenerating GAP-43+ axons/650) x 100  
 
Using this formula, the approximate mean percentages of total RGC population 
regenerating in each 15µm-thick ON section were calculated for control matrix, PD-matrix 
and ivit PN groups (Figure 6.7).        
    
 
Figure 6.7.  Estimated percentage of total axonal population (per 15µm-thick ON section) regenerating past 
the proximal boundary of the lesion site and distances of 0.25 – 1.25 mm distally.  ivit PN graft (green) and 
intra-ON PD-matrix (blue) implantation resulted in considerable axonal regeneration.  Intra-ON control 
matrix implantation (brown) did not promote axon regeneration. 
 211 
 
6.2.4  PD-matrix implantation did not enhance RGC survival  
PD-matrix implantation did not significantly affect RGC survival as compared to control-
matrix (Figure 6.8).  The mean number of RGC per field of view, as counted in the GCL in 
H&E stained retinal sections, did not alter significantly between the two groups, being 
15.0 ± 1.2 and 17.2 ± 0.8 for control and PD groups respectively.  Ivit PN group was not 
included as these animals were of a different strain – Sprague Dawley as opposed to 
Wistar  – and the two strains are known to exhibit average different RGC density (see 
discussion for details and analysis). 
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Figure 6.8.  No difference in RGC survival was found between PD-
matrix and control-matrix treatment groups. n = 4 for each group.  
Error bars represent 95% confidence intervals. 
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6.2.5  Lesion site pEGFR levels were unaffected by intra-ON PD-matrix 
 implantation 
 
In order to confirm the bioactivity of PD168393, pEGFR immunofluorescence levels were 
measured (in terms of pixel intensity) in the lesion site and the proximal and distal 
sections of each ON (see Chapter 5 introduction for further details).  The mean 
immunofluorescence values for each of these ON areas, for each group, are shown below 
(Figure 6.9), expressed as arbitrary units.  Control-matrix (blue bar) and PD-matrix (red 
bar) lesion sites exhibited no apparent differences in pEGFR staining, and lesion site 
pEGFR staining did not appear reduced, when compared to proximal/distal sections, in 
either group.  As n = 2 for each group in these immunofluorescence studies, statistical 
analysis was not possible. 
 
 
Figure 6.9  pEGFR levels in the proximal sections, lesion sites and distal sections of PD-
matrix and control-matrix implanted ON, as inferred by pEGFR immunostaining intensity.  
No difference was observed between PD-matrix (blue) and control-matrix (red) intra-
lesion site pEGFR staining intensity.  Also, pEGFR staining levels in the lesion sites of both 
groups were not notably lower than the respective proximal and distal sections of the 
same ON.  Units are mean pixel brightness values, as measured with histogram function 
within image analysis software, and are expressed as arbitrary units (a.u). 
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6.3  Discussion 
 
6.3.1  RGC axons invaded lesion sites containing PD-matrix 
 
That significant numbers of RGC axons invaded PD-matrices but not control-matrices (see 
below) strongly suggests that PD168393 promoted axonal regeneration; the first intra-ON 
confirmation of the original experiment by Koprivica et al. (2005).  A population of axons 
regenerated across each PD-matrix-implanted lesion site, with a small number even 
penetrating into the distal segment of the ON.  Having showed in Chapter 5 that 
delivering PD to the RGC somata and surrounding glia via ivit injection elicited no RGC 
axonal regeneration, the subsequent efficacy of intra-ON PD effectively narrows the 
potential target(s) of EGFRki such as PD to the cells, structures and molecules in and 
around the ON lesion site itself.  Various hypotheses as to the nature of these intra-ON 
interactions are discussed in detail below.   
 
6.3.2  RGC axons did not invade lesion sites containing control-matrix 
 
The failure of axons to invade implanted control collagen matrices may be due to the lack 
of an active growth stimulus.  It is has been shown that RGC axons fail to enter freeze-
thawed PN grafts in which all cells are dead, whilst readily invading non-freeze thawed, 
living, but otherwise identical grafts (Berry et al. 1988), and that even PN axons will not 
invade such acellular PN tissue (Anderson et al. 1983, Nadim et al. 1990).  This effect is 
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due to the secretion of survival and growth promoting NTF by Schwann cells contained 
within the graft, which drives axonal growth along the enhanced growth substrate of 
Schwann cell derived basal laminal tubes.   Interestingly, Nadim et al. (1990) showed that 
axons from the rat tibial nerve tended not to extend into sections of freeze-thawed, 
acellular tibial nerve, and those few axons which did enter the acellular graft progressed 
no further than a maximum of 1mm.  The almost complete failure of RGC axons to enter 
implanted control-collagen matrices echoes this effect; and it is hypothesised that just as 
the lack of Schwann-cell derived NTFs prevent both CNS and PNS axons from invading an 
otherwise permissive growth environment, RGC axons invading implanted PD-matrices do 
so in response to NTFs released by PD-conditioned ON glia such as astrocytes, which 
readily invade such collagen matrices soon after implantation (Gonzalez et al. 2009, 
Chapter 4, results section).  As collagen matrices have been reported to reliably retain 
molecules of DNA (Berry et al. 2001) it is likely that very little PD would escape the matrix, 
but that subsequently released NTF could diffuse out, perhaps creating neurotrophic 
gradient “up” which RGC axons could grow, causing them to enter the PD-matrix.  In the 
absence of this putative PD-provoked, glially secreted NTF support, control group axons 
would not have the stimulus to invade implanted control collagen matrices.   Once again 
it must be pointed out that the small n number for control animals, in this case n = 2, is a 
potential caveat, and it is possible that larger numbers of control matrix results may have 
exhibited more significant axon regeneration. 
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6.3.3   RGC Axonal regeneration is promoted by implanted PD-matrix  
 
Koprivica et al.(2005), using the quantification method used by Lehmann et al. (1999), 
estimated that approximately 0.5% of the total RGC population regenerated more that 
0.5mm beyond the lesion site in response to intra-ON PD168393.  The former study 
equated this level of axon regeneration to that seen in response to the Rho activity-
blocking enzyme C3 transferase(<1%), which was the primary focus of the latter study.  In 
comparison, PD-matrix and ivit PN graft groups regenerated approximately 1.2% and 3.2% 
of the total RGC population up to or beyond 0.5 mm past the lesion site.  If accurate, the 
numbers of axons regenerating in the present study, in response to intra-ON PD-collagen 
matrices, is over twice that reported by Koprivica et al(2005). in response to PD 
introduced via a gelfoam cuff around the ONC site.  The implanted collagen matrix itself 
served as a positive growth substrate for the (putatively indirectly) PD-stimulated 
advancing growth cones.  In support of this, axons of primary CNS neurons have been 
shown to grow faster in collagen gels than on flat monolayers of growth substrates such 
as laminin (Harris et al. 1985).  It should be noted at this point that while both this study 
and that of Lehman et al(1999). used rats (Rattus norvegicus) for all in vivo experiments, 
Koprivica et al(2005). performed their experiments on mice (Mus musculus).  This species 
difference makes it difficult to define real differences in percentage RGC regeneration and 
it is possible that PD-matrix implantation experiments as described here would have 
yielded different results in a mouse model. 
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6.3.4  PD-matrix did not enhance RGC survival  
Statistical analysis of retinal RGC counts showed that levels of RGC survival were not 
significantly different between intra-ON PD-matrix and control-matrix implanted groups, 
despite the apparent enhanced axon regeneration exhibited by the PD-matrix implanted 
group.  This agrees with the findings of Koprivica et al.(2005) who also found PD to have 
no effect on RGC survival, despite promoting significant axonal regeneration.  Neuronal 
survival and axonal regenerative signalling pathways often overlap to the extent that any 
factor promoting one will promote the other, both processes being primarily mediated by 
the JAK/STAT, ERK and PI3K pathways (see general introduction), although which of these 
pathways is of primary importance appears to depend on circumstance.  For example, the 
PI3K/Akt pathway has been shown to determine RGC survival following increased intra-
orbital pressure, but to be irrelevant to RGC survival in control animals (Huang et al. 
2008).  Many neuroprotective therapies can enhance RGC survival without directly 
promoting in vitro neurite outgrowth or in vivo axon regeneration, primarily by activating 
or blocking pro- and anti-apoptotic members of the BCL-2 family of mitochondrial 
permeability regulating proteins (for review see Chao and Korsmeyer, 1998).  Conversely, 
for any factor to elicit considerable in vivo axonal regeneration whilst not enhancing 
neuronal survival is unusual, but not unprecedented: Li et al. (2009) showed certain 
synthetic FGF analogues to differentially promote either in vitro neurite outgrowth or 
neuronal survival but not both and both Cui et al. (1999) and Cho et al. (1999) separately 
reported that CNTF promoted significant regeneration of axotomized hamster RGC axons, 
despite comprehensively failing to enhance RGC survival rates.  The latter study 
suggested that CNTF may exert its regenerative effects via stimulating GAP-43 which is 
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known to act both directly and indirectly on the actin cytoskeleton, as well as influencing 
microtubule dynamics (Nguyen et al. 2009).  This picture is complicated somewhat by the 
findings of Gupta et al. (2009), who show the neuroprotective effects of BDNF to be GAP-
43 dependent, linking GAP-43 directly to neuronal survival.  Nevertheless, that PD168393 
promoted in vivo RGC axonal regeneration whilst having no effect on RGC survival 
suggests that the as yet unknown mechanism of action of such EGFRki does not directly 
involve the JAK/STAT, ERK or PI3K signalling pathways, as these growth promoting 
pathways usually simultaneously promote neuronal survival. 
 
6.3.5  Lesion site pEGFR levels were unaffected by PD-matrix 
 
Despite effecting measurable axonal regeneration, implanted PD-matrices did not render 
the lesion site less pEGFR+ compared to the proximal and distal areas of the respective 
ON, and pEGFR immunofluorescence levels were not significantly different between PD- 
and control- matrix group lesion sites.  Had no axonal regeneration been obtained with 
PD-matrices, this result would have likely have been interpreted as a failure in drug 
delivery, i.e. it would have been surmised that the concentration of PD within the 
matrices was too low to effect significant pEGFR blockade, or that incorporation of PD 
into the matrices had somehow inactivated it or prevented it from being uptaken by cells 
and axons.  As significant regeneration was observed in response to PD- , but not control- 
matrix implantation, it must be assumed that PD168393 was accessible to the necessary 
cells and/or axons as well as being present at sufficient concentration to elicit this effect.  
There are three possible explanations for this result.  Firstly, it is possible that PD was 
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present and accessible to an extent which allowed the putative, as-yet unknown signalling 
pathways to promote axonal regeneration but not to an extent which produced verifiable 
pEGFR blockade.  This is possible when the potential promiscuity of many EGFRki, as 
reported by Fabian et al. (2005), is taken into account (see interim conclusions section 
below), i.e. it is possible that PD168393 may exert its beneficial effects on as yet unknown 
targets, at concentrations below that at which EGFR is affected.  This would mean EGFR 
blockade was not the primary means by which PD, and by extension, perhaps other 
EGFRki, exert their axonal regenerative effects.  Secondly, as collagen matrices are known 
to be almost fully degraded by around the time point used in the present study (Gonzalez 
et al. 2009), it is possible that the cells originally exposed to PD, and their subsequent 
abrogated pEGFR immunofluorescence, were obscured or diluted by the subsequent 
waves of invading pEGFR+ inflammatory and immune cells (as confirmed by ED-1 and OX-
42 staining, results section, Chapter 3).  This possibility highlights the inadequacy of 
attempting to ascertain EGFR phosphorylation levels via the indirect, at best semi 
quantitative methods used here.  Due to this combination of cellular events and less than 
ideal methodology, the level of ON pEGFR attenuation in response to PD-matrix 
implantation cannot be reliably ascertained from the results shown here.  Further 
evidence that the inflammatory and immune cellular invasion may have played a key role 
in masking a reduction in pEGFR immunofluorescence is the clear and significant 
attenuation of retinal EGFR phosphorylation obtained as a result of ivit PD injections 
(Chapter 5, results) – despite the well documented macrophage influx in response to ivit 
injections, the associated small injury to the eye and the presence of retinal cellular 
debris following RGC apoptosis in response to distal ONC.  The GCL, INL and IPL were all 
free from the large scale invasive cellular obfuscation seen in the injury site of the ON 
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allowing any changes in local pEGFR levels to be more readily detected. Finally, it is 
possible that a proportion of the PD contained within the matrices somehow diffused into 
the surrounding tissue, attenuating pEGFR immunofluorescence in the proximal and distal 
ON sections, leading to a lack of significant difference in fluorescence levels between the 
lesion site and the proximal and distal sections. 
 
6.3.6  Interim Conclusions 
Several hypotheses or models present themselves as to why intra-ON but not ivit PD 
would promote RGC axonal regeneration.  These are based on the proposed models for 
EGFRki mechanism of action described in the discussion sections of Chapters 3 – 5. 
 In the first model, PD is thought to act directly on intra-ON RGC growth cones by 
inhibiting EGFR phosphorylation on the surface of the growth cone itself, as suggested by 
Koprivica et al (2005.  The in vitro findings of this study, which showed evidence that 
pEGFR was associated with growth cone collapse, and those of Schachtrupp et al. (2007), 
which postulated that this signalling was mediated by the blood protein fibrinogen and 
subsequent intraneuronal β-3-integrin/EGFR interaction, would support such an intra-
axonal model.  This arrangement would mean that the primary mechanism of action of 
EGFRki such as PD and AG is to blockade the EGFR phosphorylation which occurs as a 
direct result of axons encountering fibrinogen, preventing the putative subsequent 
growth cone collapsing signalling cascade.  If this hypothesis were correct, it would 
explain why intra-ON, but not ivit EGFRki, promoted axon regeneration: fibrinogen is 
present within the ON lesion site but not the retina, thus ivit PD would not prevent the 
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putative fibrinogen-EGFR interactions reported to trigger growth cone collapse.  There 
are, however, several problems with this model.   RGC axons do not contain pEGFR 
(Chapter 3 results) and, although growth cones were not directly visualised, it is unlikely 
that pEGFR was exclusively confined to growth cones without any retro- or antero-grade 
axonal signalling to/from the cell body, which would almost certainly have been visible 
following IHC analysis.  It should be noted at this point that a Pubmed search of the 
literature failed to find a single study reporting the visualisation of EGFR on growth cones 
in vivo.  Furthermore, Douglas et al. (2009) showed that RGC in primary retinal cultures 
treated did not exhibit enhanced neurite outgrowth when treated with siRNA such that 
EGFR was knocked down by over 90%, and further showed that these RGC still responded 
to subsequent AG1478 treatment with enhanced neuritogenesis.  The present study also 
showed that ivit PD168393 successfully attenuated pEGFR levels in the GCL, yet this had 
no effect on axonal regeneration (Chapter 5), and it has been observed that all pEGFR― 
RGC, when dissociated in vitro, become highly pEGFR immunoreactive irrespective of 
subsequent neuriteogenesis (Douglas et al. 2009).  Thus it would appear that the balance 
of current evidence suggests a purely on-target, axonal/growth cone-specific role for 
PD168393 to be very unlikely.        
 In the second proposed model PD acts intraneuronally, but not specifically on 
EGFR – i.e. off target.  Many protein kinases and receptor tyrosine kinases have similar 
tyrosine phosphorylation domains and it is possible that PD168393 affected other, as yet 
unknown, kinases.  Fabian et al. (2005) created a small molecule-kinase interaction map 
for 20 clinically aimed kinase inhibitors and examined their effects of 120 kinases.  They 
showed several EGFRki to affect numerous other kinases distinct from EGFR, concluding 
that: “specificity varies widely and is not strongly correlated with chemical structure or 
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the identity of the intended target”.  PD has been shown, for example, to inhibit the 
activity of stat3 and ERK (Chen et al. 2005), albeit it at 10x the concentration needed to 
inhibit EGFR kinase activity (values were described in terms of IC50 measurements).  Also 
supporting this idea of off-target effect is the fact that Koprivica et al(2005) compiled a 
list of the effects of over 400 compounds on the disinhibition of CGN neurite outgrowth, 
including several EGFRki (Koprivica et al. (2005), supplementary material)), and while 
some EGFRki promoted considerable neurite outgrowth, (e.g. the tyrphostins A23, A46, 
A47, B44, and AG1478), other EGFRki had absolutely no effect on neuritogenesis 
(tyrphostin B42, PD153035).  It is possible that the putative unknown target or targets of 
EGFRki is/are present in the growth cones or intra-ON axons of RGC but not present in the 
retina, hence the failure of ivit PD to elicit regeneration.  In this model, EGFR is not 
directly involved in growth-inhibitory signalling at all and its identity as the original target 
of EGFRki such as PD168393 is irrelevant.      
 The third proposed model has EGFRki such as PD168393 and AG1478 achieving 
their beneficial effects on RGC axonal regeneration indirectly, through influences on ON 
glia.  Here, EGFRki is proposed to perform a dual on-target/off-target role; inhibiting the 
various previously discussed growth antagonistic cellular events linked to non-neuronal 
EGFR signalling (described in detail in the discussion section of Chapter 3), whilst 
simultaneously effecting the release of NTFs local to axons within the ON, encouraging 
regeneration.  The fact that RGC axons severed inside the retina regenerate 
spontaneously up to the optic disc (McConell and Berry 1982), while RGC axons severed 
at any point beyond the optic disc emphatically do not has been at least partially 
attributed to the lack and presence of growth inhibitory CNS myelin before and after the 
optic disc respectively.  It is possible instead/additionally that this difference is due to the 
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aforementioned actions of several cell types in the ON which are not present in the 
retina, including oligodendrocytes, symamtocytes, and numerous inflammatory/immune 
cells invading the ON after injury and subsequent disruption of the BBB. If these cell types 
and t heir associated EGFR-dependent processes are in fact a major source of axonal 
growth antagonism this would explain why intra-ON, but not ivit, PD effected 
regeneration - locally applied EGFRki would abrogate the putatively responsible EGFR 
signalling whereas ivit PD would not.  It should be noted however that glial NTF release in 
response to EGFRki has only been directly confirmed in vitro, and even then, only in 
primary retinal cultures (Douglas et al. 2009).  One potential problem with this NTF 
release hypothesis is the absence of increased RGC survival in PD treated ON, as reported 
by Koprivica et al(2005). and confirmed in this present study.  Numerous papers have 
been published on the effectiveness of both single and combinatorial NTF therapy in 
promoting significant RGC survival in vivo (see Berry et al. 2008, section 3, for review) and 
the lack of such increased RGC survival in PD treated ON is difficult to explain if local NTF 
release is part of such EGFRki’s mechanism of action.      
 The fourth and final proposed model proposes, as mentioned previously, that the 
effects of PD168393 (and by extension, potentially other EGFRki such as AG1478) on RGC 
are a result of their interaction with one or more compounds found within CNS myelin - a 
hypothesis based on the observations of Douglas et al. (2009) who reported that 
CME+EGFRki treated retinal cultures exhibited synergistic growth.  A short description of 
one such possible candidate, inosine, is described in the discussion section of Chapter 3 
(also, see Douglas et al. 2009).  If components of CNS myelin are required for EGFRki-
mediated regeneration then this could also explain why ivit PD failed to elicit RGC axonal 
regeneration; there being no myelin in the rat/mouse eye.  As mentioned previously, at 
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least one myelin derived protein, MAG, has been shown to switch from being growth 
antagonistic to being growth promoting, given sufficiently high levels of the intracellular 
secondary messenger cAMP (Cai et al. 2001) and the EGFRki AG1478 has been shown to 
elevate cAMP levels in primary retinal cultures in vitro (Douglas et al. 2009).  It is thus 
possible that some other component of CNS myelin is acting analogously and 
synergistically boosting the effects of EGFRki.  It should be noted that this model makes 
the assumption that EGFRki must be delivered intra-ON, as ivit PD treated RGC are still 
technically exposed to PD as well as CME (at the lesion site).  Thus this model suggests 
that EGFRki, working in concert with some component of CME, act synergistically on 
growth cones/ON glia.         
 A recently published study has provided evidence compatible with the third, glia-
centred model.  In a paper published in 2007, Schachtrupp et al. provided in vivo evidence 
that, following spinal cord injury, the blood protein fibrinogen can induce EGFR 
phosphorylation and transactivation via the β-3 integrin receptor, resulting in the 
abolition of neurite outgrowth.  This study showed that fibrinogen deposition coincided 
extremely closely with pEGFR staining and with local axonal regenerative failure.  In this 
final model, ONC allows blood, containing fibrinogen, to come into contact with axons 
and glial cells in the damaged ON, whereupon fibrinogen sets in motion various EGFR 
dependent growth antagonistic events known to hinder in vivo axonal regeneration, 
including CSPG deposition and increased myelin production.  In this model, the efficacy of 
intra-ON as compared to ivit application of PD is explained as a local effect on glial cells 
which would otherwise be affected by fibrinogen.  As fibrinogen is concentrated in the 
ON, ivit PD would not ameliorate its effects.  Interestingly, the success of intra ON but not 
ivit PD application suggests that at least two of these proposed mechanisms-of-action for 
 224 
 
EGFRki are mutually compatible, and may be occurring simultaneously.  EGFRki such as 
PD could be simultaneously effecting NTF release from ON glia, blockading the harmful 
effects of putatively fibrinogen-mediated glial EGFR signalling, and exerting outgrowth-
enhancing, as yet unknown off-target effects on axons and/or growth cones. 
 Irrespective of the underlying signalling mechanisms, it appears that PD168393, 
immobilised within collagen matrices implanted into the crush site of rat ON, promoted 
substantial and statistically significant RGC axonal regeneration.  This regeneration 
appears to represent around 1.2% of the total RGC population, over a twofold increase of 
the estimated 0.5% RGC which Koprivica et al(2005) reported regenerating in response to 
PD-saturated gelfoam cuffs placed around the lesion site.  In further agreement with the 
findings of this study, no effect on RGC survival was observed. 
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Chapter 7 
Summary and Final Conclusions 
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7.1 Summary 
This study had two interconnected goals.  Firstly, to determine whether or not the 
Epidermal Growth Factor Receptor is involved in the failure of RGC axons to regenerate, 
and secondly, to elucidate the means by which certain EGFRki exert their previously 
demonstrated in vitro and in vivo neuritogenic and axogenic effects.  The four preceding 
Chapters provide evidence sufficient to construct several models which simultaneously 
describe the putative roles of EGFR and those of the EGFRki investigated.  These models 
have been described in each accompanying discussion section, and what follows is a brief 
discussion of the evidence for each, taking into account all relevant recently published 
literature, including potential/additional mechanisms of action for EGFRki that are based 
on the findings of studies outside the field of CNS repair.  This analysis will culminate with 
the propounding of a final model of the involvement of EGFR and EGFRki in RGC axon 
regeneration, based on all known experimental evidence to date.    
 The first model is the intra-axonal model proposed by Koprivica et al. in 2005, 
which places the EGFR somewhere within the signalling cascade which links the 
NgR/LINGO/p75NTR (or TROY) receptor complex to the Rho A/ROCK-mediated cytoskeletal 
changes known underlying growth cone collapse and abortive regeneration.  Koprivica et 
al.(2005) showed evidence that blocking EGFR with EGFRki such as AG1478 and 
PD168393 allowed in vitro neurite outgrowth in otherwise growth-antagonistic 
conditions, and promoted in vivo RGC axonal regeneration.  By contrast Schachtrupp et al. 
(2007) showed that fibrinogen, signalling through β-3 integrin receptors, inhibited neurite 
outgrowth, and suggested that it is this process which is attenuated by EGFRki such as 
PD168393.  Both studies concluded that the neuritogenic actions of EGFRki were a result 
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of their abrogation of EGFR signalling.  However, Chapter 3 of the present study showed 
all RGC axons to be pEGFR―, both in the the retina and in the ON, both before and after 
ONC and that only a ~30% subpopulation of RGC express pEGFR at the somata – a 
precentage far greater than the population of regenerating axons seen in response to 
intra-ON EGFRki therapy.  It should also be noted that at the time of writing (2010) no 
study had demonstrated the presence of pEGFR on RGC axons.  Further, it has been 
demonstrated that AG1478 can enhance RGC neurite outgrowth in vitro even in primary 
retinal cultures which have had had EGFR levels reduced to < 10% with siRNA, and 
conversely, that this siRNA therapy alone does not promote neurite outgrowth.  Finally, it 
has been shown on numerous occasions that the blockade of any single outgrowth-
antagonistic signalling pathway alone will not result in neurite outgrowth or axonal 
regeneration (see Berry et al. 2008 for review), and even blocking critical intracellular 
effector proteins such as ROCK, which serve as nexus points for numerous outgrowth 
antagonistic pathways, will only promote modest outgrowth at best (Fischer et al. 2004).  
As such, intra-axonal EGFR signalling alone cannot explain the EGFRki-mediated in vitro 
and in vivo outgrowth of any study published to date and subsequently, of all the 
proposed models to explain the actions of EGFRki discussed in the present study, this is 
the only model which can be confidently discarded.      
 The second proposed model, illustrated in Figure 7.1 below, still has the 
axon/growth cone/RGC somata as the primary target of EGFRki therapy, but hypothesises 
that EGFRki are not exerting their effects through EGFR blockade but instead are acting 
on other, unrelated, signalling pathways, including other kinases.  Recall that Fabian et al. 
(2005) created a small molecule-kinase interaction map for 20 clinically aimed kinase 
inhibitors, including several EGFRki, and examined their effects on 120 intracellular 
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kinases.  They showed several EGFRki to affect numerous other kinases distinct from 
EGFR, concluding that: “specificity varies widely and is not strongly correlated with 
chemical structure or the identity of the intended target”.  PD168393, for example, has 
shown to partially inhibit the activity of stat3 and ERK (Chen et al. 2005), and while 
koprivica et al. showed that several EGFRki promoted considerable neurite outgrowth, 
(tyrphostins A23, A46, A47, B44, and AG1478), other EGFRki had absolutely no effect on 
neuritogenesis (tyrphostin B42, PD153035).        
 As well as these potential interactions with other kinases, there are two additional 
pathways through which EGFRki be acting.  Firstly, it was reported that AG1478 could 
strongly inhibit the activity of the calcium sensing receptor (CaR) (Tomlins et al. 2005), 
and that the CaR could signal through Rho and ROCK, causing actin stress fiber assembly 
and altered cellular morphology (Davies et al. 2006) - processes which could potentially 
lead to filopodial retraction and growth cone collapse.  Secondly, several EGFRki, 
including genistein and the tyrphostins B44 and tyrphostin 51, were also shown to 
strongly inhibit in vitro neuronal phosphodiesterase (PDE) activity (Ho et al. 1995), and to 
decrease phosphodiesterase activity 80-85% in a neural cell line (Stringfield and 
Morimoto 1997), while the PDE4 inhibitor etazolate hydrochloride was shown to elicit in 
vitro neurite outgrowth levels equivalent to that seen in response to AG1478 (Koprivica et 
al. 2005, supplementary material).  As cAMP is hydrolysed by certain PDE subtypes 
(particularly the aforementioned PDE4 in neurons) this PDE blockade results in increased 
levels of intracellular cAMP (Ho et al. 1995, Nichols and Morimoto, 1999), an event 
known to enhance (or perhaps even be required for) in vivo axonal regeneration (Cai et al. 
2001, and see Hanilla and Filbin 2006 for review).  Such elevated cAMP levels were found 
in AG 1478-treated primary retinal cultures reported by Douglas et al. (2009).  The 
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ramifications of these studies is immediately apparent; EGFRki such as AG1478 and 
PD168393 could potentially drive axonal regeneration via elevated cAMP levels resulting 
from PDE inhibition, while simultaneously  opposing (putatively) CaR-Rho-A mediated 
growth cone collapse, entirely independently of EGFR signalling. 
 
 
 
Figure 7.1.  Proposed means by which EGFRki may exert intra-neuronal axonal-regenerative effects 
independently of EGFR signalling.  1. Blockade of phosphodiesterase 4 (PDE4) causes elevated 
intraneuronal cAMP levels, leading to Trk activation and axonal outgrowth.  2. Inactivation of the calcium 
sensing receptor (CaR) prevents its signalling for growth cone collapse through ROCK and its activation of 
PDE4.  3.  EGFRki may also act synergistically with components of CNS myelin such as inosine to facilitate 
axonal regeneration.  
 
The third model proposes that EGFRki primarily promote RGC axonal regeneration in vivo, 
and neurite outgrowth in vitro, through their effects on glia, firstly via the amelioration of 
the myriad of glially mediated, EGFR signalling-dependent, regeneration antagonistic 
processes known to occur in the injured CNS, and secondly by eliciting glial NTF release.  
These growth antagonistic processes are summarised and illustrated in Figure 7.2 below.  
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In this model it is surmised that the axonal regenerative effects of intra-ON PD168393 
stem from rendering the lesion site a less hostile axon-growth environment, and by 
concomitantly stimulating the release of NTFs from local glia. This model benefits from 
having considerable evidence for each proposed glia-EGFR-axon interaction and it is very 
likely that a large part of any successful intra-ON anti-EGFR therapy will be as a direct 
result of blocking these processes.  There is less evidence for the suggested accompanying 
glial NTF release, being as it is an extrapolation of an in vitro effect seen in primary retinal 
cultures exposed to AG1478 (Douglas et al. 2009). 
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Figure 7.2.  Schematic of the post-crush optic nerve, illustrating the various regeneration-antagonistic 
processes resulting from glial EGFR signalling.  1.  Astrocytes activate, hypertrophy and migrate to lesion 
site, where they begin to simultaneously secrete growth cone-repulsive factors including semaphorins, 
ephrins, SLITS and CSPG, and along with fibroblasts, begin construction of the glial scar.  2.  Haematogenous 
monocytes enter the CNS through the compromised BBB and differentiate into phagocytic macrophages, 
debriding damaged axons and damaging them further.  This influx is in part a response to various 
macrophage attractant factors secreted by astrocytes and microglia.  3.  Microglia activate, take on a 
macrophage-like phenotype, attacking and debriding myelinated axons, whilst secreting cytotoxic  
substances including various ROS, and releasing various chemokines and cytokines which initiate 
lymphocyte and neutrophil influx, leading to futher cytotoxicity and axonal damage.  4.  Oligodendrocytes 
increase production of CNS myelin as part of an attempt to remyelinate debrided axons.  Although there is 
no extant literature concerning synantocyte EGFR signalling, these cells were included in this diagram for 
completeness. 
 
The fourth model suggests that some factor ‘x’ in CNS myelin, acting in 
conjunction with EGFRki such as PD168393, actively promotes RGC axonal regeneration 
(illustrated above in Figure 7.1).  This hypothesis is based on the fact that AG1478 elicited 
far greater in vitro RGC neuritogenesis when in the presence of CME (Douglas et al. 2009) 
and that intra-ON, but not ivit PD168393, promoted axonal regeneration (Chapters 5 and 
6, this study) - the lack of CNS myelin in the rat retina precluding any such synergistic 
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axonal growth in the ivit PD168393 experiments.  The initial candidate suggested to be 
this factor ‘x’ was inosine, identified for its previously described roles in axonal 
outgrowth.  Inosine has been shown to activate MST3b, a protein kinase critical to axonal 
outgrowth (Irwin et al. 2006) as well as serving as a ligand for the adenosine A2A receptor 
(Nascimento, 2010) which in turn can transactivate Trk receptors, resulting in growth and 
axogenic responses similar to that obtained with conventional NTF-therapy (Jeanneteau 
and Chao, 2006).  In support of this, Chapter 4 of the present study showed how the A2A 
receptor antagonist ZM21385 partially inhibited the growth promoting effects of AG1478 
on primary retinal cultures, an effect potentially attributable to either (or both) of these 
two pathways.  It is also possible that the elevated cAMP levels resulting from EGFRki 
therapy could be potentiating this effect – as seen with the switch of MAG from growth-
antagonistic to growth promoting (Cai et al. 2001).      
 With the exception of the first model, which has been rendered all but untenable 
by the results of the present study (as well as those of others in our research group), all of 
the models proposed above are in principle mutually compatible: the events described in 
each could potentially occur simultaneously.  As such, the final model illustrated in Figure 
7.3 is an amalgamation of these models and, this author believes, represents the most 
complete picture to date of how the EGFR and EGFRki are involved in the prevention and 
restoration of RGC axonal regeneration.  This model takes into account EGFR distribution 
and signalling, on- and off- target effects of EGFRki, neuronal and glial influences and is 
based on evidence from scores of studies, including the data comprising the present 
study. 
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Figure 7.3.  The final proposed model of the actions of EGFR and EGFRki in the injured optic 
nerve.  1.  EGFRki abrogate various glially  mediated growth-antagonistic  EGFR-signalling 
dependent cellular events, reducing secondary axonal damage and truncating intra-ON levels of 
growth-cone collapsing factors.  2.  In response to EGFRki, ON glia produce and secrete various 
growth-promoting NTFs.  3.  Acting intraneuronally, EGFRki simultaneously a) inhibit the function 
of the CaR, preventing it from signalling for growth cone collapse through ROCK, and b) inactivate 
PDE4, raising intraneuronal levels of cAMP, which in tandem with the NTFs released from ON glia 
activate the Trk receptors leading to further enhanced axon growth.     4.  EGFRki mediated 
effects may also include the actions of some factor present in CNS myelin - such as inosine - the 
synergistic effects of which may also facilitate axonal outgrowth.  
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7.2  Final conclusions 
 
In summary, the role of the EGFR in RGC axonal regenerative failure appears to be chiefly 
a glial one, with EGFR governing a variety of growth antagonistic processes which render 
the CNS a more growth-hostile environment.  There is no compelling evidence for, and 
considerable evidence against, a direct, intra-axonal role for EGFR, effectively excluding 
the possibility that EGFR itself is part of the NgR/LINGO/p75NTR signalling pathway 
converging on RhoA/ROCK which leads to growth cone collapse.  Mirroring this, there is a 
wealth of data to suggest that EGFRki almost certainly do not achieve their RGC axonal 
regenerative effects through the blockade of neuronal EGFR.  They likely do so instead via 
the abrogation of the various aforementioned harmful EGFR-dependent glial signalling 
processes, the stimulation of glial NTF release, the inhibition of PDE4, resulting in the 
elevation of intra-neuronal/axonal cAMP levels, and, potentially, by blockading the 
putative growth cone collapse-initiating CaR-RhoA signalling pathway and by interacting 
with an as yet unknown component of CNS myelin.     
 Thus EGFR is almost certainly not directly involved in RGC axonal growth cone 
collapse, but plays an important if indirect role via its impact on glial events, while EGFRki 
such as AG1478 and PD168393 promote axonal regeneration through off-target intra-
/neuronal and both on- and off-target effects on glia, but do not do so by blockading 
axonal EGFR signalling. 
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7.3  Futher studies 
 
This study has variously demonstrated the distribution of pEGFR in the rat visual system, 
constructed a novel in vitro inhibitory and disinhibitory assay for primary retinal cultures 
using the Nogo-P4 peptide and EFGRki, demonstrated the inefficacy of ivit PD168393 on 
post ONC axonal regeneration and shown in vivo axonal regeneration using PD-
impregnated collagen matrices implanted into the ON lesion site.  Arguably the lattermost 
is the most important result, (despite the limitations of the experiment and the need for 
its repetition – discussed below) the axonal regeneration obtained from PD168393-
impregnated collagen matrices being approximately double that of that reported by 
Koprivica et al.(2005) in response to PD-soaked gelfoam placed around the crushed 
mouse ON (~1.2% to ~0.5% respectively).  Although EGFRki are a modestly promising 
potential therapeutic tool, the use of EGFRki-implanted collagen matrices would perhaps 
achieve greater regeneration if used in some form of combinatorial therapy.  Almost as 
remarkable as the regeneration obtained by both this approach and that of Koprivica et 
al.(2005)  is the complete lack of enhanced RGC survival which normally accompanies 
such regrowth.  While the reasons for this apparent paradox remain unclear, it suggests 
that if collagen matrices were impregnated not only with EGFRki, but with other factors 
conducive to RGC survival, such as BDNF, greater levels of regeneration might be 
obtained.  Previous studies have shown that collagen matrices can be successfully 
impregnated with viruses or naked-plasmids containing the genes for growth promoting 
agents, or can be made to contain such factors themselves, and that such agents remain 
almost entirely with the matrix whilst being readily endocytosed by invading cells/axons 
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and as such a combinatorial cocktail of such factors or genes, along with EGFRki such as 
PD168393 could potentially promote RGC survival, as well as providing a regenerative 
drive and a strong growth substrate through which to progress.  It should also be recalled 
that the axonal regeneration in response to intra-ON PD-matrix implantation reported 
here is considerably less robust than that observed to occur in response to several other 
previously described therapies, such as ivit PN graft implantation or multiple NTF therapy, 
and that almost all previously reported regeneration-promoting therapies also promoted 
significant RGC survival, which PD-matrix implantation did not.   
 While this study has provided substantial evidence as to the actions of EGFR and 
EGFRki in the injured visual system, several of the results obtained need to be confirmed 
through extra experiments, and many of the constituent pathways and interactions in the 
proposed final model require experimental confirmation.     
 Although absolutely no axon pEGFR was observed in the axonal/pEGFR 
colocalisation studies comprising Chapter 3, and despite the lack of any reports of axonal 
pEGFR in the literature, to finally exclude intra-RGC growth cone EGFR signalling, an IHC 
colocalisation study should be performed in the post ONC ON using antibodies to both 
growth-cone specific proteins such as the actin-associated protein 2G13p and to pEGFR.  
 Due to loss of considerable control-matrix group ON tissue, the intra-ON PD-
matrix experiments detailed in Chapter 6 suffered from insufficient n  numbers in the 
control-matrix group, and barely sufficient numbers (n = 3) in the PD-matrix treatment 
group.  As such these experiments should be repeated such that n = 4 (at least) for each 
treatment and control group, each accompanied by retinal RGC survival counts.  Until this 
is accomplished the results shown in Chapter 6 cannot be fully trusted or published in a 
peer reviewed journal.  Although the primary result - that PD-matrix implantation led to 
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RGC axonal regeneration - was confirmed in triplicate, and only the relative contribution 
of the collagen matrix itself, illustrated by the presence/absence of control-matrix group 
axonal regeneration, is technically in question, n = 3 is the minimum number which allows 
statistical analysis, and thus additional n numbers for each group would reduce error 
margins and is thus desirable.  These two studies could potentially be combined into a 
single experiment, allowing for both the confirmation of the effects of intra-ON PD-matrix 
implantation and edification as to the existence of growth cone pEGFR in vivo in both 
regenerating and non-regenerating models.      
 The various potentially axon growth-arresting actions of the neuronal calcium 
sensing receptor (CaR) is perhaps the most potentially rewarding area of futher research.  
This receptor appears to be able to signal through ROCK while lowering the levels of 
intraneuronal cAMP through activation of PDE4, and it has been reported that the CaR 
can be inactivated by AG1478 .  This suggests that not only could CaR inactivation 
underlie much of the effects of EGFRki, this receptor could potentially be another key 
activator of the inhibitory signalling cascade which leads to growth cone arrest and 
collapse.  To investigate this, the effects of CaR inactivation should be investigated, 
initially in vitro, via such methods as siRNA knockdown combined with pharmacological 
blockade of the CaR itself using CaR-specific antagonists such as SB-423562 and SB-
423557 (taken from Kumar et al. 2010) or agents similar to those described by Arey et al. 
(2005).  The latter study describes a factor designated “Compound 1” which is a potent, 
selective CaR antagonist with a relatively long half life (systemically measured to be 
greater than 1 hour in adult rats), the longevity of which would likely be extended by its 
immobilisation within a collagen matrix in vivo, however this compound may not be 
generally available.  Were CaR antagonism to prove neuritogenic in vitro, CaR blocking 
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agents or CaR specific siRNA sequences could constitute part of a ‘cocktail’ to be 
immobilised within collagen matrices for subsequent intra-ON implantation , with the 
hope of promoting RGC survival and axonal regeneration. 
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